# Orchestration Log V3

## 2026-05-26 18:41 UTC

Started V3 continuation after external interruption. Re-read/confirmed the four prior artifacts:

- `MS_RESEARCH_LOG_2026-05-26.md`
- `FINDING_EXECUTION_PHASE.md`
- `FINDING.md`
- `EXHAUSTION.md`

Repo status at start: only unrelated untracked `prompt.md`. Existing V2 code/results are present.

Initial decision:

- Primary track is cross-autoimmune lipid-lysosomal inflammatory myeloid module resolution.
- `ACSL1` is retained as a marker/comparator, not a lead.
- `NAMPT` is retained as a strong but prior-arted comparator, not automatically promoted.
- Foundation-model work must be real or explicitly blocked; no simulated/fabricated foundation-model output.

Created V3 directories:

- `phases/v3/results`
- `phases/v3/subagents`
- `phases/v3/literature`
- `data/raw_v3`
- `data/derived_v3`
- `phases/v3/models`
- `phases/v3/tmp`

Created initial control documents:

- `REFRAME_V3.md`
- `TOOLS_V3.md`
- `SUBAGENTS_V3.md`
- `PLAN_V3.md`

## Pending Dispatch

First-wave subagents to be spawned after the V3 control documents exist:

- disease specialists: MS, RA, SLE/LN, Crohn's, UC, psoriasis, T1D, Sjogren, ankylosing spondylitis, myasthenia gravis, autoimmune thyroid disease, celiac, PBC;
- modality specialists: genetics, cell state/spatial, perturbation/foundation models, druggability/prior art, cross-domain mechanism transfer.

## 2026-05-26 18:45 UTC

First dispatch attempt hit active thread limit. Three stale subagents from V2 were still open:

- `019e6567-bba2-7a90-8ec9-73ff43283baf`
- `019e6567-bbde-78d3-bf1c-962ec9093e54`
- `019e6567-bc08-7ce1-9d3a-148397da27a1`

Closed those stale agents and preserved their returned status in tool output. This is a system concurrency ceiling, not a scientific blocker.

Current V3 agents launched:

| Agent | Role |
|---|---|
| `019e659a-5934-7970-b740-4a28eb3e61d4` / Fermat | MS disease specialist |
| `019e659a-5956-7aa2-9526-ba29260b3b92` / Heisenberg | RA disease specialist |
| `019e659a-5980-7f92-b472-a674ed6d93a9` / Hume | SLE/lupus nephritis disease specialist |
| `019e659a-a81c-7560-bb60-1d2ea7182128` / Russell | Crohn's disease specialist |
| `019e659a-a82a-7ef1-86e7-9ed1cba71ad8` / Ptolemy | ulcerative colitis disease specialist |
| `019e659a-a876-7df1-9425-234530e7b1c0` / Lovelace | psoriasis disease specialist |

Dispatches for T1D, Sjogren, ankylosing spondylitis, myasthenia gravis, autoimmune thyroid disease, celiac disease, PBC, and modality specialists are queued until one of the active six returns or can be closed.

## 2026-05-26 18:52 UTC

Returned disease reports integrated from:

- MS (`019e659a-5934-7970-b740-4a28eb3e61d4`)
- SLE/LN (`019e659a-5980-7f92-b472-a674ed6d93a9`)
- Crohn's (`019e659a-a81c-7560-bb60-1d2ea7182128`)
- UC (`019e659a-a82a-7ef1-86e7-9ed1cba71ad8`)
- psoriasis (`019e659a-a876-7df1-9425-234530e7b1c0`)

Convergence so far:

- The shared state is not uniformly a foamy/lipid-droplet state.
- Psoriasis contradicts the lipid-loader genes (`ACSL1`, `APOE`, `GPNMB`, `LPL`, `PLIN2`, `MERTK`) while supporting lysosomal/APC/protease/inflammatory genes (`IFI30`, `CTSB`, `CTSD`, `LIPA`, `CXCL10`, `IL1B`, `C1QB`, `NAMPT`).
- MS supports `GPNMB`, `IFI30`, `TPP1`, `LAMP1`, `CTSD`, `NAMPT`; spatial support is strongest for `GPNMB` but broad therapeutic direction is unsafe/unclear.
- SLE/LN supports disease-associated macrophage/monocyte states with `SPP1/CTSD/APOE/TREM2/CD9/CD63`, complement, `IFI30`, `LIPA`, `CXCL10`; direct `ACSL1` is not a kidney target.
- Crohn/UC support inflammatory monocyte/macrophage expansion plus lysosomal antigen-processing, IFN/HIF/glycolytic, eicosanoid, OSM/TREM1/stromal crosstalk axes.

Interim central-node candidates:

- `IFI30` / GILT as less-owned lysosomal antigen-processing anchor.
- `STAT1/IRF1 -> IFI30/HLA-II/CD74` transition as upstream regulatory frame.
- `HIF1A -> NAMPT/LDHA/SLC2A1` metabolic licensing as a strong but prior-art/direction-risk comparator.
- `SPP1/GPNMB/TREM2/APOE/CTSD` state as repair/injury marker family, not automatically a target.

Local first-pass V3 ranking executed:

- `phases/v3/results/existing_evidence_candidate_matrix.tsv`
- `phases/v3/results/central_node_first_pass_rank.tsv`
- `phases/v3/results/axis_level_convergence.tsv`
- `phases/v3/results/central_node_first_pass_summary.json`

The top heuristic genes are `NAMPT`, `IFI30`, `CXCL10`, `C1QB`, `CTSB`, `SPP1`, `IL1B`, `C1QA`, `TNF`, `MSR1`. This is a triage result only.

Foundation-model provisioning:

- Created `.venv_v3_py312`.
- Installed `scanpy`, `anndata`, `scikit-learn`, `networkx`, `requests`, `biopython`, `huggingface_hub`.
- Installed `arc-state==0.10.2`, `arc-stack==0.1.3`, `torch==2.12.0`.
- Found Arc Hugging Face released checkpoints/outputs: `arcinstitute/ST-HVG-Parse`, `arcinstitute/ST-HVG-Tahoe`, `arcinstitute/Stack-Large`, `arcinstitute/Stack-Large-Aligned`, `arcinstitute/SE-600M`, Evo 2 model repos.
- Downloaded official State Parse split 4 CD14 monocyte predicted/real DE outputs under `data/raw_v3/state_parse_split4`.
- Evo 2 remains local-blocked by macOS/no CUDA; hosted API would require credentials.

## 2026-05-26 18:56 UTC

Closed returned disease agents and launched second-wave agents for:

- T1D: `019e65a2-e1fe-7852-b515-f0a25177d90e`
- Sjogren: `019e65a2-e1df-7041-9b3a-6918c260e8ef`
- ankylosing spondylitis / SpA: `019e65a2-e232-7201-a767-8929c5797144`
- myasthenia gravis: `019e65a2-e27f-7c92-b6b9-b59b946469f8`
- autoimmune thyroid disease: `019e65a2-e2a4-70b3-b8fb-883d9cfce74e`

Closed RA agent after its return and launched cross-autoimmune genetics modality agent:

- genetics: `019e65a4-e588-7e02-9b93-59822da6f7f2`

State output correction: the first implementation guessed feature-to-gene mapping and was invalid. The script was revised to avoid gene mapping and record the blocker. No biological module conclusion will use the guessed output.

## 2026-05-26 19:03 UTC

Integrated and closed second-wave returns:

- autoimmune thyroid disease: `019e65a2-e2a4-70b3-b8fb-883d9cfce74e` / Dirac
- Sjogren disease: `019e65a2-e1df-7041-9b3a-6918c260e8ef` / Arendt

Preserved summaries:

- `phases/v3/subagents/autoimmune_thyroid_dirac_report.md`
- `phases/v3/subagents/sjogren_arendt_report.md`

Integration decision: both diseases support the IFN/APC arm, especially
`STAT1/IRF1/CXCL10/HLA-II/CD74`, but neither can currently promote the full
lysosomal inflammatory myeloid state. AITD is dominated by thyroid epithelial
autoantigen and lymphoid/B-cell architecture. Sjogren local evidence is bulk
minor salivary gland and blocks myeloid-specific interpretation.

Dispatched remaining minimum disease specialists:

- celiac disease: `019e65ac-0910-7593-894f-720936207c59` / Plato
- primary biliary cholangitis: `019e65ac-094c-7a93-88b8-54e9c112a32c` / Goodall

Myasthenia gravis agent `019e65a2-e27f-7c92-b6b9-b59b946469f8` failed because
the subagent ran out of context. This output is not counted. Closed it and
re-dispatched a narrow replacement:

- myasthenia gravis replacement: `019e65ac-dd68-7b50-8f83-60e8051487a4` / Dalton

Integrated T1D return:

- T1D: `019e65a2-e1fe-7852-b515-f0a25177d90e` / Rawls
- preserved summary: `phases/v3/subagents/t1d_rawls_report.md`

Integration decision: T1D promotes the broader IFN/MHC-II/metabolic-stress axis
in islets and cytokine perturbation systems, but not a clean blood-monocyte or
myeloid-transition recurrence. This argues against a strictly myeloid central
node and toward a cross-cell APC/metabolic stress transition.

Integrated myasthenia gravis replacement return:

- MG: `019e65ac-dd68-7b50-8f83-60e8051487a4` / Dalton
- preserved summary: `phases/v3/subagents/myasthenia_gravis_dalton_report.md`

Integration decision: MG is partial and thymus/PBMC-anchored. It supports
IFN/APC and MHC-II/lysosomal processing, but the disease-defining NMJ lesion is
antibody/complement effector dominant. It should not be a core convergence
disease for the target claim.

Integrated SpA and celiac returns:

- ankylosing spondylitis / SpA: `019e65a2-e232-7201-a767-8929c5797144` / Planck
- celiac disease: `019e65ac-0910-7593-894f-720936207c59` / Plato
- preserved summaries:
  - `phases/v3/subagents/spa_as_psa_planck_report.md`
  - `phases/v3/subagents/celiac_plato_report.md`

Integration decision: SpA strengthens inflammatory APC/myeloid convergence in
synovial fluid, while celiac strengthens IFN/APC plus antigen processing but
points to disease-specific antigen-entry logic (`TGM2/LRP1/HLA-DQ`) rather than
generic lipid-loader repair.

Dispatched focused modality agents after axis reranking:

- target/intervention scout: `019e65b3-023d-7e42-a17a-92978404a88a` / Ohm
- foundation-model/perturbation route scout: `019e65b3-025d-7d82-a953-2578a86bdc5d` / Hubble

Integrated PBC return:

- PBC: `019e65ac-094c-7a93-88b8-54e9c112a32c` / Goodall
- preserved summary: `phases/v3/subagents/pbc_goodall_report.md`

Integration decision: PBC strongly supports the portal IFN/APC plus
CTSS/CD74/HLA-II lysosomal antigen-processing arm. It weakens lipid-loader and
NAMPT as pan-autoimmune anchors. CXCL10 remains a biomarker/recruitment readout,
not a lead intervention, because prior PBC anti-CXCL10 work reportedly achieved
target engagement without biochemical improvement.

Integrated genetics return:

- cross-autoimmune genetics: `019e65a4-e588-7e02-9b93-59822da6f7f2` / James
- preserved summary: `phases/v3/subagents/genetics_james_report.md`

Integration decision: promote `IFI30 + IRF1/HLA-II antigen-processing` as the
best genetics-compatible central axis. `NAMPT/HIF1A/NAD` is demoted to
expression/perturbation support, not a genetics-led anchor. Directionality
remains unresolved, so no direct `IFI30` inhibition/activation claim is allowed.

Integrated intervention scout return:

- target/intervention scout: `019e65b3-023d-7e42-a17a-92978404a88a` / Ohm
- preserved summary: `phases/v3/subagents/intervention_ohm_report.md`

Integration decision: the best therapeutic path is not a novel first-in-class
CTSS/IFI30 claim. It is a stratified CD74/MIF-high progressive MS program with
cross-autoimmune APC-state support, using CTSS as a mechanistic comparator and
biomarker arm. CTSS is druggable but prior-arted and clinically haircutted.
CXCL10, NAMPT, OSMR, TGM2/LRP1, TREM1, and C1Q/SARM1 are demoted for this V3
claim.

Integrated foundation/perturbation route return:

- foundation-model/perturbation scout: `019e65b3-025d-7d82-a953-2578a86bdc5d`
  / Hubble
- preserved summary: `phases/v3/subagents/foundation_hubble_report.md`

Integration decision: de novo State is invalid in this workspace without
compatible AnnData. State remains feature-agnostic cytokine-response validation.
The proper next perturbation branch is LINCS/CMap reversal plus real
Perturb-seq/Mixscale IFN/TNF data. The current CD74/MIF stratification concept
therefore cannot yet be called a DoD-complete breakthrough.

## 2026-05-26 19:31 UTC

Started large State artifact download:

- `adata_real.h5ad` from `arcinstitute/ST-HVG-Parse/fewshot/split_4/eval_best.ckpt`
- size: 9.11 GB
- purpose: recover exact HVG feature-to-gene mapping for released State CD14
  monocyte perturbation outputs.

Dispatching a focused second wave while the download runs:

- foundation-model alternatives and real perturbation data: identify a feasible
  gene-specific route if State HVG recovery fails or remains insufficient.
- CD74/MIF novelty and translational audit: determine whether a
  CD74/MIF-receptor-high progressive MS stratification claim is actually novel
  after patents, trials, and preprints.
- cross-autoimmune cell-state replication scout: identify the fastest
  accessible single-cell/spatial datasets to quantify `CD74/CD44/CXCR4/HLA-II`
  and IFN/lysosomal APC states outside MS.

Spawn notes:

- Initial spawn attempt with `fork_context=true` plus explicit agent settings
  was rejected by the tool; reran with inherited settings.
- foundation/perturbation alternatives: `019e65c5-8dfd-7303-a30f-8bcb44e76fdc`
  / Bernoulli
- CD74/MIF novelty and translational audit:
  `019e65c5-ac49-7fc0-b879-585722c5fd6a` / Galileo
- cross-autoimmune cell-state replication scout:
  `019e65c5-c595-71b2-9e3b-f82cef4a3b92` / Zeno

## 2026-05-26 19:36 UTC

Integrated foundation-alternative return:

- foundation/perturbation alternatives:
  `019e65c5-8dfd-7303-a30f-8bcb44e76fdc` / Bernoulli
- preserved summary: `phases/v3/subagents/foundation_alt_bernoulli_report.md`

Integration decision: promote Mixscale Perturb-seq `GSE281048` / Zenodo
`14035992` to the primary gene-specific perturbation branch. This is stronger
than L1000FWD because it directly perturbs `STAT1`, `IRF1`, `IFNGR1/2`, `JAK2`,
and related regulators under cytokine stimulation and can test readouts such as
`CD74`, HLA-II genes, `IFI30`, and `CTSS`.

Integrated CD74/MIF novelty audit:

- CD74/MIF novelty and translational audit:
  `019e65c5-ac49-7fc0-b879-585722c5fd6a` / Galileo
- preserved summary: `phases/v3/subagents/cd74_mif_novelty_galileo_report.md`

Integration decision: the broad CD74/MIF/ibudilast progressive MS therapeutic
claim is blocked by publications, trials, and patents. Only a narrower
predictive enrichment biomarker claim survives: `CD74/CD44/CXCR4/HLA-II`-high
myeloid receptor state as a treatment-selection variable for MIF/CD74-axis
modulation. This cannot serve as the main novel therapeutic target unless tied
to a cleaner, less prior-arted intervention point.

Integrated cross-autoimmune cell-state replication scout:

- cross-autoimmune cell-state replication:
  `019e65c5-c595-71b2-9e3b-f82cef4a3b92` / Zeno
- preserved summary: `phases/v3/subagents/cell_state_replication_zeno_report.md`

Integration decision: quantify `CD74/CD44/CXCR4/HLA-II` plus
`STAT1/IRF1/IFI30/CTSS` in disease-relevant compartments using CELLxGENE where
available, and use donor/compartment-restricted statistics. Avoid whole-tissue
bulk-style scoring.

## 2026-05-26 20:31 UTC

Orchestrator integration after local execution:

- Mixscale perturb-seq branch succeeded and supersedes the weaker L1000FWD
  reversal branch for gene-specific perturbation evidence.
- Direct h5ad cell-state validation succeeded for IBD colon, psoriasis skin,
  and Sjogren labial gland, after routing around slow CELLxGENE Census
  expression extraction.
- Central mechanism is now reformulated as IFN-gamma-licensed antigen
  processing/APC transition:
  `IFNG -> IFNGR1/IFNGR2 -> JAK1/JAK2 -> STAT1 -> CIITA/NLRC5/RFX5 ->
  HLA-II/CD74 + IFI30/CTSS/TAP/B2M`.
- The older "lipid-lysosomal myeloid module" label is too broad and partially
  misleading. The cross-disease recurrence is not always myeloid; in Sjogren
  the stronger signal is salivary epithelial HLA-II/CD74 state.
- Current unresolved bottleneck is intervention-point novelty. Direct IFN-gamma,
  IFNGR, JAK, and CTSS approaches are likely heavily prior-arted; a viable V3
  finding may need to be a stratification or delivery-specific therapeutic
  concept rather than a naive pathway blockade claim.

## 2026-05-26 21:02 UTC

Dispatched Wave 3:

- genetics/colocalization scout: `019e6615-9c23-7700-940b-536d3eb478e7` /
  Kierkegaard
- IFI30/state novelty and patent scout: `019e6615-b9cc-7882-a73d-112908ac114b`
  / Epicurus
- disease-breadth expansion scout: `019e6615-e412-7d60-88bf-320a2bc7ff74` /
  Kepler

Integration rule for this wave: no single-gene therapeutic claim can proceed
unless the genetics scout can identify acceptable anchoring or the novelty scout
finds a clean stratification/intervention niche. Disease-breadth output should
drive the next local downloads rather than adding more narrative-only disease
support.

## 2026-05-26 21:14 UTC

Integrated disease-breadth expansion return:

- disease-breadth expansion scout: `019e6615-e412-7d60-88bf-320a2bc7ff74` /
  Kepler
- preserved summary: `phases/v3/subagents/wave3_disease_breadth_kepler_report.md`

Integration decision: prioritize RA synovium/macrophage `E-MTAB-8322` as the
next new disease tissue because it has direct h5ad plus disease, response, donor,
and cell-type metadata. T1D HPAP `GSE148073` is second. Autoimmune thyroid
spatial `GSE248205` is the small backup if a rapid third new tissue is needed.

## 2026-05-26 21:17 UTC

Integrated novelty/prior-art return:

- IFI30/state novelty and patent scout: `019e6615-b9cc-7882-a73d-112908ac114b`
  / Epicurus
- preserved summary: `phases/v3/subagents/wave3_novelty_epicurus_report.md`

Integration decision: demote broad `IFI30/GILT` inhibition/activation/modulation
as a therapeutic lead. It is prior-arted and mechanistically risky in MS/EAE.
Only a narrow combined tissue/cell-state companion biomarker claim survives:
`IFN-gamma + HLA-II + CD74 + IFI30/GILT` for treatment-by-biomarker interaction.

Integrated genetics return:

- genetics/colocalization scout: `019e6615-9c23-7700-940b-536d3eb478e7` /
  Kierkegaard
- preserved summary: `phases/v3/subagents/wave3_genetics_kierkegaard_report.md`

Integration decision: use genetics as pathway support only. HLA-II/MHC is broad
but non-specific; `IRF1/CARINH` is the best non-MHC cross-disease regulatory
anchor; `IFI30` is MS-specific coloc-grade support, not a pan-autoimmune target.
No final claim may say a single named candidate has true cross-disease MR/coloc
support across four or more diseases.

## 2026-05-26 21:31 UTC

Local route-around after the RA EBI transfer blocker:

- analyzed autoimmune thyroid spatial dataset `GSE248205`;
- added `scripts/v3_analyze_gse248205_thyroid_spatial.py` to the reproducible
  V3 runner;
- outputs preserved under `phases/v3/results/gse248205_thyroid_spatial/`.

Integration decision: count Hashimoto thyroiditis as an additional
cross-autoimmune tissue where the IFN-gamma/HLA-II/CD74/GILT/TAP state recurs,
with strict caveats for small sample size and Visium spot-level tissue mixture.
Do not count Graves disease as positive; it is directionally supportive only.

## 2026-05-26 21:34 UTC

Closed six completed earlier subagent threads after preserving their reports,
because the thread limit blocked new dispatch.

Dispatched intervention scout:

- tractable intervention-point scout:
  `019e6635-e038-70c1-965e-adf427af7967` / Aquinas

Task: rank non-obvious intervention handles for the
`IFNG/HLA-II/CD74/GILT/TAP` transition, excluding unqualified broad JAK
inhibition and obvious prior-art-blocked claims. The report is advisory only;
the orchestrator must verify before integration.

## 2026-05-26 21:36 UTC

Dispatched hour-3 hostile critique:

- critique subagent: `019e6637-5b9b-7383-8127-d3690d0001c5` / Cicero

Critique mandate: attack whether the transition is generic inflammation,
whether disease signals are immune infiltration or tissue severity, whether
thyroid spatial and GSE253006 are weak proxies, whether foundation-model and
genetic evidence fail the V3 DoD, and whether any intervention point survives
novelty/prior art.

## 2026-05-26 21:38 UTC

Dispatched foundation-model fallback scout:

- foundation-model fallback: `019e6639-aab3-71e1-8fb3-8e56c595e8f2` / Harvey

Task: identify a CPU-feasible, gene-resolved cellular/genomic foundation-model
route if the State `adata_real.h5ad` gene mapping download remains incomplete.
Synthetic pseudo-inputs are disallowed.

## 2026-05-26 21:44 UTC

Integrated hour-3 critique locally, before waiting for the intervention scout.
Action taken: added IFN-residualization analysis and wrote
`CRITIQUE_V3.md`.

Integration decision: demote the broad pan-autoimmune IFN/APC transition. The
state is recurrent but mostly collapses under same-sample IFN-score control.
Continue the run by either narrowing to residual MS/Sjogren CD74/HLA
receptor-state stratification or pivoting to a different mechanism that survives
generic IFN orthogonalization.

## 2026-05-26 21:57 UTC

Integrated T1D direct h5ad extension and reran convergence/residualization.

New data incorporated:

- T1D pancreatic beta, ductal, and acinar compartments from the downloaded
  direct h5ad dataset.
- Extended direct module panel including `lipid_loader_repair`,
  `hif_nampt_metabolic`, `inflammatory_nfkb`, and
  `complement_phagocytosis`.

Updated convergence result:

- Raw IFN/HLA/CD74 transition breadth remains high: 8 diseases tested, 5 strong
  diseases, 7 supportive-or-better diseases.
- The strongest raw module by breadth is `mif_cd74_receptor_state`: 8 diseases
  tested, 3 strong diseases, 6 supportive-or-strong diseases.
- T1D adds nominal/strong ductal and acinar support for HLA/CD74/IFN modules,
  with the top T1D direct module result being acinar
  `inflammatory_nfkb` high-fraction delta 0.527, Hedges g 3.842, p=0.00246,
  FDR=0.0482, and ductal `mif_cd74_receptor_state` mean-score delta 0.172,
  Hedges g 1.142, p=0.00364, FDR=0.0482.

Updated hostile-control result:

- Residualization inputs increased from 148 to 217 donor/sample units.
- Tests increased from 44 to 56.
- Raw nominal target-module supports increased to 30.
- IFN-residual nominal supports remain only 4, with no residual global-FDR
  support.
- Residual positives are MS white-matter microglia
  `mif_cd74_receptor_state`, MS white-matter microglia `lysosomal_apc`,
  Sjogren epithelial `mif_cd74_receptor_state`, and T1D acinar
  `mixscale_validated_ifng_readout`.

Integration decision: the broad IFN/APC transition is still a recurrent
cross-autoimmune state but not an IFN-independent pan-autoimmune mechanism.
Do not advance it as the V3 central claim unless the intervention point is
narrowed to a specific cell-state gate and externally validated. Continue two
lanes: (1) narrow residual CD74/HLA receptor-state biology in MS/Sjogren/T1D;
(2) revived lipid-lysosomal `LIPA`/acid-lipase lane because gene-level direct
outputs show T1D ductal and psoriasis keratinocyte LIPA signals and it maps
closer to the original reviewer-specified module.

## 2026-05-26 21:59 UTC

Integrated intervention scout from
`phases/v3/subagents/intervention_scout_report.md`.

Scout recommendation: local PDE4/cAMP-PKA modulation of the
CIITA/MHC-II/CD74 gate in biomarker-high UC is the nearest-term tractable
modality. The report explicitly rejects broad JAK/IFNGR/STAT1 blockade, CTSS,
IFI30/GILT, direct CD74/MIF, statins, and TYK2 as primary new claims.

Orchestrator decision: accept the report as a translational hypothesis and
assay-design aid, not as a finding. Its lead indication is UC and its prior-art
risk is medium-high; it does not by itself satisfy the cross-autoimmune V3 DoD
after IFN residualization.

Integrated foundation-model fallback scout from
`phases/v3/subagents/foundation_fallback_report.md`.

Scout recommendation: State remains the best route if `adata_real.h5ad` opens
and provides gene mapping. Geneformer V2-104M is the CPU-feasible fallback but
only yields model-hypothesis embedding shifts, not expression-level evidence.
Mixscale real CRISPRi remains stronger substitute evidence than any anonymous
or synthetic foundation-model output.

Orchestrator decision: keep the State download alive; do not claim
foundation-model perturbation until gene-resolved output exists. If the State
file remains blocked, route to Geneformer only after the hour-4 checkpoint.

## 2026-05-26 22:01 UTC

Closed completed advisory agents after preserving and integrating their reports:

- Aquinas intervention scout
- Cicero hour-3 critique
- Harvey foundation fallback scout

Prepared second wave because the broad IFN/APC transition was demoted and the
analysis now has two viable but incomplete lanes:

1. `LIPA`/acid-lipase lipid-lysosomal lane, revived by T1D ductal and psoriasis
   keratinocyte gene-level signals and closer to the original module.
2. residual CD74/HLA receptor-state lane, strongest in MS white-matter microglia
   and weakly present in Sjogren/T1D after IFN orthogonalization.

Dispatched wave-4 agents:

- Boole `019e664d-7a6d-7e01-8af3-82e199152d43`: `LIPA` /
  lipid-lysosomal central-node scout. Deliverable:
  `phases/v3/subagents/wave4_lipa_scout_report.md`.
- Leibniz `019e664d-7b33-71b3-958d-4816ea6c90c6`: residual CD74/HLA
  receptor-state scout. Deliverable:
  `phases/v3/subagents/wave4_residual_cd74_scout_report.md`.
- Mill `019e664d-7c86-7de3-9353-46643fe5d93f`: foundation-model gate runner.
  Deliverable: `phases/v3/subagents/wave4_foundation_gate_report.md`.

## 2026-05-26 22:04 UTC

Integrated Mill's foundation-model gate report:
`phases/v3/subagents/wave4_foundation_gate_report.md`.

Gate result:

- State `adata_real.h5ad` is truncated and unreadable:
  local size 5,619,356,404 bytes vs HDF5 stored EOF 9,112,404,896 bytes.
- Current State output tables remain anonymous `FEATURE_n`; named genes
  `CD74`, `IFI30`, `CTSS`, `STAT1`, `TAP1`, `B2M`, and `HLA-DRA` appear zero
  times in `phases/v3/results/state_parse_cd14_de_with_gene_symbols.tsv`.
- State is valid only for feature-agnostic calibration: IFN-gamma Spearman
  0.4793, direction match 0.7087, significant-feature recall 0.8174,
  precision 0.7397.

Integration decision: foundation-model named-gene evidence is still blocked.
The resumed State download is active, but until the h5ad opens cleanly, Mixscale
CRISPRi remains the only valid named-gene perturbation backbone. Geneformer is
kept as a CPU-feasible follow-up model-hypothesis route, not current evidence.

## 2026-05-26 22:09 UTC

Integrated Leibniz's residual CD74/HLA receptor-state report:
`phases/v3/subagents/wave4_residual_cd74_scout_report.md`.

Scout conclusion: demote residual CD74/HLA receptor-state to biomarker-only.

Key rationale:

- MS white-matter microglia is the only credible residual signal.
- Sjogren epithelial signal is weak and mostly IFN-explained
  (`target_vs_ifn_r2` 0.902).
- T1D ductal/acinar CD74/HLA support collapses under IFN residualization.
- Direct therapeutic handles are prior-arted, too broad, or weakly druggable.

Integration decision: residual CD74/HLA is no longer an active central-node
lane. It remains a useful enrichment/PD biomarker for resident-cell APC-like
state. The only active lane after this integration is `LIPA`/lipid-lysosomal,
and even that is now compartment-specific rather than pan-autoimmune.

## 2026-05-26 22:11 UTC

Integrated Boole's `LIPA` scout report:
`phases/v3/subagents/wave4_lipa_scout_report.md`.

Scout conclusion: demote `LIPA` as a V3 central cross-autoimmune node.

Key rationale:

- `LIPA` is not gene-level significant in MS white-matter microglia; MS support
  is module-level only.
- Direct h5ad positives are epithelial/structural: T1D ductal, psoriasis
  keratinocyte, and weak Crohn epithelial.
- Myeloid/APC compartments contradict: Crohn myeloid and UC myeloid are
  nominally negative; Sjogren APC trends negative.
- No broad cross-autoimmune genetic anchor is present.
- A 2026 white-matter injury/remyelination LAL/Lipa paper blocks broad novelty
  for an MS repair claim.

Integration decision: all current central-node lanes are demoted or on hold by
hour 4. This is not exhaustion; it is a forced pivot. Next direction should
search for a different cross-disease node that explains the lipid-lysosomal /
resident-cell stress observations without requiring directionally inconsistent
single-gene claims. Priority candidates from first-pass breadth and available
genetics include `OSMR/OSM`, complement/C1q, and `IRF1`-anchored tissue
licensing, with the explicit requirement that any new lane pass residual and
prior-art guardrails before being promoted.

## 2026-05-26 22:13 UTC

Closed wave-4 completed agents and dispatched wave 5:

- Euclid `019e6656-7b7c-7e81-954d-124054878be8`: `OSM/OSMR`
  tissue-licensing axis scout. Deliverable:
  `phases/v3/subagents/wave5_osmr_scout_report.md`.
- Helmholtz `019e6656-7c43-7e83-ab04-a16bd2b37e42`: complement/C1q
  resident-myeloid axis scout. Deliverable:
  `phases/v3/subagents/wave5_complement_scout_report.md`.
- Jason `019e6656-7d69-7792-b565-89dc5e55f343`: local OSMR/complement
  quantification worker. Deliverable:
  `phases/v3/subagents/wave5_local_quant_report.md`.

Pivot standard: no promotion unless a candidate shows direction-stable,
compartment-plausible cross-disease evidence after basic residual controls and
has a clearer intervention path than the demoted hour-4 lanes.

## 2026-05-26 22:15 UTC

Dispatched wave 6 foundation-model fallback worker:

- Nash `019e665a-f973-75d1-ae8c-456de8c05f77`: test whether a real
  named-gene cellular/genomic foundation-model perturbation can be run locally
  for `OSM/OSMR/IL6ST/STAT3/SOCS3`, complement/C1q candidates, and residual
  IFN/CD74 controls. Deliverable:
  `phases/v3/subagents/wave6_foundation_named_gene_report.md`.

Reason: Arc State has quantitative anonymous IFN-gamma calibration but still
lacks named-gene interpretability until the full `adata_real.h5ad` is readable.
The central-node claim cannot rely on foundation-model evidence unless a named
gene route becomes real, reproducible output rather than a model aspiration.

## 2026-05-26 22:23 UTC

Integrated wave-5 reports:

- Helmholtz `phases/v3/subagents/wave5_complement_scout_report.md`: complement/C1q
  no-go as V3 central node. MS chronic-active lesion and lupus nephritis
  biology are real but disease-specific, directionally inconsistent in local
  donor-level myeloid data, and heavily prior-arted for complement blockade.
- Jason `phases/v3/subagents/wave5_local_quant_report.md`: local OSM/OSMR passes only
  as a continuation signal in Crohn, UC, and T1D epithelial/ductal-like
  compartments; C1q/complement no-go.
- Euclid `phases/v3/subagents/wave5_osmr_scout_report.md`: OSM/OSMR no-go for V3
  central-node status because MS evidence is absent/ambiguous, local OSMR
  expression is not direction-stable, and IBD/RA/skin prior art is direct.

Supplemental orchestrator analysis `scripts/v3_analyze_osmr_complement_axes.py`
expanded the local pass to stromal/endothelial compartments. It reproduced the
main pattern: OSM/OSMR is strongest in UC/Crohn/T1D tissue compartments and
complement remains inconsistent. Neither axis currently satisfies MS anchoring,
five-disease breadth, or novelty.

Decision: do not promote OSM/OSMR or complement. The next step is a broader
gene-level discovery pass over local single-cell matrices plus existing MS and
cross-disease evidence, because repeated hand-picked rescue of the lipid module
is producing comparator biology rather than a DoD-grade therapeutic claim.

2026-05-26 22:27 UTC - Wave 6 foundation fallback completed: `phases/v3/subagents/wave6_foundation_named_gene_report.md` created; State remains blocked for named genes, Geneformer V2-104M scratch inference ran on real local cells with weak/non-decisive OSMR/complement support.

## 2026-05-26 22:31 UTC

Orchestrator broad-discovery pivot completed:

- Added and ran `scripts/v3_broad_h5ad_gene_discovery.py`.
- Output: 282,630 donor-level gene contrasts across 17 local h5ad
  disease/compartment analyses; 25,176 ranked genes.
- Top broad signals are mostly generic antiviral/chromatin/tissue-stress
  markers, not final targets.
- Current focused candidates:
  - `LTA4H`: best druggable lipid-mediator enzyme emerging from the screen,
    MS-positive and positive in Crohn/UC myeloid plus T1D acinar.
  - `CHI3L1`: strong MS/stromal injury comparator but likely biomarker/prior-art
    heavy.
  - `C15ORF48` and `SNX10`: strong marker candidates, weak intervention
    tractability.

Added `scripts/v3_geneformer_candidate_delete_screen.py` to apply the real
Geneformer V2-104M named-gene route from Wave 6 to the new candidate set.

## 2026-05-26 22:34 UTC

Integrated Geneformer candidate deletion screen:

- `LTA4H` demoted: expression screen was attractive, but Geneformer deletion
  support is zero by the posthoc rule (4 contexts with token, 6 disease cells,
  aggregate cosine/projection shifts negative), and LTA4H inhibitor prior art in
  inflammatory disease/MS-EAE is blocking.
- `CHI3L1` retained only as tissue-injury/fibrosis comparator: expression
  support is strong, model support mixed, and MS biomarker/prior-art burden is
  high.
- `IFITM3` and `CBX3` are the strongest Geneformer/broad-expression markers,
  but are not suitable final therapeutic nodes now: `IFITM3` lacks MS positivity
  in GSE111972 and is generic antiviral/IFN biology; `CBX3` lacks a clear
  lipid-lysosomal/druggable intervention path.

Decision: no current candidate satisfies V3 DoD. Continue pivoting; do not
force `LTA4H` or `CHI3L1`.

2026-05-26 22:40 UTC - Wave 7 lipid-myeloid target scout completed:
`phases/v3/subagents/wave7_lipid_myeloid_target_scout_report.md` created. Best
computational handoff is `LGALS3` only as a fail-fast test; `LTA4H` remains
demoted after Geneformer/prior-art integration. `GPNMB` is marker/PD only;
cathepsins, `SPP1/CD44`, TAM/TREM2, `LRP1/CALR`, `PLA2G7`, `TBXAS1`, and
`MGLL/MAGL` are hold/no-go comparators, not final findings.

## 2026-05-26 22:41 UTC

Actual hour-4 checkpoint written:

- `MILESTONE_2.md`

The mandatory hour-4 content is partially met: cross-disease shared genes and
cell states have been enumerated with statistics, and first-pass central-node
candidates are ranked. Foundation-model predictions are traceable but currently
weak: State is feature-agnostic only because the readable `adata_real.h5ad`
lacks gene symbols; Geneformer V2-104M named-gene deletion supports `IFITM3`
most strongly but that marker lacks MS-positive direction in the current MS
anchor.

Integration decision:

- Do not promote `IFITM3`, `CBX3`, `LTA4H`, `CHI3L1`, OSM/OSMR, or complement.
- Move the hour-4 to hour-6 forcing question to lipid-lysosomal
  receptor/effector candidates with intervention plausibility: `FABP5`, `MSR1`,
  `SCARB2`, and glycan-checkpoint comparators (`LGALS1/LGALS3`).
- Keep RA direct h5ad acquisition active only opportunistically because the
  `E-MTAB-8322` route has repeatedly timed out.

## 2026-05-26 22:44 UTC

Dispatched wave 8 sidecar workers:

- Feynman `019e6673-c40a-7240-a7d7-d2c497fe690f`: target/prior-art and
  druggability scout for `FABP5`, `MSR1`, `SCARB2`, `LGALS1`, `LGALS3`, with
  required search queries, source links, patent/trial red flags, and
  go/no-go/uncertain ratings. Deliverable:
  `phases/v3/subagents/wave8_target_prior_art_druggability_report.md`.
- Avicenna `019e6673-e045-7e02-a867-290b2125c823`: local data-breadth scout
  for the same candidates and adjacent lipid-lysosomal/glycan-checkpoint genes,
  using `phases/v3/results/broad_h5ad_gene_discovery/` and other local evidence.
  Deliverable: `phases/v3/subagents/wave8_candidate_breadth_report.md`.

Local orchestrator task while wave 8 runs: produce a focused candidate triage
table from the actual result files and test whether any of these candidates
deserves deeper foundation-model or perturbation analysis.

## 2026-05-26 22:56 UTC

Integrated wave-7 handoff and ran a fail-fast LGALS3/glycan-checkpoint test:

- Added `scripts/v3_lgals3_glycan_checkpoint_analysis.py`.
- Added the script to `scripts/entrypoints/run_v3_analysis.sh`.
- Output directory: `phases/v3/results/lgals3_glycan_checkpoint/`.

Result:

- `LGALS3` is demoted as a V3 central node despite MS foamy/MIMS2 support.
- Candidate crosswalk shows `LGALS3` has direct positive disease count 0,
  direct negative disease count 4, direct negative compartment count 5, and 0
  residual-retained positive tests in local h5ad data.
- The negative local compartments are Crohn myeloid/stromal, UC myeloid,
  psoriasis keratinocyte, and T1D stellate.
- `LGALS3` remains a valid MS foamy-state / repair-risk comparator, not an
  integrated cross-autoimmune target.

Residual positives that survived the harder test are not yet target claims:

- `CD44`: residual-positive in Crohn/UC epithelial contexts and MS-positive,
  but prior-art/integrin biology is crowded and tissue-injury confounding is
  high.
- `TYROBP`: residual-positive in Sjogren epithelium and UC myeloid contexts,
  but intervention direction is difficult because it may represent repair or
  phagocytic activation rather than a safe blockade target.
- Cathepsins `CTSB/CTSL`: residual-positive in psoriasis/Crohn contexts, but
  known lysosomal/APC and repair-liability problems remain.

Decision: do not promote LGALS3. The next forcing question becomes whether
`TYROBP`/DAP12-phagolysosomal signaling or `CD44`/matrix-retention is a
broader residualized mechanism, and whether either can clear novelty,
druggability, and foundation-model constraints.

## 2026-05-26 22:50 UTC

Integrated Avicenna wave-8 data-breadth report:

- `phases/v3/subagents/wave8_candidate_breadth_report.md`
- `phases/v3/subagents/wave8_candidate_breadth_contrast_extract.tsv`

Key vetted conclusions:

- The five named post-hour-4 candidates (`FABP5`, `MSR1`, `SCARB2`, `LGALS1`,
  `LGALS3`) are weak on direct cross-disease h5ad breadth.
- `FABP5` is best of those five but conflicted within UC and likely
  prior-arted.
- `MSR1` and `SCARB2` have MS-positive signals but no direct local positive
  non-MS breadth.
- `LGALS3` is directly contradicted by the orchestrator's residualized
  fail-fast analysis.
- Avicenna's next-validation panel is `ACSL3`, `APOC1`, `CD44`, `LAMP3`,
  `CTSL`, with `CHI3L1` only as benchmark.

Action:

- Closed Avicenna after return.
- Started `scripts/v3_geneformer_phagolysosomal_matrix_screen.py` to test
  the overlapping residual/breadth candidates (`CD44`, `TYROBP`, cathepsins)
  and conflicted lipid/glycan comparators with the same named-gene Geneformer
  deletion route used for the `LTA4H` veto.

## 2026-05-26 22:56 UTC

Integrated Feynman wave-8 target/prior-art/druggability report:

- `phases/v3/subagents/wave8_target_prior_art_druggability_report.md`

Vetted conclusion:

- `FABP5`, `MSR1`, `SCARB2`, `LGALS1`, and `LGALS3` should not be promoted.
- `FABP5` is tractable but directionally conflicted and has direct EAE/MS and
  psoriasis prior-art risk.
- `MSR1` and `SCARB2` are mechanistically plausible but poor or unclear
  intervention points.
- `LGALS1/3` are crowded, broad immunoregulatory/repair-risk axes.
- Feynman's proposed pivots are `LGALS8`, `UGCG/GBA2`, and `CD300F`; these
  must pass local expression/breadth before any elevation.

Closed Feynman after report return.

## 2026-05-26 23:00 UTC

Geneformer phagolysosomal/matrix deletion screen completed:

- Script: `scripts/v3_geneformer_phagolysosomal_matrix_screen.py`
- Output directory: `phases/v3/results/geneformer_phagolysosomal_matrix_delete/`
- Added to `scripts/entrypoints/run_v3_analysis.sh`.

Key result:

- `CTSB`: strongest model-normalization signal among this family
  (7 contexts, 34 disease cells, mean cosine shift 0.000173, mean projection
  shift 0.0134, support contexts 3, positive-projection contexts 6).
- `CTSL`: support contexts 3 but mean projection shift negative; weaker than
  `CTSB`.
- `CD44`: 9 contexts and 75 disease cells with token, but support contexts 0,
  mean cosine shift -0.000296, mean projection shift -0.00506. This vetoes
  promotion despite residualized Crohn/UC epithelial expression support.
- `TYROBP`: weak/negative aggregate support (support contexts 1, mean cosine
  shift -0.000311, mean projection shift -0.0162).
- `LGALS3`: remains weak/negative aggregate support (support contexts 1,
  mean cosine shift -0.000124, mean projection shift -0.0291).

Decision:

- Do not promote `CD44`, `TYROBP`, or `LGALS3`.
- Cathepsins become the strongest surviving model-supported biology, but not a
  final target yet because cathepsin inhibition is crowded and may impair debris
  clearance/repair. Next test should include Avicenna's broader panel
  (`ACSL3`, `APOC1`, `CD44`, `LAMP3`, `CTSL`) and Feynman's pivots (`LGALS8`,
  `UGCG`, `GBA2`, `CD300F`) against direct local breadth and prior-art gates.

## 2026-05-26 23:01 UTC

Added and ran `scripts/v3_pivot_panel_triage.py`.

Purpose:

- Replace ad hoc pivot selection with an auditable routing table integrating
  broad h5ad statistics, the MS white-matter signature, previous local evidence,
  and existing Geneformer screens.

Key routing result:

- `APOC1` is the only current candidate routed to new foundation-model testing.
  It has MS white-matter positive signal plus direct positives in T1D acinar,
  Sjogren epithelial, and UC epithelial compartments, with one UC stromal
  negative.
- `CTSL` and `CTSB` remain model-supported comparator biology, not target
  nominations, because of cathepsin repair/debris-clearance liability and
  crowded prior art.
- `ACSL3`, `LAMP3`, `CD300E`, `CD300LF`, `LGALS8`, `UGCG`, `GBA2`, `TYROBP`,
  `APOE`, and `PLIN2` fail the MS anchor gate or local directionality gate.

Dispatched wave 9 sidecars:

- Pasteur `019e6682-f55c-7290-9517-d8c2a86dc9d9`: APOC1 prior-art,
  druggability, and translational feasibility audit.
- Hilbert `019e6682-f57d-7d62-a4d2-d081ebea33a6`: APOC1 genetics and
  causal-anchoring audit, especially APOC1-vs-APOE locus separability.

Local orchestrator task:

- Run `scripts/v3_geneformer_pivot_panel_screen.py` to test whether APOC1 token
  deletion normalizes disease-cell embeddings across IBD, psoriasis, Sjogren,
  and T1D contexts.

## 2026-05-26 23:09 UTC

APOC1 failed the foundation-model perturbation gate:

- `scripts/v3_geneformer_pivot_panel_screen.py`
- `APOC1`: 3 contexts with token, 4 disease cells with token, support contexts
  0, mean cosine z vs random -1.0917, mean projection shift -0.0171.

Routing decision:

- Demote APOC1 as an intervention hypothesis. It remains a low-frequency local
  marker but not a model-supported perturbable node.

Reopened unrestricted broad h5ad survivor scan:

- Added `scripts/v3_unrestricted_survivor_scan.py`.
- Added `scripts/v3_geneformer_unrestricted_survivor_screen.py`.
- Added both scripts to `scripts/entrypoints/run_v3_analysis.sh`.

Second-pass foundation-model result:

- `SNX10` is the strongest model-supported survivor: contexts with token 7,
  disease cells with token 25, support contexts 4, strong support contexts 1.
- Local expression support: MS white-matter `delta_log2=0.712`, `p=0.0127`;
  Crohn myeloid +1.945, `p=1.21e-4`; UC myeloid +1.306, `p=0.00257`;
  T1D endothelial +2.531, `p=0.00285`; T1D stellate +1.719, `p=0.0169`.

Sidecar integration:

- Banach returned `phases/v3/subagents/wave10_survivor_cell_state_biology_report.md`.
  Vetted conclusion: the unrestricted survivors split into inflammatory
  myeloid/immunometabolic (`C15ORF48`, `SNX10`), barrier/stromal/endothelial
  remodeling (`FMNL2`, `SDC4`, `ABHD2`), and generic stress/survival tails.

SNX10 novelty/targetability check:

- Web/PubMed search found direct IBD prior art: SNX10 macrophage/colitis
  literature, an SNX10 inhibition mucosal-healing paper, and DC-SX029 listed as
  an SNX10-PIKFYVE PPI inhibitor for IBD research.
- Decision: hold SNX10 as a mechanistic comparator and possible cross-disease
  extension clue, not a final target. It does not yet meet V3 breadth or novelty
  requirements.

## 2026-05-26 23:20 UTC

Resumed after interruption and reopened the V3 critical path.

Current integration state:

- `APOC1` remains demoted after foundation-model failure.
- `SNX10` is the best local model-supported survivor, but direct IBD target
  prior art and insufficient disease breadth block promotion.
- `C15ORF48` is a strong inflammatory-myeloid expression marker but is blocked
  by the current Geneformer token dictionary and has unclear targetability.
- `CTSB/CTSL/CTSS` and `IFI30` remain mechanistic comparators rather than final
  targets because of repair/debris-clearance liabilities, generic antigen-
  processing biology, and/or prior-art crowding.

Dispatched wave 11 sidecars:

- Beauvoir `019e6696-5535-7fe3-b296-7cd6b913bee6`: genetics and prior-art
  scout across current survivors and adjacent lipid-lysosomal myeloid nodes.
- Ampere `019e6696-7597-71d0-b6d8-a66b6a871a2d`: cross-domain intervention
  scout for non-generic ways to modulate the lipid-lysosomal inflammatory
  myeloid module.

Attempted to dispatch a wave 11 hostile critic, but the agent thread limit was
reached. I will either close completed agents or use local critique until a slot
is available.

## 2026-05-26 23:23 UTC

Integrated Lorentz wave-10 unrestricted survivor target scout:

- Report: `phases/v3/subagents/wave10_unrestricted_survivor_target_scout.md`
- Top-line vetted result: no clean target among unrestricted survivors.
- `SNX10` and `C15ORF48` remain the only plausible fail-fast rescue hypotheses,
  but neither is a promotion candidate: `SNX10` is prior-arted and weakly
  targetable; `C15ORF48` is biologically coherent but model-blocked and has
  poor modality clarity.
- `PPP3CA`, `CXCL9`, `IL2RG`, `BIRC3`, and `SDC4` are mostly blocked by prior
  art, safety, or generic immunosuppression / repair-risk biology.
- `FMNL2`, `SEL1L3`, `PLEK2`, and `DAP` are too marker-like or poorly
  targetable for a V3 therapeutic finding.

Closed Lorentz to free an agent slot.

## 2026-05-26 23:27 UTC

Integrated wave-9 APOC1 sidecars:

- Pasteur report: `phases/v3/subagents/wave9_apoc1_prior_art_druggability_report.md`
- Hilbert report: `phases/v3/subagents/wave9_apoc1_genetics_report.md`

Vetted conclusion:

- `APOC1` is a no-go as a novel cross-autoimmune therapeutic target.
- Prior-art blockers span MS biomarker work, RA APOC1+ fibroblast preprint
  evidence, UC/DSS APOC1-JNK/P38 work, T1D serum/CETP physiology, Hashimoto
  APOC1-pyroptosis, and broad microglial siRNA patent language naming APOC1/MS.
- Genetics audit found no acceptable APOC1-specific autoimmune anchoring; the
  APOE/APOC1 locus is a proxy-risk region and exact GWAS/FinnGen disease
  endpoint checks did not support a causal target claim.

Closed Pasteur and Hilbert after integration.

## 2026-05-26 23:35 UTC

Integrated wave-11 sidecars and closed Beauvoir, Ampere, and Singer:

- Ampere report:
  `phases/v3/subagents/wave11_cross_domain_intervention_scout_report.md`
- Singer report:
  `phases/v3/subagents/wave11_hostile_critique_report.md`
- Beauvoir report:
  `phases/v3/subagents/wave11_genetics_prior_art_scout_report.md`

Vetted conclusion:

- No current survivor is a V3-ready therapeutic finding.
- `SNX10`-PIKFYVE remains the best fail-fast mechanistic comparator but is
  direct-IBD-prior-arted and lacks target genetics.
- `C15ORF48` remains a coherent inflammatory mitochondrial/autophagy state
  marker but lacks a current model route, genetics, and modality.
- TYK2/JAK/IFN is the positive-control genetics/clinical tractability axis but
  is saturated by drugs and prior art.
- `IFI30` is MS-genetics-compatible as an antigen-processing state marker, not
  a cross-autoimmune intervention.
- Direct cathepsin and generic IFN/APC routes remain blocked by prior art,
  safety, and repair/debris-clearance liabilities.

Local execution added a stricter post-APOC1 no-go gate:

- Script: `scripts/v3_snx10_c15orf48_residual_gate.py`
- Output:
  `phases/v3/results/snx10_c15orf48_residual_gate/snx10_c15orf48_residual_gate.tsv`
- `scripts/entrypoints/run_v3_analysis.sh` now runs the gate.

Residual-gate result:

- `SNX10`: raw positive in Crohn and UC myeloid only; retained residual signal
  remains IBD-only; strict core-covariate surviving analysis count = 0.
- `C15ORF48`: raw positive in Crohn myeloid, UC myeloid, and T1D endothelial;
  one non-IBD retained residual signal appears in T1D endothelial, but strict
  core-covariate surviving analysis count = 0.

Decision:

- Demote `SNX10` and `C15ORF48` as V3 target anchors. They can stay as state
  markers/comparators but not as promoted central nodes.
- The next route must stop trying to rescue unrestricted survivor genes and
  instead search for a different intervention point or cross-disease circuit
  that survives strict covariate, genetics/prior-art, and model-perturbation
  gates.

## 2026-05-26 23:47 UTC

Integrated wave-12 broad residual pivot:

- Added and ran `scripts/v3_broad_residual_gate.py`.
- Added and ran `scripts/v3_geneformer_broad_residual_screen.py`.
- Added both scripts to `scripts/entrypoints/run_v3_analysis.sh`.
- Reports integrated:
  - `phases/v3/subagents/wave12_broad_residual_genetics_prior_art_report.md`
  - `phases/v3/subagents/wave12_hostile_critique_report.md`

Broad residual-gate result:

- The top strict residual survivors were `ATOX1`, `SQLE`, `TPM4`, `LDLRAD3`,
  `C1QTNF1`, `HIF1A`, `CBX3`, `CFB`, and `TIMP1`.
- Most strict survival was IBD stromal (`ibd_crohn_stromal` and/or
  `ibd_uc_stromal`), not a cross-autoimmune myeloid or MS-anchored signal.
- The broad-residual top rows are mostly copper/sterol/cytoskeletal/stromal/
  complement/hypoxia/matrix biology rather than the original lipid-lysosomal
  myeloid module.

Geneformer broad residual screen:

- Output:
  `phases/v3/results/geneformer_broad_residual_delete/geneformer_broad_residual_gene_summary.tsv`
- Strongest model-supported genes were `SEC61B`, `MTHFD2`, `HIF1A`,
  `SEC61A1`, `TMSB10`, `RPL17`, `TPM4`, `DAP`, and `SQLE`.
- This is a generic ER-translocation/metabolic/structural/stress profile, not
  a coherent therapeutic target mechanism.

Vetted wave-12 sidecar result:

- Genetics/prior-art scout: no broad residual-gate candidate clears
  cross-autoimmune genetics, plausible modality, and non-blocking prior art.
  `CFB` is the strongest druggable/genetics comparator but is saturated by
  complement/factor-B therapeutic prior art. `ATOX1` and `SQLE` remain only
  fail-fast biology/modeling scouts.
- Hostile critique: the pivot is hypothesis drift and mostly IBD stromal
  residual biology; do not write `FINDING_V3` around the broad residual
  candidates.

Decision:

- Demote the broad residual-gate leaders as therapeutic candidates.
- Treat the result as evidence that the current local data stack is
  over-selecting generic diseased-tissue, stromal-remodeling, secretory, and
  metabolic programs after each stricter filter.
- Next pivot: improve breadth and independence rather than continue
  candidate-shopping inside the same local h5ad panel. Priority is to add
  independent RA/SLE or other missing autoimmune tissue data if a tractable
  public download route exists.

## 2026-05-26 23:55 UTC

Restarted the disease-breadth pivot after resolving the earlier CELLxGENE route
confusion.

Local actions:

- Queried the CELLxGENE Census `census_info/datasets` metadata table directly
  instead of relying on guessed REST endpoints or the hanging
  `get_source_h5ad_uri()` helper.
- Resolved RA source h5ad version
  `dbed890d-a14a-4502-a413-b57a4650d3af.h5ad` for dataset
  `d18736c3-6292-4379-919a-d6d973204c87` (108,717 cells, 247 MB).
- Resolved SLE source h5ad version
  `4118e166-34f5-4c1f-9eed-c64b90a3dace.h5ad` for dataset
  `218acb0f-9f2f-4f76-b90b-15a4b7c7f629` (1,263,676 cells, 11.3 GB).
- Downloaded the RA h5ad to
  `data/raw_v3/cell_state/ra_binvignat_blood.h5ad`, MD5
  `e66d70ceffdaa99f824181d06cd76302`.
- Added a `ra_blood_myeloid` direct h5ad config covering classical monocytes,
  non-classical monocytes, and myeloid dendritic cells.

Subagent wave 13 dispatched:

- Linnaeus (`019e66b7-1269-77d0-af1b-e507a92755c1`): disease-atlas expansion
  scout for tractable additional autoimmune single-cell/spatial datasets.
- Dewey (`019e66b7-1318-7e32-b0e5-32592a3c2ebd`): genetics/prior-art re-open
  around lipid-lysosomal inflammatory myeloid/APC candidate nodes.
- Schrodinger (`019e66b7-13d1-7081-8199-8f8b38c5b430`): perturbation and
  foundation-model intervention scout.

Decision:

- Count RA as the immediate local critical-path expansion.
- Treat SLE full h5ad download as too large for a casual branch; use Census
  targeted extraction, a smaller derived asset, or a subagent-identified
  alternative route before spending another 11.3 GB download.

## 2026-05-27 00:07 UTC

RA expansion integrated:

- Direct h5ad cell-state, direct gene-replication, and OSMR/complement-axis
  scripts were rerun with `ra_blood_myeloid`.
- RA blood myeloid did not support the lipid-lysosomal / IFN-HLA / MIF-CD74
  positive module pattern:
  - lipid-loader mean-score delta 0.0126, Hedges g 0.263, p 0.426;
  - IFN/APC mean-score delta -0.0460, g -0.249, p 0.450;
  - HLA-II/APC mean-score delta -0.0678, g -0.450, p 0.176;
  - MIF/CD74 receptor-state mean-score delta -0.0451, g -0.266, p 0.420.
- OSMR/complement axis summary now has zero nominal RA positives for both
  `osm_osmr` and `complement_c1q`.

SLE targeted branch:

- Added `scripts/v3_analyze_sle_census_targeted.py` to query Perez et al. SLE
  PBMCs through CELLxGENE Census selected-gene extraction instead of full
  11.3 GB h5ad download.
- Added an opt-in `RUN_SLE_CENSUS_TARGETED=1` branch to `scripts/entrypoints/run_v3_analysis.sh`.
- The SLE selected-gene extraction is running as a remote/CPU-heavy job.

Integrated Schrodinger wave-13 perturbation scout:

- Report: `phases/v3/subagents/wave13_perturbation_intervention_scout.md`.
- Vetted result: perturbation support is strongest for the
  IFNG/IFNGR/JAK/STAT1 -> CIITA/RFX5 -> MHC-II/CD74 transition.
- Broad JAK/IFNGR is retained only as a positive control and prior-arted
  non-novel comparator.
- `RFX5/CIITA` and `GSK3B` are testable intervention-controller scouts, not yet
  therapeutic leads. They require genetics, disease-breadth, tissue-specific
  safety, and novelty checks.

Decision:

- The central-node search must now account for an explicit RA contradiction.
- Continue SLE and disease-atlas expansion before promoting any IFN/APC or
  lipid-lysosomal node.

## 2026-05-27 00:36 UTC

Wave-13 agent handles were closed after their written reports were preserved in
`phases/v3/subagents/`. No files were reverted.

Wave-14 dispatched:

- Lagrange (`019e66dd-4d80-7371-9589-f0476206c5a0`): hour-6 hostile critique
  of the current IFNG/HLA-II/CD74 central-state direction, including RA
  contradiction, celiac marker-derived evidence, foundation-model weaknesses,
  prior art, and DoD gaps.
- Darwin (`019e66dd-761b-7d13-aaba-d87e93e18e4f`): GSK3B/CIITA perturbation
  worker. Assigned write scope:
  `scripts/v3_wave14_gsk3b_ciita_perturbation.py`,
  `phases/v3/results/wave14_gsk3b_ciita_perturbation/`,
  `data/raw_v3/wave14_gsk3b_ciita/`, and
  `phases/v3/subagents/wave14_gsk3b_ciita_perturbation.md`.
- Hypatia (`019e66dd-94f5-7932-836a-ff28648e5918`):
  SLC15A4/TASL/IRF5 fail-fast worker. Assigned write scope:
  `scripts/v3_wave14_slc15a4_tasl_failfast.py`,
  `phases/v3/results/wave14_slc15a4_tasl_failfast/`, and
  `phases/v3/subagents/wave14_slc15a4_tasl_failfast.md`.
- Mendel (`019e66dd-b315-7880-819b-3285b7d40bfc`): myasthenia gravis breadth
  worker around `GSE227835` or a tractable fallback. Assigned write scope:
  `scripts/v3_wave14_gse227835_myasthenia_marker.py`,
  `phases/v3/results/wave14_gse227835_myasthenia/`,
  `data/raw_v3/gse227835/`, and
  `phases/v3/subagents/wave14_myasthenia_breadth.md`.

Integration decision:

- The working central-state hypothesis is now the
  IFNG/IFNGR/JAK/STAT1 -> CIITA/RFX5 -> HLA-II/CD74 antigen-presentation
  transition, not the original lipid-loader module.
- Candidate therapeutic handles remain unpromoted. The current intervention
  scouts are `GSK3B`/CIITA/RFX5 as a narrow HLA-II gate and
  `SLC15A4`/TASL/IRF5 as an endolysosomal APC checkpoint. Both must survive
  perturbation, breadth, genetics, and prior-art scrutiny before any V3 finding.

## 2026-05-27 00:46 UTC

Hour-6 critique integrated:

- Lagrange report:
  `phases/v3/subagents/wave14_hour6_hostile_critique.md`.
- Verdict accepted: IFNG/HLA-II/CD74 is a recurrent autoimmune state, not a
  defensible therapeutic central node with current evidence.

Orchestrator-side gate work:

- Added `scripts/v3_wave14_candidate_gate_matrix.py`.
- Ran it with `.venv_v3_py312/bin/python`.
- Output:
  `phases/v3/results/wave14_candidate_gate_matrix/wave14_candidate_gate_matrix.tsv`.
- Gate result: `SLC15A4/TASL/IRF5` and `PTPN2` are the only candidates passing
  simple expression+genetics gates; both are crowded, and `PTPN2` has poor
  direct therapeutic direction.

Foundation-model focused screen:

- Added and ran
  `scripts/v3_wave14_geneformer_narrowed_candidate_screen.py`.
- Output:
  `phases/v3/results/wave14_geneformer_narrowed_candidate_delete/`.
- Result: Geneformer did not support broad control-like normalization for
  `SLC15A4`, `IRF5`, `GPR65`, `GSK3B`, `CIITA`, `RFX5`, `CD74`, or `CTSS`.
  It gave the most support to `PTPN2`, `TNFAIP3`, and `SH2B3`, which are
  genetic negative-regulator anchors rather than clean direct drug targets.

New sidecar:

- Tesla (`019e66e5-1f91-7ce0-b627-f75413f58284`): target-level genetics worker
  for narrowed candidates. Assigned write scope:
  `scripts/v3_wave14_target_level_genetics.py`,
  `phases/v3/results/wave14_target_level_genetics/`, and
  `phases/v3/subagents/wave14_target_level_genetics.md`.

## 2026-05-27 00:49 UTC

Integrated Hypatia wave-14 SLC15A4/TASL fail-fast.

- Report: `phases/v3/subagents/wave14_slc15a4_tasl_failfast.md`.
- Outputs: `phases/v3/results/wave14_slc15a4_tasl_failfast/`.
- Accepted recommendation: no-go for cross-autoimmune central/intervention
  nomination.

Reason:

- The branch passed the crude gate matrix only as a composite circuit, but the
  focused worker showed no FDR10 local recurrence, IRF5-heavy/SLE-heavy
  genetics, no direct branch perturbation evidence, and blocking lupus/TLR
  prior art.

Decision:

- Demote `SLC15A4/TASL/IRF5` to comparator biology.
- Continue remaining active lines: GSK3B/CIITA perturbation, target-level
  genetics, and independent disease breadth.

## 2026-05-27 00:53 UTC

Completed orchestrator feedback-vs-brake test for the negative-regulator
branch.

- Script: `scripts/v3_wave14_negative_regulator_feedback_test.py`.
- Output: `phases/v3/results/wave14_negative_regulator_feedback/`.
- Result: `PTPN2`, `SH2B3`, and `TNFAIP3` do not show repeated donor-level
  anticorrelation with IFN/HLA/CD74 modules. `PTPN2` and `SH2B3` mostly
  correlate positively with the inflammatory state; `TNFAIP3` is mixed.

Decision:

- Do not promote `PTPN2`/`TNFAIP3`/`SH2B3` as expression-defined therapeutic
  brakes.
- Keep them as genetic anchors pending Tesla's target-level genetics report.

## 2026-05-27 00:56 UTC

Integrated Darwin wave-14 GSK3B/CIITA perturbation scout.

- Report: `phases/v3/subagents/wave14_gsk3b_ciita_perturbation.md`.
- Outputs: `phases/v3/results/wave14_gsk3b_ciita_perturbation/`.
- Accepted verdict: public macrophage perturbation data support `GSK3B` as a
  testable upstream controller of IFN-gamma-induced CIITA/MHC-II/CD74, but not
  as a final therapeutic finding.

Integration decision:

- Keep `GSK3B` in the active scout lane only.
- Immediate required gates: local cross-autoimmune expression/marker
  recurrence for `GSK3B`/`MED16`, target-level genetics, prior-art saturation,
  and selectivity liabilities.

## 2026-05-27 00:03 UTC

Completed wave-13 genetics/prior-art reopen requested for central nodes around
the lipid-lysosomal inflammatory myeloid/APC module.

New report:

- `phases/v3/subagents/wave13_genetics_prior_art_reopen.md`

New verification artifact:

- `phases/v3/tmp/wave13_opentargets_gwas_credible_sets.tsv`

Result:

- The demoted local-expression hits remain demoted.
- `GPR65` emerged as the best non-saturated fail-fast scout: scoped Open
  Targets credible-set evidence in MS, Crohn, UC, psoriasis, and AS; direct GPCR
  druggability; strong pH/endolysosomal/myeloid proximity; but directionality is
  unresolved across IBD-protective versus EAE/Th17 contexts.
- `SLC15A4`/`TASL`/`IRF5` emerged as the strongest endolysosomal APC checkpoint
  branch. It has strong mechanistic fit and emerging chemical matter, but
  `SLC15A4` is SLE-heavy in scoped genetics and the lane is already prior-arted
  by inhibitors, patents, and TLR7/8 clinical programs.
- `TNFAIP3`, `PTPN2`, `CLEC16A`, `SH2B3`, and `IL10` are strong genetic anchors
  with poor or wrong-direction direct modality.
- `OSMR`, `IL6R`, `TYK2`, `CFB`, `CTSS`, and `MIF/CD74` remain prior-arted
  comparator or stratification lanes, not final target claims.

Decision:

- Next computational branch should test `GPR65` and `SLC15A4`/`TASL`/`IRF5`
  fail-fast perturbation logic, while using the strong genetic negative
  regulators as genotype-to-module anchors and the saturated target classes as
  comparators.
- No final V3 therapeutic finding is claimed from wave 13.

## 2026-05-27 01:00 UTC

Completed orchestrator local gate for the `GSK3B`/CIITA perturbation scout.

- Script: `scripts/v3_wave14_gsk3b_local_gate.py`.
- Outputs: `phases/v3/results/wave14_gsk3b_local_gate/`.
- Repair made before rerun: Europe PMC and ClinicalTrials.gov API failures are
  now recorded as errors instead of aborting the analysis; an unused grouping
  loop was removed.

Key results:

- `CD74` remains the broadest recurrent state marker among the checked genes:
  3 FDR10-positive diseases and 5 trend-or-better diseases across the local
  atlas panel.
- `CIITA` and `RFX5` had 2 FDR10-positive diseases and 3 trend-or-better
  diseases each, consistent with the state transition but not sufficient as
  drug targets.
- `GSK3B` had only 1 FDR10-positive disease and 2 trend-or-better diseases
  (`Crohn disease`, `ulcerative colitis`); MS microglia were negative/null
  (`delta_log2 = -0.132`, `hedges_g = -0.311`, `p = 0.475`).
- Donor-level correlations with IFN/HLA/CD74 modules were modest for `GSK3B`
  (`median Spearman r = 0.262`; 35/192 tests with r > 0.5), far below `CD74`
  (`median r = 0.829`) and `CIITA` (`median r = 0.575`).
- Prior-art saturation is high: Europe PMC hit counts were 3,576 for
  `GSK3B`+autoimmune, 13,366 for `GSK3 inhibitor`+autoimmune, and 1,073 for
  `GSK3B`+CIITA/MHC-II/CD74. ClinicalTrials.gov returned 3 lithium/MS studies.

Integration decision:

- Demote `GSK3B` from candidate central node to mechanistic perturbation
  comparator. It is useful evidence that CIITA/MHC-II/CD74 can be decoupled
  from generic IFN signaling in macrophage perturbation data, but it fails
  breadth, MS local recurrence, and novelty gates.
- Do not claim a `GSK3B` therapeutic finding.
- Next forcing question: find an intervention point that controls the
  recurring `CD74`/`CIITA`/HLA-II state with better breadth, targetability, and
  novelty than `SLC15A4/TASL`, `GSK3B`, or the broad genetic negative
  regulators.

## 2026-05-27 01:03 UTC

Prepared wave-15 dispatch around the resolved bottleneck:

- Do not retest whether the `CD74`/`CIITA`/HLA-II state exists.
- Search for targetable dependencies that control that state with a better
  selectivity/novelty profile than direct IFN/JAK/MHC-II/GSK3/SLC15A4 lanes.
- Worker plan appended to `SUBAGENTS_V3.md`.

## 2026-05-27 01:14 UTC

Integrated target-level genetics worker return from Tesla.

- Report: `phases/v3/subagents/wave14_target_level_genetics.md`.
- Outputs: `phases/v3/results/wave14_target_level_genetics/`.
- Conservative call accepted: no-go for V3 target-level genetics among the
  narrowed candidates. Broad locus-level autoimmune evidence exists for
  `IRF5`, `PTPN2`, `CLEC16A`, `SH2B3`, and `GPR65`, but none has validated
  target-level coloc/MR across the required disease breadth in accessible
  resources.

Implication:

- Genetics cannot currently rescue `CIITA`, `RFX5`, `GSK3B`, `CD74`,
  `SLC15A4/TASL`, or the negative-regulator branch as V3 therapeutic claims.
- Future claims must either obtain formal summary-stat coloc/MR inputs or
  clearly mark genetics as insufficient.

## 2026-05-27 01:14 UTC

Integrated Wave15-B perturbation/drug-response worker return.

- Report: `phases/v3/subagents/wave15_perturbation_drug_response.md`.
- Outputs: `phases/v3/results/wave15_perturbation_drug_response/`.
- Accepted verdict: no compound is strong enough to nominate from available
  perturbation/drug-response evidence.

Key constraints:

- `Med16_KO` is a strong non-druggable comparator: target antigen-presentation
  module `-3.140`, generic IFN `-0.798`.
- `Gsk3b_KO` remains a druggable-ish comparator, not a nomination: target
  module `-1.622`, generic IFN `-0.795`.
- `RFX5` CRISPRi is a clean selective genetic gate in Mixscale: target module
  `-0.552`, generic IFN `+0.083`, but it is not directly druggable.
- Ruxolitinib/JAK collapses generic IFN harder than the target module and
  remains a broad-control comparator.
- L1000FWD hits are cell-line signature reversals and too nonspecific for
  nomination.

## 2026-05-27 01:14 UTC

Completed orchestrator wave-15 dependency scans around the `CD74`/HLA-II state.

New scripts and outputs:

- `scripts/v3_wave15_orchestrator_dependency_scan.py`
- `phases/v3/results/wave15_orchestrator_dependency_scan/`
- `scripts/v3_wave15_geneformer_loader_dependency_screen.py`
- `phases/v3/results/wave15_geneformer_loader_dependency_delete/`
- `scripts/v3_wave15_loader_external_gate.py`
- `phases/v3/results/wave15_loader_external_gate/`

Result:

- The highest-ranked non-state local dependency candidate is `CTSH`, ahead of
  saturated or non-druggable comparators such as `CTSS`, `HLA-DMA`, `HLA-DMB`,
  and `LIPA`.
- `CTSH` local evidence: 1 FDR10-positive disease and 3 trend-or-better
  diseases for case/control expression; 4 residual state-support diseases
  after adjusting for IFN and case/control.
- `CTSH` foundation-model evidence is weak/moderate, not decisive:
  Geneformer deletion had 3 support contexts but 0 strong support contexts.
- `CTSH` external gate: Open Targets `gwas_credible_sets` rows in T1D and MS
  with max score `0.974`, but this is locus-level only. ClinicalTrials.gov
  returned 0 hits for `CTSH OR "cathepsin H"`.
- Europe PMC query counts for `CTSH` are high and require close prior-art
  review: 911 autoimmune hits, 968 antigen-presentation hits, and 2,500
  inhibitor/therapeutic hits. Closest examples include cathepsin/autoimmune MR
  and cathepsin H therapeutic-target papers.

Decision:

- Keep `CTSH` as active fail-fast lead, not a finding. It is currently the only
  new candidate combining local dependency signal, some foundation-model
  support, MS/T1D locus-level genetics, and no obvious clinical-trial hit.
- Immediate risk: existing cathepsin autoimmune MR/therapeutic prior art may
  directly publish the same claim. The next step is detailed prior-art and
  mechanism specificity review before any nomination.

## 2026-05-27 01:19 UTC

Integrated Wave15-A surface/trafficking dependency worker return.

Report:

- `phases/v3/subagents/wave15_surface_trafficking_dependency.md`

Outputs:

- `phases/v3/results/wave15_surface_trafficking_dependency/`

Accepted result:

- The worker independently ranked `CTSH` as the leading local `GO_SCOUT`
  intervention-adjacent dependency candidate after screening 78 HLA-loading,
  protease, trafficking, glycosylation, uptake, and lysosomal genes.
- `CTSH` support in that screen: 5 disease-control trend-or-better diseases,
  1 FDR10-positive disease, 8 residual state-coupling diseases, and no negative
  disease-control trends.
- Other `GO_SCOUT` candidates were `CTSS`, `LGALS9`, and `LAPTM5`; `CTSS` and
  `LGALS9` remain heavily prior-arted or directionally complex, while `LAPTM5`
  is less tractable and currently lower priority.

Vetting decision:

- Accept the local ranking as evidence that CTSH is worth detailed stress
  testing.
- Do not promote CTSH to a finding: disease-control expression support is not
  broad enough, state coupling may still reflect APC compartment structure, and
  the foundation-model deletion signal is weak/moderate.

## 2026-05-27 01:22 UTC

Prior-art stress test found direct CTSH/cathepsin autoimmune genetics prior
art.

Verified sources:

- Wu et al. 2024, `Medicine`, DOI `10.1097/MD.0000000000040268`, PMID
  `39470488`: bidirectional MR across autoimmune diseases reports cathepsin H
  as protective for celiac disease and risk-increasing for type 1 diabetes and
  primary biliary cholangitis.
- Lin et al. 2024 medRxiv, DOI `10.1101/2024.09.05.24313125`: MR preprint
  reports cathepsin H association with MS (`IVW P=0.036`, `OR=1.095`,
  `95% CI=1.006-1.192`).
- Faraco et al. 2013, PLoS Genetics, DOI `10.1371/journal.pgen.1003270`:
  ImmunoChip narcolepsy work already frames CTSH as an antigen-presentation
  gene in MHC-II-positive immune cells.

Decision:

- CTSH cannot be claimed as a novel autoimmune genetic target.
- The only possible remaining novelty would be a narrower claim: CTSH as a
  cross-autoimmune CD74/HLA-II lysosomal loading-state dependency with
  cell-state and foundation-model evidence, not as a first genetics link.
- This narrower claim still lacks enough perturbation and chemistry support.

## 2026-05-27 01:24 UTC

Wave16 dispatch planned.

- CTSH chemistry/selectivity worker: determine whether selective CTSH
  modulation is tractable relative to CTSS/CTSB/CTSL/CTSC, using ChEMBL, PDB or
  AlphaFold structures, inhibitor literature, and safety liabilities.
- Hostile critique worker: attack the CTSH-centered claim and decide whether it
  is overprioritized given prior art, weak Geneformer support, mixed genetics,
  and expression/state-coupling confounding.
- Alternative dependency worker: compare `LAPTM5`, `LGALS9`, `CTSS`, and other
  Wave15 survivors against CTSH for novelty, tractability, and disease breadth.

## 2026-05-27 01:26 UTC

Integrated myasthenia gravis breadth worker return.

Report:

- `phases/v3/subagents/wave14_myasthenia_breadth.md`

Outputs:

- `phases/v3/results/wave14_gse227835_myasthenia/`

Accepted result:

- GSE227835 PBMCs add a real independent disease-breadth test, but only as
  marker-derived compartments because GEO lacks curated cell labels.
- Strongest support is a lysosomal/APC module in marker-derived B/APC-like
  PBMCs: AChR-positive MG vs healthy `g=2.252`, `FDR=0.0111`; untreated MG vs
  healthy `g=1.729`, `FDR=0.0111`.
- Lipid-loader support appears mainly in seronegative MG myeloid/APC-like cells.
- This dataset contradicts a universal HLA-II/CD74 mechanism: seronegative
  pre-treatment B/APC-like and plasmablast-like compartments show negative
  HLA-II/CD74 and IFNG/HLA-II/CD74 trends.

Decision:

- Count MG as breadth support for a compartment-specific lysosomal/APC axis.
- Do not count MG as support for a pan-compartment IFNG/HLA-II/CD74 or CTSH
  therapeutic mechanism.

## 2026-05-27 01:31 UTC

Integrated Wave16 hostile critique and alternatives comparison.

Reports:

- `phases/v3/subagents/wave16_hostile_ctsh_critique.md`
- `phases/v3/subagents/wave16_alternative_dependency_comparison.md`

Decisions:

- Accept hostile critique verdict: `CTSH` is no-go for central-node or
  intervention promotion under current V3 evidence.
- Keep `CTSH` only as a local dependency scout/reference and possible future
  peptidome perturbation target.
- Accept alternatives worker ranking with caveat: `LAPTM5` is the best
  novelty-first contingency but lacks a credible intervention modality; `CTSS`
  is the best enzyme comparator but is prior-art/clinical-history blocked;
  `LGALS9` is accessible but crowded and directionally complex.

Rationale:

- The intervention route cannot be rescued by proximity to the `CD74`/HLA-II
  state alone.
- Next active branch should prioritize perturbation-derived controllers whose
  effect is selective for the HLA-II/CD74 target module over generic IFN/JAK
  collapse. Current best positive control is `Med16_KO`; the druggable analog
  to test is Mediator kinase / transcriptional co-regulator pharmacology
  (`CDK8`/`CDK19`/Cyclin C and related Mediator module control).

## 2026-05-27 01:33 UTC

Wave17 dispatch planned.

- Wave17-A Mediator kinase route: determine whether `MED16` perturbation can be
  translated to a druggable `CDK8/CDK19` or Mediator-module intervention that
  selectively downshifts IFN-gamma-induced CIITA/MHC-II/CD74 across autoimmune
  contexts without broad IFN collapse.
- Wave17-B LAPTM5 route: determine whether `LAPTM5` has a plausible modality
  or should remain a novelty-only biomarker/dependency readout.

## 2026-05-27 01:47 UTC

Integrated Wave16-A CTSH chemistry/selectivity worker return.

- Closed the worker after completion.
- Accepted verdict: selective CTSH/cathepsin H modulation is a no-go as the V3
  intervention point on current public chemistry.
- Preserved outputs under `phases/v3/subagents/wave16_ctsh_chemistry_selectivity.md`
  and `phases/v3/results/wave16_ctsh_chemistry_selectivity/`.
- Decision: CTSH remains a lysosomal/APC state marker and possible assay
  readout, not a therapeutic nomination.

## 2026-05-27 01:48 UTC

Integrated Wave17 returns.

- Mediator/CDK8-CDK19 route:
  `phases/v3/results/wave17_mediator_route_gate/` and
  `phases/v3/subagents/wave17_mediator_kinase_route.md`.
- Accepted park verdict. `Med16_KO` remains a strong perturbation clue, but
  CDK8/CDK19 promotion is blocked by weak local recurrence, absent inhibitor
  phenocopy in local autoimmune APC data, broad transcriptional risk, and
  broad autoimmune patent prior art.
- LAPTM5 route: `phases/v3/subagents/wave17_laptm5_modality_route.md`.
- Accepted park verdict. LAPTM5 is credible as a module marker/readout but not
  as a current direct intervention.

## 2026-05-27 01:49 UTC

Integrated local treatment-response reformulation.

- Added `scripts/v3_analyze_gse253006_tofacitinib_marker_compartments.py`.
- The reformulation avoids the earlier all-cell/sample-level proxy by using
  marker-derived compartments.
- Result: no corrected baseline responder/nonresponder module separation in
  UC tofacitinib samples; responder paired pre/post data show nominal-to-FDR10
  pharmacodynamic decreases in IFN/antigen-presentation readouts.
- Decision: tofacitinib remains a pharmacodynamic comparator, not a V3
  stratification or intervention discovery claim.

## 2026-05-27 01:53 UTC

Wave18 dispatch planned.

- Wave18-A: treatment-response dataset scout. Goal is to determine whether the
  shared lysosomal/APC/HLA-II state can become a baseline stratifier or only a
  pharmacodynamic comparator.
- Wave18-B: accessible/druggable state-component rescue. Goal is to find a
  tractable extracellular, membrane, receptor, secreted, or enzyme intervention
  point that has not already been blocked by CTSH/CTSS/CD74/MIF/LGALS9-style
  concerns.
- Wave18-C: foundation-model rescue. Goal is to re-rank candidates using
  existing Geneformer/State-parse outputs and compare those hypotheses against
  real perturbation datasets.

## 2026-05-27 05:53 UTC

Wave18-A returned and was locally vetted.

- Agent: `019e671f-f30f-79b3-9ae7-0297ffe1809e`.
- Report: `phases/v3/subagents/wave18_treatment_response_scout.md`.
- Accepted outputs: `scripts/v3_wave18_treatment_response_scout.py` and
  `phases/v3/results/wave18_treatment_response/`.
- Vetting: parsed `summary.json`; confirmed `GSE183047_RAW.tar` completed and
  matrices extracted; checked that RA and UC baseline predictor FDR values match
  the report.
- Decision: baseline treatment-response biomarker branch is no-go for the
  current V3 module readouts. Keep only weak pharmacodynamic comparator
  evidence.

## 2026-05-27 05:55 UTC

Wave18-B returned and was locally vetted.

- Agent: `019e671f-f334-79a2-a1b6-86f56a71b80d`.
- Report: `phases/v3/subagents/wave18_accessible_target_rescue.md`.
- Accepted outputs: `scripts/v3_wave18_accessible_target_rescue.py` and
  `phases/v3/results/wave18_accessible_target_rescue/`.
- Vetting: parsed `summary.json` (`0 GO`, `11 PARK`, `13 NO_GO`) and checked
  the candidate table/source log.
- Decision: no accessible surface/secreted/enzyme state component is promotable
  after recurrence, druggability, direction, and prior-art gates.

## 2026-05-27 05:57 UTC

Wave18-C result integrated from local reproducible outputs.

- Report: `phases/v3/subagents/wave18_foundation_rescue.md`.
- Accepted outputs: `scripts/v3_wave18_foundation_rescue.py` and
  `phases/v3/results/wave18_foundation_rescue/`.
- Decision: strict foundation-model plus real-perturbation rescue candidate set
  is empty. Geneformer/State evidence is retained as veto/triage only.

## 2026-05-27 05:59 UTC

Wave19 pivot planned.

Rationale:

- Direct state markers, accessible myeloid receptors, cathepsins, CD44/SPP1,
  galectins, Mediator kinase, and baseline-treatment-response branches all
  failed hard promotion gates.
- The remaining plausible space is not another marker-ranking pass. It is a
  controller search: upstream tolerogenic myeloid checkpoints, lysosomal stress
  regulators, and disease-specific lead indications where the cross-autoimmune
  module can be intervened on without hitting saturated prior art.

Planned dispatch:

- Wave19-A: inhibitory/tolerogenic myeloid checkpoint controllers (`VSIR`,
  `LILRB4`, `LAIR1`, `CD200R1`, `SIGLEC10`, `PIR/B`, related axes), focusing
  on local recurrence, state coupling, drug modality, and novelty.
- Wave19-B: lysosomal stress and lipid-handling controllers (`TFEB/TFE3`,
  `MCOLN1`, `PIKFYVE`, `LIPA`, `NPC1/2`, `GBA/GBA2`, `LRRK2`, `PPARG/LXR`
  routes), focusing on druggability and whether activation/inhibition direction
  is plausible.
- Wave19-C: hostile critique of the current evidence state and pivot logic.

## 2026-05-27 06:02 UTC

Wave19-C hostile critique returned and was accepted as a hard gate.

- Agent: `019e6801-eab2-7d43-bb3c-49e2d3370bf6`.
- Report: `phases/v3/subagents/wave19_hostile_critique.md`.
- Bottom line accepted: the V3 package currently supports a recurrent
  autoimmune IFN/APC/lysosomal tissue state, not a therapeutic target.
- Adopted promotion gates: residual specificity beyond IFN/APC/myeloid density,
  real perturbation causality, explicit direction, modality feasibility,
  repair/viability preservation, and prior-art delta.
- Integration entry written to `CRITIQUE_V3.md`.

## 2026-05-27 06:04 UTC

Orchestrator-side controller triage executed.

- Script: `scripts/v3_wave19_orchestrator_controller_triage.py`.
- Output: `phases/v3/results/wave19_orchestrator_controller_triage/`.
- Result: 69 controller candidates screened; `66 DEMOTE_LOCAL_TRIAGE`, `3
  PARK_FOR_WORKER_REVIEW`, `0 FOLLOW_UP_NOW`.
- Parked stress-test candidates only: `LIPA`, `CD274`, `NPC1`.

## 2026-05-27 06:08 UTC

Wave20 unrestricted successor search planned.

Rationale:

- Wave19 critique and local triage indicate that continuing to rank the same
  lipid/APC state markers is not scientifically defensible.
- Prior unrestricted scans still have under-reviewed survivors (`SNX10`, `DAP`,
  `FMNL2`, `TNFAIP8L1`, `PPIL3`, `NCK1`, `PLEK2`, `SEL1L3`, `AQR`,
  `C15ORF48`) with cross-disease expression and some model support.
- A separate genetic/druggable alternate-axis search is needed to test whether
  the right target sits outside the lipid-lysosomal/APC module.

Planned dispatch:

- Wave20-A: unrestricted survivor stress test.
- Wave20-B: genetic/druggable alternate-axis search.

## 2026-05-27 06:14 UTC

Wave19-B lysosomal/lipid-controller audit returned and was vetted.

- Agent: `019e6801-b632-7422-951b-b438f4b7661e`.
- Report: `phases/v3/subagents/wave19_lysosomal_controller.md`.
- Script/output: `scripts/v3_wave19_lysosomal_controller.py`,
  `phases/v3/results/wave19_lysosomal_controller/`.
- Validation: `summary.json` reports 35 candidates, 12 routes, and
  `promoted_go_routes: []`; route summary and candidate table agree.
- Integrated call: no upstream lysosomal/lipid controller is promotable.
  `LIPA/LAL_enhancement`, `NPC1/NPC2_cholesterol_egress`, and
  `LRRK2_inhibition` remain parked/readout or disease-specific branches only.
- Decision: do not rescue the V3 finding by broadening to generic
  lysosome/CLEAR/autophagy/cholesterol-efflux activation. The strongest
  detectable biology remains downstream APC/HLA-II/lysosomal machinery, but it
  still lacks a selective intervention package.

## 2026-05-27 06:17 UTC

Wave19-A tolerogenic/checkpoint-controller audit returned and was vetted.

- Agent: `019e6801-b5eb-7861-9bcb-2d385229386a`.
- Report: `phases/v3/subagents/wave19_tolerogenic_checkpoint.md`.
- Script/output: `scripts/v3_wave19_tolerogenic_checkpoint.py`,
  `phases/v3/results/wave19_tolerogenic_checkpoint/`.
- Validation: reran the script locally; `summary.json` reports 29 candidates,
  `PROMOTE: 0`, `PARK: 5`, `PARK_LOW: 6`, `NO_GO: 18`.
- Integrated call: no tolerogenic or inhibitory myeloid checkpoint controller
  rescues the V3 module. `CD274`, `CD24`, `BTLA`, `CD200`, and `CD47` are
  parked comparator axes only.
- Decision: do not claim PD-L1/CD24/CD200/CD47-style checkpoint engagement as
  a novel autoimmune lipid-lysosomal/APC intervention. The local state-coupling,
  directionality, and prior-art gates fail.

## 2026-05-27 06:18 UTC

Wave20-A unrestricted survivor stress test returned and was vetted.

- Agent: `019e6809-cdca-7821-bbba-dd1a1d6668ef`.
- Note: an earlier poll used a mistyped agent path ending in `bb3c`; that
  `not_found` was a polling error, not a subagent failure.
- Report: `phases/v3/subagents/wave20_unrestricted_survivor.md`.
- Script/output: `scripts/v3_wave20_unrestricted_survivor.py`,
  `phases/v3/results/wave20_unrestricted_survivor/`.
- Validation: reran the script locally; `summary.json` reports
  `promoted_targets: []` and `least_bad_comparator: SNX10`.
- Integrated call: no unrestricted survivor is promotable. `SNX10` is only a
  fail-fast comparator; `C15ORF48` is a state marker; `NCK1` is a modality
  comparator in the wrong biological context; `FMNL2`, `DAP`, `PPIL3`,
  `PLEK2`, `TNFAIP8L1`, `SEL1L3`, and `AQR` are intracellular/stress/repair or
  core-machinery no-go routes.

## 2026-05-27 06:23 UTC

Wave20-B genetic/druggable alternate-axis scout returned and was vetted.

- Agent: `019e6809-cdea-7613-acf7-1bf574c45230`.
- Report: `phases/v3/subagents/wave20_genetic_druggable_altaxis.md`.
- Script/output: `scripts/v3_wave20_genetic_druggable_altaxis.py`,
  `phases/v3/results/wave20_genetic_druggable_altaxis/`.
- Validation: reran the script locally; it completed with `promoted_count: 0`
  after a non-fatal pandas mixed-type warning from a local TSV input.
- Integrated call: no alternate genetically anchored and druggable axis outside
  the exhausted lipid-lysosomal/APC space is promotable. `PTPN2`, `SH2B3`,
  `CLEC16A`, `ATG16L1`, `OSMR`, `GPR65`, `IRF5`, `CARD9`, `IL10`, `TNFAIP3`,
  `IL6R`, and `TYK2` all fail at least one hard gate.
- Decision: the failure mode is not lack of autoimmune genetics. It is lack of
  a target-level, correct-direction, druggable, perturbation-supported, and
  novel intervention point.

## 2026-05-27 06:24 UTC

Convergence Check 5 written.

- File: `CONVERGENCE_CHECK_5.md`.
- Integrated interpretation: Wave19 and Wave20 agree that the cross-autoimmune
  tissue-state signal is real but no intervention point survived the hard
  promotion gates.
- Next forcing question: whether strict-residual, externally druggable
  candidates outside the exhausted hand-curated lists were missed by the
  prior target inventories.

## 2026-05-27 06:25 UTC

Wave21 planned and recorded in `SUBAGENTS_V3.md`.

- Wave21-A: independent local/API residual-druggability scan.
- Wave21-B: novelty/modality hostile review for residual candidates.
- Orchestrator local task in parallel: implement a minimal Wave21 scan if
  subagents are slow, then integrate only candidates that pass strict residual
  and modality gates.

## 2026-05-27 06:26 UTC

Wave21 dispatch completed after one spawn retry.

- Initial attempt to spawn both Wave21 workers with full-history fork and
  explicit worker settings failed because the agent manager disallows overriding
  agent type/reasoning on a full-history fork.
- Retried without fork. Wave21-A spawned successfully as
  `019e681b-d8c0-70b0-b47d-fa09ae1bd75b` (`Pauli`).
- Wave21-B first retry hit the active thread limit. Completed Wave19/Wave20
  agents were closed after their reports had been written and vetted.
- Wave21-B then spawned successfully as
  `019e681c-23d7-75c1-aefc-51cf7068cd1e` (`Hooke`).

## 2026-05-27 06:31 UTC

Orchestrator-side Wave21 residual-druggability scan completed.

- Script/output: `scripts/v3_wave21_residual_druggability_scan.py`,
  `phases/v3/results/wave21_residual_druggability_scan/`.
- Scope: 271 residual candidates, top 80 API-scanned against ChEMBL and
  UniProt with cached raw responses.
- Result: `0 FOLLOW_UP_NOW`, `0 PARK_PRIOR_ART_REVIEW`,
  `8 PARK_LOCAL_RESIDUAL_ONLY`, `72 DEMOTE_WAVE21`.
- Parked residual-only genes: `ATOX1`, `TPM4`, `LDLRAD3`, `SQLE`, `CFB`,
  `TIMP1`, `COL4A1`, and `CBX3`.
- Decision: no target rescue. The parked genes fail breadth, modality,
  mechanistic direction, or prior demotion gates and are mostly IBD stromal or
  tissue-remodeling signals rather than cross-autoimmune intervention points.

## 2026-05-27 06:36 UTC

Wave21-A residual-druggability worker returned and was vetted.

- Agent: `019e681b-d8c0-70b0-b47d-fa09ae1bd75b` (`Pauli`).
- Report: `phases/v3/subagents/wave21_residual_druggability_scan.md`.
- Script/output: `scripts/v3_wave21_residual_druggability_scan.py`,
  `phases/v3/results/wave21_residual_druggability_scan/`.
- Important integration note: the worker refined and superseded the earlier
  orchestrator-side rough Wave21 script/output in the same assigned write
  scope. The retained output is the worker's stricter 26-candidate screen, while
  the older rough tables remain as auxiliary files.
- Result: 26 strict-residual candidates scanned; `1 GO_REVIEW`,
  `5 PARK_REVIEW`, `20 NO_GO`.
- `SQLE` is `GO_REVIEW` only in the sense of routing to hostile novelty and
  modality review. It is not promoted. Blockers remain: no local genetics, no
  perturbation evidence, no MS anchor, and strict residual survival limited to
  Crohn/UC stromal compartments.
- Parked review candidates: `LDLRAD3`, `C1QTNF1`, `TGM2`, `REG1A`, and
  `PTPRE`, all with missing direction, genetics/MS support, perturbation, or
  modality.

## 2026-05-27 06:38 UTC

Active-time accounting corrected per user instruction.

- File: `TIME_ACCOUNTING_V3.md`.
- Rule: usage-limit waiting time does not count toward the twelve-hour floor.
- Observed excluded gap: approximately 2026-05-27 01:53 UTC to 05:53 UTC.
- Current active-time estimate: about 7 hours 57 minutes, not twelve hours.
- Consequence: do not write `MILESTONE_6.md` or `MILESTONE_6_MISS.md` at the
  06:41 UTC wall-clock mark. Continue the run until twelve active hours are
  reached or a real breakthrough is ready.

## 2026-05-27 06:39 UTC

Wave21-B hostile prior-art/modality review returned and was vetted.

- Agent: `019e681c-23d7-75c1-aefc-51cf7068cd1e` (`Hooke`).
- Report: `phases/v3/subagents/wave21_residual_candidate_prior_art.md`.
- Output: `phases/v3/results/wave21_residual_candidate_prior_art/`.
- Coverage: 18 candidates, 126 exact source-query rows, PubMed, Europe PMC,
  Europe PMC preprints, ClinicalTrials.gov, Google Patents, ChEMBL, and UniProt
  with raw captures under `raw_api/`.
- Integrated call: no residual candidate is promoted. `SQLE` is reduced from
  `GO_REVIEW` routing to conditional stress-test comparator only. `CFB`,
  `IL15`, `IL7R`, `CXCL8`, and `HIF1A` are comparator-only
  prior-art/generic-modality failures.
- Decision: Wave21 closes without a target. If `SQLE` is pursued at all, it
  must be as a fail-fast perturbation/foundation stress test, not as a
  therapeutic nomination.

## 2026-05-27 06:55 UTC

Wave22 orchestrator-side SQLE fail-fast completed and vetted.

- Script: `scripts/v3_wave22_sqle_failfast.py`.
- Output: `phases/v3/results/wave22_sqle_failfast/`.
- Runner entry added: `scripts/entrypoints/run_v3_analysis.sh`.
- Result: `NO_GO_SQLE_FAILFAST`.
- Failed gates: local gate, MS anchor, cross-disease residual specificity,
  foundation-plus-real perturbation alignment, real perturbation alignment,
  L1000 disease-signature reversal, and novel autoimmune delta.
- Integration decision: no subagent rerun needed because the result directly
  reconciles Wave21-A, Wave21-B, Wave18 foundation synthesis, and L1000 outputs.

Next dispatch will pivot away from residual expression/druggability scans toward
independent evidence channels: metabolite/barrier-repair circuits,
genetics-first restoration modalities, and treatment-response stratification.

## 2026-05-27 07:00 UTC

Wave23 planned and recorded in `SUBAGENTS_V3.md`.

- Wave23-A: metabolite/barrier-repair circuit scout.
- Wave23-B: genetics-first restoration modality scout.
- Wave23-C: treatment-response stratification scout.
- Orchestrator local task in parallel: implement an independent, non-expression
  axis triage that merges the existing local target/genetics/perturbation/L1000
  outputs and identifies whether any of these three routes deserves deeper
  execution.

## 2026-05-27 07:02 UTC

Wave23 dispatch completed.

- Wave23-A metabolite/barrier circuit scout spawned as
  `019e6831-6a5d-7902-b7fc-ffbeeae78e91` (`Noether`).
- Wave23-B genetics-first restoration modality scout spawned as
  `019e6831-6a97-7d72-8da5-5403fbc8ee27` (`Wegener`).
- Wave23-C treatment-response stratification scout spawned as
  `019e6831-6ac9-7ec3-a044-67c5c8b5e143` (`Gibbs`).

## 2026-05-27 07:08 UTC

Orchestrator-side Wave23 route triage completed.

- Script/output: `scripts/v3_wave23_orchestrator_nonexpression_axis_triage.py`,
  `phases/v3/results/wave23_orchestrator_nonexpression_axis_triage/`.
- Initial treatment-response gate was too permissive; I corrected it to count
  corrected baseline associations, then reran the script.
- Corrected result: `2 PARK_REVIEW`, `14 NO_GO`, `0 GO_REVIEW`.
- Parked only for worker/hostile follow-up:
  `GPR65_pH_endolysosomal_gpcr` and `PTPN2_TCPTP_restoration`.
- Baseline biomarker route is `NO_GO`: 10 nominal baseline associations, 0
  corrected baseline associations, 1 corrected pharmacodynamic signal.

Integration note:

- This does not duplicate Wave23-A/B/C. It provides a local evidence table for
  vetting their free-text reports.

## 2026-05-27 07:13 UTC

Wave23-D hostile critique dispatched.

- Agent: `019e6838-43cf-7b42-8f41-06e963367ec6` (`Carver`).
- Scope: attack GPR65, PTPN2 restoration, and the baseline module-response
  biomarker route; identify neglected non-redundant routes.
- Write scope: `phases/v3/subagents/wave23_hostile_critique.md`.

## 2026-05-27 07:18 UTC

Wave23-B genetics-restoration modality worker returned and was vetted.

- Agent: `019e6831-6a97-7d72-8da5-5403fbc8ee27` (`Wegener`).
- Report: `phases/v3/subagents/wave23_genetics_restoration_modality.md`.
- Script/output: `scripts/v3_wave23_genetics_restoration_modality.py`,
  `phases/v3/results/wave23_genetics_restoration_modality/`.
- Validation: `py_compile` passed locally.
- Result: `0 GO`, `2 PARK`, `12 NO_GO`.
- Parked by worker: `GPR65`, `IL10`.
- Integrated call: no target. `GPR65` and `IL10` remain comparator/future
  follow-up branches only; `PTPN2` restoration is demoted because available
  chemistry is wrong-direction and no TCPTP-restoring modality exists locally.

## 2026-05-27 07:24 UTC

Wave24 perturbation-first L1000 recurrent reversal triage completed.

- Script/output: `scripts/v3_wave24_l1000_recurrent_reversal_triage.py`,
  `phases/v3/results/wave24_l1000_recurrent_reversal/`.
- Result: no repurposing candidate promoted.
- 123 grouped compounds were triaged from 144 opposite-mode L1000 rows.
- `0 PARK_REVIEW`; 61 unknown-target/MOA compounds are parked only for
  deconvolution and cannot support a claim.
- Known recurrent opposite hits are filtered as cytotoxic/stress, oncology,
  steroid, or generic/prior inflammatory mechanisms.
- Decision: close the L1000 recurrence shortcut unless a future step can
  deconvolve the unknown BRDs and show non-cytotoxic mechanism.

## 2026-05-27 07:31 UTC

Wave23-D hostile critique returned and was vetted.

- Agent: `019e6838-43cf-7b42-8f41-06e963367ec6` (`Carver`).
- Report: `phases/v3/subagents/wave23_hostile_critique.md`.
- Changed files: report only.
- Accepted critique: route labels are not enough; `GPR65`, `PTPN2`, and the
  baseline biomarker branch remain weak under promotion-grade gates.
- Wrote `CONVERGENCE_CHECK_7.md`.
- Integration decision: demote all current PARK labels to comparator/future data
  needed; pivot next to target-resolved causal genetics to module state.

## 2026-05-27 07:05 UTC

Wave23-A metabolite/barrier circuit worker returned and was vetted.

- Agent: `019e6831-6a5d-7902-b7fc-ffbeeae78e91` (`Noether`).
- Report: `phases/v3/subagents/wave23_metabolite_barrier_circuit.md`.
- Script/output: `scripts/v3_wave23_metabolite_barrier_circuit.py`,
  `phases/v3/results/wave23_metabolite_barrier_circuit/`.
- Worker-reported validation: script run and `py_compile` passed.
- Result: `7 NO_GO`, `0 PARK`, `0 GO`.
- Integrated call: no metabolite/barrier route is promoted. AHR/tryptophan is
  biology-only, FXR/TGR5 is locally unsupported, and the remaining route
  classes are generic/prior-arted or not tied to the V3 state.
- Agent closed after integration.

## 2026-05-27 07:07 UTC

Wave25 orchestrator-side target-resolved genetics-to-module proxy audit
completed.

- Script/output: `scripts/v3_wave25_causal_genetics_module_proxy.py`,
  `phases/v3/results/wave25_causal_genetics_module_proxy/`.
- Runner entry: `scripts/entrypoints/run_v3_analysis.sh`.
- Result: no target-resolved causal genetics claim is available.
- Counts: `206` candidates; `0` candidates with proper coloc/MR feasibility;
  `1 COLOC_NEEDED_NOT_CLAIMABLE` (`PTPN2`), `14 MODULE_MARKER_NOT_GENETICALLY_ANCHORED`,
  `191 NO_GO_CAUSAL_PROXY`.
- Data audit: local GWAS Catalog parquet is readable but top-association only,
  not coloc-sufficient.
- Integration decision: do not promote `PTPN2`, `GPR65`, `SH2B3`, `CLEC16A`,
  `IRF5`, or module-marker genes from genetics proxies. Target causality remains
  a claim-blocking gap.

## 2026-05-27 07:13 UTC

Wave26 strict treatment-response biomarker audit completed.

- Script/output: `scripts/v3_wave26_treatment_response_strict_audit.py`,
  `phases/v3/results/wave26_treatment_response_strict_audit/`.
- Runner entry: `scripts/entrypoints/run_v3_analysis.sh`.
- Purpose: reconcile Wave18 no-corrected-predictor conclusion with the Wave23-C
  `GO` row for `GSE138746` anti-TNF / adalimumab `CD4_T_cell` `ifn_apc`.
- Result: the prior `GO` is demoted. It had within-scope FDR 0.068654 but
  global baseline FDR 0.773794, global generic-adjusted FDR 0.971730, and zero
  independent same-module/direction replications.
- Integration decision: treatment-response stratification is closed under
  current data. The RA signal remains hypothesis-only.

## 2026-05-27 07:20 UTC

Wave27 L1000 unknown-BRD deconvolution completed.

- Script/output: `scripts/v3_wave27_l1000_unknown_deconvolution.py`,
  `phases/v3/results/wave27_l1000_unknown_deconvolution/`.
- Runner entry: `scripts/entrypoints/run_v3_analysis.sh`.
- First run failed on duplicate `cmap_name` columns after merging LINCS
  metadata; fixed and rerun.
- Result: 62 unknown parked compounds audited; 61 `NO_GO`, 1
  `PARK_EXTERNAL_TARGET_LOOKUP_ONLY`.
- The six recurrent unknowns resolve to purine/cAMP, Aurora kinase,
  prostanoid, natural-product, or unresolved-BRD chemistry. None is promotable.
- Integration decision: close the unknown-L1000 deconvolution route as a
  therapeutic source.

## 2026-05-27 07:26 UTC

Outstanding Wave23-C treatment-response subagent closed.

- Agent: `019e6831-6ac9-7ec3-a044-67c5c8b5e143` (`Gibbs`).
- Status before closure: running.
- Reason: the local Wave26 strict audit superseded the branch and demoted the
  only prior `GO` row under global correction and replication gates. Keeping the
  worker open would not change the integration decision without a new,
  stricter result.

Wave28 orchestrator-side target-first rescue audit completed.

- Script/output: `scripts/v3_wave28_target_first_rescue.py`,
  `phases/v3/results/wave28_target_first_rescue/`.
- Runner entry: `scripts/entrypoints/run_v3_analysis.sh`.
- First pass exposed a ClinicalTrials.gov count parser issue; fixed by adding
  target-specific `query.term`, autoimmune `query.cond`, and `countTotal=true`,
  then reran.
- Result: `26` druggable/target-first candidates audited; `0 GO`, `1 PARK`,
  `25 NO_GO`.
- Parked only: `SQLE`, because it has residual/module evidence and a druggable
  enzyme modality but lacks target-level genetics and perturbation/foundation
  support.
- Best non-park comparator: `PTPN2`, because it carries the strongest broad
  genetics-proxy signal but remains blocked by no correct-direction TCPTP
  restoration modality and prior-art/saturation.
- Integration decision: target-first rescue does not produce a claim. Continue
  to a different modality or a deeper intervention-modeling branch; do not
  promote residual expression or broad druggability alone.

## 2026-05-27 07:34 UTC

Wave29 PTPN2 restoration model completed.

- Script/output: `scripts/v3_wave29_ptpn2_restoration_model.py`,
  `phases/v3/results/wave29_ptpn2_restoration_model/`.
- Runner entry: `scripts/entrypoints/run_v3_analysis.sh`.
- Orchestration note: the initial 750-sample-per-condition sweep was too slow
  and was killed. The final run uses 125 samples per condition; this downscope
  is documented in the script and notebook.
- Result: no PTPN2 restoration setting reaches the predefined selective window.
  `ptpn2_restore_to_125pct` gives median APC/lipid-module drop 0.130 and median
  host-defense drop 0.365, with selective-window fraction 0.0.
- Integration decision: PTPN2 is now a genetics/mechanism benchmark, not an
  intervention candidate. A future PTPN2 branch would require real
  correct-direction perturbation data and target-resolved coloc/MR before
  reopening.

## 2026-05-27 07:44 UTC

Wave30 upstream niche-driver audit completed and reformulated.

- Added `scripts/v3_wave30_niche_driver_audit.py`; output:
  `phases/v3/results/wave30_niche_driver_audit/`.
- First run was rejected by the orchestrator because broad `ifn_apc` module
  breadth was incorrectly allowed to count as evidence for every annotated
  ligand/receptor axis. This overpromoted OSM/OSMR, CD40/CD40LG,
  CD24/SIGLEC10, CCL2/CCR2, and related generic inflammatory routes.
- Script was patched so candidate-specific breadth is separate from global
  module breadth and gates depend on candidate-specific ligand/receptor
  recurrence.
- Corrected call counts: `18` axes audited; `0 GO_TO_HOSTILE_NOVELTY_REVIEW`;
  `4 CENTRAL_STATE_DRIVER_NOT_SELECTIVE_THERAPEUTIC`; `14 NO_GO_NICHE_DRIVER`.
- Remaining central-state drivers:
  `IFNG_IFNGR_JAK_STAT1_CIITA`, `MIF_CD74_CXCR4_CD44`,
  `LILRB_HLA_INHIBITORY_MYLOID_CHECKPOINT`, and
  `SPP1_CD44_INTEGRIN_RETENTION`.
- Integration decision: upstream niche-driver analysis does not produce a V3
  therapeutic claim. It clarifies the state neighborhood but reinforces the
  same blocker: no selective intervention point decouples HLA-II/CD74 antigen
  presentation from generic inflammatory host-defense programs.

## 2026-05-27 07:53 UTC

Wave31 dynamic transition-controller audit completed.

- Added `scripts/v3_wave31_dynamic_transition_controller_audit.py`; output:
  `phases/v3/results/wave31_dynamic_transition_controller_audit/`.
- Added the script to `scripts/entrypoints/run_v3_analysis.sh`.
- Call counts: `17` candidates audited; `0 GO_TO_HOSTILE_NOVELTY_REVIEW`;
  `1 PARK_STRONG_PERTURBATION_NO_DRUGGABLE_HANDLE`;
  `2 PARK_SELECTIVE_PERTURBATION_BUT_TRANSLATION_BLOCKED`;
  `9 NO_GO_L1000_ONLY_CONTROLLER`; `5 NO_GO_DYNAMIC_CONTROLLER`.
- `MED16` is the cleanest immune-cell perturbation comparator
  (`target_suppression=3.14`, `generic_ifn_suppression=0.80`,
  `margin=2.34`) but fails druggability, translational phenocopy, and
  cross-disease target-support gates.
- `CDK8_CDK19_MEDIATOR_KINASE` remains parked/blocked because it has chemical
  matter but no direct autoimmune APC phenocopy and high prior-art risk.
- Integration decision: close the direct dynamic-controller route. Do not claim
  a target based on MED16 by target-neighborhood analogy. Pivot to a downstream
  resolution/repair axis that may preserve host defense while resolving the
  lipid-lysosomal inflammatory state.

## 2026-05-27 07:56 UTC

Wave32 downstream-resolution rescue subagents dispatched.

- Initial dispatch attempt with explicit `agent_type` plus full-context fork was
  rejected by the tool because forked agents inherit type/model settings.
- Retried without explicit `agent_type`; all three dispatched successfully.
- `Wave32-A` (`019e686e-89a3-7071-a3d4-20e220ed9f6a`, Copernicus): cross-
  autoimmune efferocytosis/lipid-clearance target scan.
- `Wave32-B` (`019e686e-8ae0-7741-a402-4b299c9f4404`, Sagan):
  perturbation/dataset availability scan for resolution-axis nodes.
- `Wave32-C` (`019e686e-8c5f-77f0-9310-c75471cd1de0`, Laplace): prior-art and
  translational-feasibility attack.
- Orchestrator local work while agents run: build a strict candidate audit from
  existing V3 data for downstream resolution nodes, then vet agent outputs
  against local evidence.

## 2026-05-27 08:12 UTC

Wave32-C prior-art/translation audit integrated.

- Added and ran `scripts/v3_wave32c_resolution_prior_art_audit.py`.
- Output:
  `phases/v3/results/wave32c_resolution_prior_art_audit/`.
- Human-curated audit:
  `WAVE32C_PRIOR_ART_AUDIT.md`.
- Ranked TSV:
  `phases/v3/results/wave32c_resolution_prior_art_audit/route_feasibility_ranked.tsv`.

Vetting notes:

- Initial ClinicalTrials query for `AL002 TREM2` missed known AL002 studies.
  Script patched to query `AL002` and `INVOKE-2`; rerun captured
  `NCT03635047`, `NCT04592874`, and related AL002 records.
- Espacenet produced HTTP 403 in this runtime; Google Patents URLs and
  Espacenet search URLs were retained. Google Patents pages were directly
  accessible for sampled patents.
- Source inventory now covers PubMed, Europe PMC, ClinicalTrials.gov, ChEMBL,
  PubChem, Google Patents, and Espacenet URL records.

Integration decision:

- Wave32-C does not nominate a target. It narrows the downstream-resolution
  search space.
- Routes blocked or wrong-direction: generic `LXR/ABCA1`, `PPAR/RXR/retinoid`,
  `TREM2 agonism` as novelty route, `TAM inhibition`, and `GPNMB` depletion.
- Routes not fully blocked but insufficient: `NPC1/NPC2` functional rescue,
  `LIPA/LAL` enhancement, `TAM` agonism/GAS6/PROS1 biologics, non-depleting
  `GPNMB` handle.
- Best remaining whitespace: biased `FPR2`/specialized-pro-resolving mediator
  agonism and receptor-specific `CD300` modulation. Neither is claim-ready
  without perturbation evidence in disease-relevant myeloid cells.

## 2026-05-27 08:01 UTC

Wave32 downstream-resolution local audit completed.

- Added `scripts/v3_wave32_resolution_rescue_audit.py`; output:
  `phases/v3/results/wave32_resolution_rescue_audit/`.
- Added the script to `scripts/entrypoints/run_v3_analysis.sh`.
- Call counts: `14` routes audited; `0 GO_TO_HOSTILE_NOVELTY_REVIEW`;
  `1 PARK_RESOLUTION_BIOLOGY_NO_CAUSAL_ANCHOR`;
  `1 NO_GO_RESOLUTION_PRIOR_ART_BLOCKED`;
  `8 NO_GO_RESOLUTION_MARKER_OR_UNVALIDATED_ROUTE`;
  `4 NO_GO_RESOLUTION_ROUTE`.
- `TREM2_APOE_LIPID_REPAIR` is the only parked branch. It passes local
  breadth/MS-anchor/correct-direction-modality/safety gates but fails
  density-confounder, causal/real perturbation, prior-art, and independent
  validation gates.
- `NPC1_NPC2_CHOLESTEROL_EGRESS` scores highest numerically but is explicitly
  no-go because state coupling is density/confounder-dominated and lacks MS,
  causal, and perturbation anchors.
- Integration decision: downstream-resolution biology does not yet produce a
  therapeutic claim. Await Wave32 subagent reports for specific perturbation
  datasets or translational windows that could reopen a branch.

## 2026-05-27 08:03 UTC

Wave32-D / Hour-9 hostile critique dispatched.

- Agent: `019e6874-c729-78f3-a53c-240fce344fa0` (`Sartre`).
- Scope: attack Waves 30-32, decide whether the lipid-lysosomal/IFN-HLA-II
  module should be considered exhausted as a therapeutic-discovery route, define
  evidence required to reopen `TREM2/APOE`, `MERTK/TAM`, `LIPA`, or `NPC1/NPC2`,
  and recommend the next forced pivot outside the module.

## 2026-05-27 08:04 UTC

Wave32-A target-scan synthesis returned locally as
`WAVE32A_EFFEROCYTOSIS_RESOLUTION_SCAN.md`.

Vetting decision:

- Treat as a branch-ranking and evidence map, not a target claim.
- Automated Wave32 route audit remains binding for local evidence: no target is
  promoted; only `TREM2_APOE_LIPID_REPAIR` is parked.
- External synthesis identifies `FPR2/ALX` + `ANXA1` biased pro-resolution
  agonism as a new follow-up branch because it has direct pharmacological
  efferocytosis evidence in colitis, mechanistic LN macrophage support, and a
  druggable GPCR. It is Crohn/UC/LN-skewed and lacks an MS perturbation anchor.
- `MERTK/TAM` remains the strongest mechanistic breadth comparator but fails
  correct-direction agonist modality maturity and local V3 recurrence gates.
- `GPNMB`, `LIPA`, `NPC1/NPC2`, `CD300`, and PPAR/LXR/retinoid routes stay
  demoted as marker/readout, prior-art-saturated, or directionally ambiguous
  routes.

Next forcing question: does Wave32-B or Wave32-C provide a real perturbation
dataset, drug-response window, or prior-art-clean modality that can convert the
`FPR2/ANXA1`, `TREM2/APOE`, or `MERTK/TAM` branch from parked comparator into
a testable therapeutic program?

## 2026-05-27 08:04 UTC

Wave32-D / Hour-9 hostile critique returned and integrated.

- Report: `phases/v3/subagents/wave32d_hour9_hostile_critique.md`.
- Verdict: reject the lipid-lysosomal/IFN-HLA-II module as the active
  therapeutic-discovery route under the V3 DoD; keep it only as state scaffold,
  comparator, or biomarker hypothesis.
- Reopening rule: `TREM2/APOE`, `MERTK/TAM`, `LIPA`, and `NPC1/NPC2` require
  disease-relevant perturbation or target-level genetic evidence plus repair and
  host-defense guardrails; expression/state-coupling is insufficient.
- Next forced pivot: test the `CD226`/`TIGIT`/`PVR`-`PVRL2` lymphocyte
  checkpoint axis with hard genetics, cell-state, perturbation, modality, and
  prior-art gates.

## 2026-05-27 08:15 UTC

Wave33 local CD226/tolerance-costimulation pivot audit completed before a new
subagent wave.

- Added `scripts/v3_wave33_tolerance_costimulation_audit.py` to
  `scripts/entrypoints/run_v3_analysis.sh` and ran it.
- Output: `phases/v3/results/wave33_tolerance_costimulation_audit/`.
- Result: `13` tolerance/costimulation axes audited; `0` promoted.
- Calls: `11 NO_GO_TOLERANCE_PRIOR_ART_BLOCKED`,
  `2 NO_GO_TOLERANCE_AXIS`.
- `CD226_TIGIT_PVR_BALANCE` showed broad weak GWAS Catalog mapped-gene
  breadth (`15` autoimmune traits) but failed local cell-state support,
  MS-anchor, and prior-art gates. It is demoted as the active pivot.

Wave34 pivot fleet dispatch:

- Initial dispatch attempt with explicit reasoning override plus full-context
  fork was rejected; forked agents inherit parent settings.
- Wave34-A genetics-first target rescue dispatched:
  `019e687d-4588-7bb3-8689-d7a2e7a4ec13` (`Boyle`).
- Wave34-B `FPR2`/`ANXA1` efferocytosis branch dispatched:
  `019e687d-46f5-7721-8137-e9c6b6de5419` (`Socrates`).
- Wave34-C checkpoint/prior-art sanity check initially failed due thread limit.
  Completed Wave32-A and Wave32-D agents were closed, then Wave34-C was
  dispatched:
  `019e687d-eadb-7e01-9a2b-4aaa2a71312f` (`Einstein`).
- Wave32-B and Wave32-C still have no returned status; they are treated as
  pending/stale, not integrated.

## 2026-05-27 08:16 UTC

Wave32-B perturbation/dataset availability scan completed locally.

- Report: `phases/v3/subagents/wave32b_perturbation_dataset_availability_scan.md`.
- Matrix: `phases/v3/results/wave32b_dataset_availability_scan/candidate_dataset_matrix.tsv`.
- Scope guard: this is a dataset availability and recommended-analysis result,
  not a therapeutic finding.
- `32` rows catalogued; `15` primary or primary-screen candidate datasets.
- Strongest immediate local tests:
  `GSE156234` (`MERTK`/efferocytosis single-cell),
  `GSE212008` primary macrophage efferocytosis CRISPR screen,
  `GSE169160` human efferocytosis/LXR-PPARD macrophages,
  `GSE325329` IFNg/IL10 polarized BMDM apoptotic-cell phagocytosis,
  `GSE302857` Trem2KO/cuprizone microglia,
  `GSE100260`/`GSE243117`/`GSE285961` LIPA loss/gain, and
  `GSE274954` GPNMB lipid-loaded macrophages.
- `CD300*` and clean `AXL/TYRO3/PROS1` macrophage perturbation transcriptomes
  remain blocked or weak in this scan.

## 2026-05-27 08:21 UTC

Wave34-A genetics-first target rescue was executed locally in the shared repo
context after the external limit reset.

- Script: `scripts/v3_wave34a_genetics_first_target_rescue.py`.
- Report: `phases/v3/subagents/wave34a_genetics_first_target_rescue.md`.
- Results: `phases/v3/results/wave34a_genetics_first_target_rescue/`.
- Standard runner updated: `scripts/entrypoints/run_v3_analysis.sh`.
- Scope: broad autoimmune genetics-first scan for druggable candidates missed
  by expression-first screens; GWAS Catalog mapped-gene overlap treated as
  weak unless backed by local credible-set/eQTL/coloc-like evidence.
- Scale: `23` candidate genes, `15,875` local GWAS Catalog autoimmune rows,
  ChEMBL/GTEx/Europe PMC/ClinicalTrials.gov public API lookups cached under
  `phases/v3/results/wave34a_genetics_first_target_rescue/raw_api/`.
- Result: no candidate promoted. Parked: `IRF5`, `IL10`, `PTPN22`, `FAP`,
  `GPR65`, `CCR6`, `TNFRSF14`. Demoted: all others including `CD226`.
- Integration decision: do not claim a genetics-first target. The strict
  validation requirement for `CD226` is formal target-level coloc/eQTL/pQTL
  plus disease-tissue T/NK-state support.

## 2026-05-27 08:47 UTC

Wave35 corrected perturbation rerun completed locally after mapping audit.

- Script patched: `scripts/v3_wave35_resolution_perturbation_analysis.py`.
- Failure mode: failed Ensembl REST symbol lookups had been cached as empty
  mappings, producing artificially poor module coverage in Ensembl-indexed
  perturbation datasets.
- Fix: exact-symbol MyGene.info fallback mapping plus failed-cache handling.
- Corrected coverage in `GSE253577`, `GSE325329`, `GSE274954`, `GSE287142`:
  28/28 resolution genes, 21/27 lipid/APC genes, 13/15 IFN genes, 11/11 stress
  genes, 6/7 fibrosis genes.
- Corrected result: 10 datasets, 29 contrasts, 145 module-contrast rows, 0
  strict controller-like perturbation contrasts.
- Integration decision: downstream resolution/efferocytosis perturbation
  remains negative under strict controller criteria. Before closing the route,
  dispatch Wave36 to ask whether gene-level structure is masked by module
  averages and to run a hostile critique.

Wave36 dispatch:

- Wave36-A gene-level perturbation controller rescue dispatched:
  `019e689f-3fa9-7570-8133-ea5e1e02802b` (`Parfit`).
- Wave36-B hostile critique dispatched:
  `019e689f-4007-7d72-a024-47a07cd62fea` (`Euler`).

## 2026-05-27 08:58 UTC

Wave36-A and Wave36-B returned and were integrated.

- Wave36-B report: `phases/v3/subagents/wave36b_hostile_critique.md`.
- Wave36-B verdict: pivot away from active resolution/efferocytosis target
  discovery; keep the branch only as biomarker/readout panel and comparator.
- Wave36-A report: `phases/v3/subagents/wave36a_gene_level_controller_rescue.md`.
- Wave36-A script/results:
  `scripts/v3_wave36a_gene_level_controller_rescue.py`,
  `phases/v3/results/wave36a_gene_level_controller_rescue/`.
- Wave36-A result: 9 submodule-gate contexts and 13 gene-rescue-shaped contexts
  found under permissive scans, but 0 promotion-ready target routes.

Local Wave37/Wave38 rescue added and integrated:

- Wave37 direct screen script:
  `scripts/v3_wave37_gse212008_crispr_efferocytosis_screen.py`.
- Wave37 data: `GSE212008`, 74,674 sgRNAs, 19,672 genes.
- Wave37 result: 214 permissive KO-enhancer negative regulators and 54
  KO-impaired positive regulators. Canonical resolution candidates did not
  rescue the route; `FCGRT` was the most superficially tractable KO-enhancer.
- Wave38 rescue script:
  `scripts/v3_wave38_crispr_state_druggability_rescue.py`.
- Wave38 result: 184 screen-derived candidates scanned; 184
  `NO_GO_CRISPR_RESCUE`; 0 promoted. `FCGRT` failed disease-state direction,
  MS-anchor, and prior-art gates.

Integration decision:

- Accept the pivot: stop active discovery inside the resolution/efferocytosis
  branch and search outside the branch for a cross-autoimmune mechanism.

## 2026-05-27 09:05 UTC

Convergence Check 14 written: `CONVERGENCE_CHECK_14.md`.

Integration decision:

- The resolution/efferocytosis route is closed as an active target-discovery
  branch after corrected perturbation, gene-level rescue, direct CRISPR screen,
  disease-state integration, druggability, and critique gates.
- The branch remains an assay/readout scaffold only.

Wave39 dispatch:

- Wave39 local orchestrator scan initiated: accessibility-first rescue over
  broad cross-autoimmune recurrence outside the already-demoted downstream
  resolution branch.
- Wave39-B hostile accessibility/prior-art critique dispatched:
  `019e68b0-467c-7291-aa59-0bd5e4dec3de` (`Chandrasekhar`).

Hard gate:

- No promotion without cross-disease breadth, MS anchor, accessibility, feasible
  modality, non-crowded novelty, and explicit therapeutic direction.

## 2026-05-27 09:20 UTC

Wave39 and Wave40 integrated.

Wave39 local scan:

- Script: `scripts/v3_wave39_surfaceome_rescue_after_resolution_pivot.py`.
- Results: `phases/v3/results/wave39_surfaceome_rescue_after_resolution_pivot/`.
- Scope: broad h5ad recurrence pool filtered through UniProt accessibility,
  ChEMBL target/activity, Europe PMC/ClinicalTrials.gov saturation, prior V3
  demotion flags, and MS-anchor/direction gates.
- Scale: 224 candidate genes, 224 UniProt lookups, 90 ChEMBL target/activity
  lookups, and 60 Europe PMC/ClinicalTrials.gov prior-art lookups.
- Bug found and corrected: initial `PSMA3` `GO_REVIEW` was a classifier
  artifact. `PSMA3` is cytoplasmic/nuclear proteasome core machinery; the
  accessibility test matched incidental wording and lacked proteasome-core hard
  exclusion. After patch and rerun, `PSMA3` became `NO_GO_SURFACEOME_RESCUE`.
- Corrected result: 0 `GO_REVIEW`, 6 `PARK_REVIEW`, 218
  `NO_GO_SURFACEOME_RESCUE`.

Wave39-B critique:

- Report: `phases/v3/subagents/wave39b_accessibility_prior_art_critique.md`.
- Accepted verdict: the accessibility-first route is a hostile filter, not a
  finding engine. Accessible candidates require independent target-level
  causal or perturbation evidence before promotion.

Wave40 parked candidate fail-fast:

- Script/results: `scripts/v3_wave40_parked_surface_failfast.py`,
  `phases/v3/results/wave40_parked_surface_failfast/`.
- Parked rows tested: `MMP7`, `CD82`, `FXYD5`, `SCD`, `CCL20`, `IL23A`.
- Outcome: 5 `NO_GO_PARKED_SURFACE_FAILFAST`; `FXYD5`
  `PARK_ONLY_IF_NEW_PERTURBATION`.

Integration decision:

- Do not promote any surfaceome/accessibility-first candidate.
- `FXYD5` can only be reopened with independent human perturbation and a
  defined non-depleting modality; it is not a V3 target.

## 2026-05-27 09:32 UTC

Convergence Check 15 written: `CONVERGENCE_CHECK_15.md`.

Wave41 local execution:

- Script: `scripts/v3_wave41_l1000_external_unknown_deconvolution.py`.
- Targeted unresolved item: Wave27 `PARK_EXTERNAL_TARGET_LOOKUP_ONLY`
  `BRD-A72180425` / `K784-3188`.
- First run failure: report generation used `pandas.to_markdown()` without
  `tabulate`; patched to local markdown rendering and reran successfully.
- Result: `BRD-A72180425` resolves to PubChem CID `3689416`, ChEMBL
  `CHEMBL1472126`, and an ML162/RAS-selective-lethal probe-family context.
- Gate result: `NO_GO_CYTOTOXIC_PROBE_ANALOG`, no promotion.

Integration decision:

- The perturbation-first repurposing branch is closed. L1000 recurrence did
  not produce a targetable, selective autoimmune intervention.
- Pivot to genetics-first lipid biology, starting with the unresolved
  `FADS1/FADS2` desaturation locus because it is lipid-relevant, genetically
  broad, and not already exhausted by expression-based module testing.

## 2026-05-27 09:34 UTC

Wave42 dispatch:

- Local orchestrator scan opened for the `FADS1/FADS2` desaturation locus.
- Wave42-B hostile reviewer dispatched:
  `019e68ca-40be-78a1-997b-1fe65cecfe12` (`Kuhn`).
- First spawn attempt with `fork_context=true` was rejected by the tool because
  full-history forks inherit agent settings. Retried without `fork_context`;
  dispatch succeeded.

Integration rule:

- Subagent output will be treated as critique only. No FADS claim can be made
  without local code-backed evidence, target-level genetic direction or an
  explicit failure note, and prior-art vetting.

## 2026-05-27 09:45 UTC

Wave42 integrated:

- Local script: `scripts/v3_wave42_fads_lipid_desaturation_axis.py`.
- Results: `phases/v3/results/wave42_fads_lipid_desaturation_axis/`.
- Bugfix: ClinicalTrials.gov empty-result parsing corrected; `AMG 786` and
  `D5D inhibitor` queries added.
- Local conclusion: `FADS1/FADS2` is not promotable. The signal is broad but
  locus-level, direction unresolved, weak/non-MS in local cell-state evidence,
  absent from residual gates, and lacks LINCS perturbagen validation.
- Subagent Wave42-B (`Kuhn`) completed and was closed. The critique verdict
  was `DEMOTE`, consistent with local gates.

Integration decision:

- Park `FADS1/FADS2` only for future target-resolved coloc/MR, lesion
  lipidomics, and disease-relevant FADS perturbation experiments.
- Continue searching; do not convert the branch into a target claim.

## 2026-05-27 09:47 UTC

Wave43 integrated:

- Script: `scripts/v3_wave43_genetic_druggable_failfast.py`.
- Results: `phases/v3/results/wave43_genetic_druggable_failfast/`.
- Scope: the four Wave34 `PARK_GENETIC_DRUGGABLE_NEEDS_CELL_STATE` rows:
  `FADS1`, `TYK2`, `NOD2`, and `JAK2`.
- Result: 0 promotions; calls were one `NO_GO_ALREADY_DEMOTED_WAVE42`, two
  `NO_GO_PRIOR_ART_AND_GENERIC_IMMUNOSUPPRESSION`, and one
  `NO_GO_DIRECTION_AND_CONTEXT_MISMATCH`.

Integration decision:

- Genetics-plus-druggability without cell-state/perturbation support is closed.
- Next route: complement factor B / alternative complement as a
  biomarker-selected repurposing or stratification candidate, not as a generic
  complement story.

## 2026-05-27 09:52 UTC

Wave44 integrated:

- Script: `scripts/v3_wave44_cfb_complement_stratification_audit.py`.
- Results: `phases/v3/results/wave44_cfb_complement_stratification_audit/`.
- Patch: fixed Wave21 prior-art join from `gene` to `candidate`.
- Result: `NO_GO_COMPLEMENT_STRATIFICATION_PRIOR_ART_BLOCKED`.

Integration decision:

- `CFB` is retained only as a complement-high assay/comparator route.
- It is not promotable as a V3 finding because there is no MS anchor, no
  target-resolved causal genetic package, only Crohn-stromal strict residual
  survival, do-not-promote foundation/perturbation status, and heavy factor-B
  inhibitor prior art.

## 2026-05-27 09:55 UTC

Wave45 integrated:

- Script: `scripts/v3_wave45_regulatory_controller_audit.py`.
- Results: `phases/v3/results/wave45_regulatory_controller_audit/`.
- Scope: `TNFAIP3`, `SBNO2`, `SP140`, `GPR65`, `IL10`, `MED16`,
  `CDK8_CDK19_MEDIATOR_KINASE`, and `GSK3B`.
- Result: 0 promotions.

Integration decision:

- Regulatory/restoration controllers remain biologically instructive but not
  translationally actionable under the current V3 constraints.
- Continue searching outside the current candidate lists rather than reopening
  A20/SBNO2/SP140/MED16 variants.

## 2026-05-27 10:02 UTC

Wave46 integrated:

- Script: `scripts/v3_wave46_central_axis_closure_audit.py`.
- Results: `phases/v3/results/wave46_central_axis_closure_audit/`.
- Scope: the five central axes from
  `phases/v3/results/central_and_intervention_candidate_rank.tsv`.
- Result: 0 promotions.

Integration decision:

- Close the original central-axis intervention set:
  IFNGR/JAK/STAT1, CD74/HLA-II, CIITA/RFX5/NLRC5, IFI30/GILT, and CTSS.
- The model-backed distinction is decisive: upstream IFNGR/JAK suppression
  controls the transition but is generic/prior-arted; IFI30 and CTSS are
  downstream effectors and do not control the transition.
- Future work should not reopen these axes unless it adds a genuinely new
  modality, target-resolved causal genetics, or disease-relevant perturbation
  evidence.

## 2026-05-27 10:05 UTC

Wave47-G dispatch plan added:

- Role: hostile late-stage overlooked-route critique.
- Purpose: challenge the post-Wave46 closure boundary and identify any
  surviving therapeutic route that is not a relabel of a demoted axis.
- The subagent output is advisory only and requires local vetting before any
  integration.

## 2026-05-27 10:12 UTC

Wave48-G dispatch plan added:

- Role: adversarial resolution-reopener reviewer.
- Scope: stress-test the two non-relabel reopeners from Wave47-G:
  biased `FPR2/ANXA1` pro-resolution agonism and receptor-specific `CD300`
  tuning.
- Local orchestrator will run a separate evidence audit so subagent output is
  treated as untrusted until reconciled with code-backed tables.

## 2026-05-27 10:20 UTC

Wave47 and local Wave48 integrated:

- Wave47 local map: `scripts/v3_wave47_late_stage_survivor_map.py` and
  `phases/v3/results/wave47_late_stage_survivor_map/`.
- Wave47 result: 0 promotable late-stage routes; 15 reopen-only routes remain
  but none satisfies the V3 therapeutic gates now.
- Wave48 local audit: `scripts/v3_wave48_resolution_reopener_audit.py` and
  `phases/v3/results/wave48_resolution_reopener_audit/`.
- Wave48 result: 0 promotions.

Integration decision:

- `FPR2/ANXA1` is retained only as a wet-lab pro-resolution assay branch.
- `CD300` is retained only as a receptor-specific perturbation branch.
- Neither branch can be used for `FINDING_V3.md` without new perturbation and
  MS-anchor evidence.
- Wave48-G is still running; its output will be reconciled with the local
  audit when it returns.

## 2026-05-27 10:22 UTC

Wave48-G returned and was closed.

- Preserved report:
  `phases/v3/subagents/wave48g_resolution_reopener_critique.md`.
- Subagent verdict matched the local audit: no `PROMOTE_CANDIDATE`;
  `FPR2/ANXA1` and receptor-specific `CD300` are only narrow wet-lab
  reopeners.
- Additional external details from the subagent were treated as advisory
  rather than promotion-grade because the local gates still lack strict MS
  anchor and direct receptor/ligand perturbation evidence.

## 2026-05-27 10:24 UTC

Wave49-G dispatch plan added:

- Role: adversarial `PTPN22` directionality and modality reviewer.
- Scope: decide whether the top Wave47 reopen-only genetics route has a
  target-resolved direction and feasible selective modality, or whether broad
  autoimmune genetics are misleading.
- Local orchestrator will run a separate code-backed `PTPN22` audit in
  parallel.

## 2026-05-27 10:28 UTC

Local Wave49 integrated:

- Script: `scripts/v3_wave49_ptpn22_directionality_audit.py`.
- Results: `phases/v3/results/wave49_ptpn22_directionality_audit/`.
- Verdict: `PTPN22` is `NO_GO_BROAD_GENETICS_WITH_UNRESOLVED_DIRECTION_AND_SELECTIVITY`.
- Pass count: 2/9 gates. The branch has broad genetics and chemical matter,
  but fails target-resolved direction, strict MS anchor, disease-cell
  perturbation, phosphatase selectivity, disease-safe modulation direction, and
  novelty/prior-art gates.
- Wave49-G remains in flight; its output will be reconciled when returned.

## 2026-05-27 10:30 UTC

Wave49-G returned and was closed.

- Preserved report:
  `phases/v3/subagents/wave49g_ptpn22_directionality_critique.md`.
- Subagent verdict matched the local audit: `PTPN22` is `NO_GO`, not a V3
  therapeutic candidate.
- The advisory prior-art details strengthened the closure: broad PTPN22
  inhibitor autoimmune and MS patent claims appear to cover the obvious
  intervention route.

## 2026-05-27 10:31 UTC

Wave50-G dispatch plan added:

- Role: adversarial `GPR65` acid-sensing GPCR reviewer.
- Scope: decide whether GPR65 agonism/PAM has enough non-IBD/MS direction and
  perturbation support to overcome prior art, or whether it is no-go.
- Local orchestrator is running a code-backed Wave50 audit in parallel.

## 2026-05-27 10:35 UTC

Local Wave50 integrated:

- Script: `scripts/v3_wave50_gpr65_acid_sensing_gpcr_audit.py`.
- Results: `phases/v3/results/wave50_gpr65_acid_sensing_gpcr_audit/`.
- Verdict: `GPR65` is `NO_GO_GPR65_PRIOR_ART_AND_LOCAL_CELLSTATE_MISMATCH`.
- Pass count: 3/8 gates. The branch passes genetics, modality, and clinical
  whitespace but fails target-resolved coloc/MR, strict MS anchor, local
  cell-state alignment, real perturbation, and novelty/prior-art gates.
- Wave50-G remains in flight; its output will be reconciled when returned.

## 2026-05-27 10:39 UTC

Local Wave51 integrated:

- Script: `scripts/v3_wave51_reachable_stromal_surface_audit.py`.
- Results: `phases/v3/results/wave51_reachable_stromal_surface_audit/`.
- Verdicts:
  - `FAP`: `NO_GO_REACHABLE_SURFACE_STROMAL_ROUTE`, 2/8 gates passed.
  - `FXYD5`: `NO_GO_REACHABLE_SURFACE_STROMAL_ROUTE`, 1/8 gates passed.
- Integration decision: accessible/stromal expression is insufficient without
  strict MS anchoring, perturbation, direction/safety, and non-blocking
  prior-art evidence.

## 2026-05-27 10:41 UTC

Hour-12 active-work checkpoint reached.

- Wrote `MILESTONE_6_MISS.md`.
- Rationale: no candidate currently satisfies the V3 DoD, so `FINDING_V3.md`
  would be overstated.
- Per the user's stop conditions, the session continues rather than writing
  `EXHAUSTION.md`.

## 2026-05-27 10:43 UTC

Wave50-G returned and was closed.

- Preserved report:
  `phases/v3/subagents/wave50g_gpr65_critique.md`.
- Integration decision: local Wave50 and Wave50-G agree on `GPR65` `NO_GO`.
  The branch remains a wet-lab reopener only because genotype-stratified acidic
  pH primary-cell PAM biology could still be useful, but it cannot support a
  V3 therapeutic claim.

## 2026-05-27 10:48 UTC

Local Wave52 started:

- Script: `scripts/v3_wave52_remaining_mechanistic_reopeners.py`.
- Scope: consolidated hard-gate audit of `CCR6`, `TREM2/APOE`, `SQLE`, and
  localized `IL10`.
- Integration logic: a candidate cannot promote unless route-level biology is
  backed by target-specific MS evidence, target-resolved genetics or coloc,
  foundation/real perturbation agreement, safe intervention direction, and a
  non-blocked novelty delta.

## 2026-05-27 10:51 UTC

Local Wave52 integrated.

- Results: `phases/v3/results/wave52_remaining_mechanistic_reopeners/`.
- Verdicts:
  - `CCR6_TH17_TRAFFICKING`:
    `NO_GO_CROWDED_TRAFFICKING_NO_COLOC_LOCAL_SUPPORT`, 2/8 gates passed.
  - `TREM2_APOE_LIPID_REPAIR`:
    `NO_GO_TREM2_PRIOR_ART_MARKER_CONFOUNDER`, 3/8 gates passed.
  - `SQLE_STEROL_STROMAL`: `NO_GO_SQLE_FAILFAST_RECONFIRMED`, 2/8 gates
    passed.
  - `LOCALIZED_IL10_RESTORATION`:
    `NO_GO_IL10_PRIOR_ART_SYSTEMIC_CYTOKINE_DELIVERY`, 2/8 gates passed.
- Integration decision: the Wave47 reopen-only list is now closed for V3
  therapeutic promotion unless new external wet-lab or coloc data are added.
  Continue by pivoting to a different evidence axis.

## 2026-05-27 10:56 UTC

Wave53 dispatch plan added:

- Wave53-G: adversarial review of whether strong `Med16_KO` perturbation can
  be translated through a druggable Mediator/CDK8/19-like intervention without
  collapsing into broad transcriptional toxicity.
- Wave53-H: hostile review of treatment-response stratification outputs, with
  the explicit standard that baseline signals must survive correction,
  generic-inflammation residualization, and independent replication.
- Wave53-I: cross-domain scout for new intervention mechanisms that map to the
  lipid-lysosomal / antigen-processing myeloid module while avoiding all
  already-closed axes.

## 2026-05-27 10:58 UTC

Wave53 subagents dispatched:

- Wave53-G `019e6919-5f4a-79c0-b30f-45d977d3997d` (`Maxwell`):
  MED16/Mediator perturbation-first druggability review.
- Wave53-H `019e6919-609b-7973-b7e5-1d856126450e` (`Erdos`):
  treatment-response stratification rescue review.
- Wave53-I `019e6919-6223-7763-8b87-ef9a631356ab` (`Huygens`):
  cross-domain intervention scout.

## 2026-05-27 11:04 UTC

Local Wave53 perturbation-first audit started.

- Script: `scripts/v3_wave53_perturbation_first_pivot.py`.
- Scope: evaluate perturbation-positive routes (`MED16/Mediator`, `GSK3B`,
  `TNFRSF1A`, `RFX5`, `CHUK`) against real perturbation selectivity,
  foundation/model support, cross-disease cell-state breadth, strict MS anchor,
  genetics or treatment-response anchor, druggability, safe direction, and
  novelty gates.

## 2026-05-27 11:08 UTC

Wave53 integrated:

- Wave53-G `Maxwell`: closed; `WETLAB_ONLY` for MED16/Mediator.
- Wave53-H `Erdos`: closed; `NO_GO` for treatment-response stratification.
- Wave53-I `Huygens`: closed; no therapeutic shortlist, one `MFGE8`
  `PARK_EX_VIVO_ONLY` reopener.
- Local Wave53 results:
  `phases/v3/results/wave53_perturbation_first_pivot/`.
- Integration decision: no perturbation-first therapeutic claim is available.
  Continue with a focused Wave54 audit of `MFGE8` because it is the only new
  cross-domain mechanism that is not just a relabel of prior closed axes.

## 2026-05-27 11:13 UTC

Local Wave54 started:

- Script: `scripts/v3_wave54_mfge8_debris_opsonin_audit.py`.
- Scope: decide whether `MFGE8` debris-opsonin augmentation is promotable or
  only an ex vivo wet-lab idea.
- Key gates: cross-domain mechanistic anchor, local cross-autoimmune support,
  strict MS anchor, efferocytosis screen support, tractable modality,
  bystander phagocytosis safety, prior-art/clinical crowding, and promotion-
  grade package.

## 2026-05-27 11:16 UTC

Local Wave54 integrated:

- Results: `phases/v3/results/wave54_mfge8_debris_opsonin_audit/`.
- Verdict: `MFGE8` is `PARK_EX_VIVO_ONLY_MFGE8_DEBRIS_OPSONIN`, 3/8 gates
  passed.
- Integration decision: `MFGE8` is not a V3 therapeutic finding. The branch is
  useful only as a concrete wet-lab assay design because local MS/cross-disease
  support and efferocytosis screen support are weak, while bystander
  phagocytosis risk is unresolved.

## 2026-05-27 11:18 UTC

Local Wave55 started:

- Script: `scripts/v3_wave55_external_genetics_druggability_sweep.py`.
- Scope: live Open Targets cross-autoimmune associated-target sweep, joined to
  local cell-state/perturbation evidence, ChEMBL druggability, and Europe PMC
  literature counts.
- Guardrail: Open Targets associated-target evidence is not treated as
  coloc/MR; the coloc/MR-grade gate remains false unless paired summary-stat
  analysis is actually run.

## 2026-05-27 11:20 UTC

Local Wave55 integrated:

- Results: `phases/v3/results/wave55_external_genetics_druggability_sweep/`.
- Scope completed: 12 autoimmune diseases queried through live Open Targets
  GraphQL; results joined to local cell-state, perturbation, foundation-model,
  ChEMBL, and Europe PMC summary channels.
- Summary:
  - raw Open Targets associated-target rows: 6000.
  - non-closed ranked targets: 2815.
  - promoted targets: 0.
  - reopen-priority targets: 2 (`SP140`, `IL12A`).
- Integration decision:
  - `SP140` is the stronger next forcing target because it combines
    cross-autoimmune external genetics with local cross-disease cell-state
    replication and less early literature saturation.
  - `IL12A` is held as a tractable comparator, not a lead, because it lacks
    local module replication and is likely crowded by IL-12/23 autoimmune
    therapeutic prior art.
  - No Wave55 result can satisfy the V3 genetics gate without real coloc/MR
    or similarly target-resolved causal evidence.

## 2026-05-27 11:23 UTC

Wave56 dispatch plan added:

- Wave56-J: `SP140` genetics and prior-art audit.
- Wave56-K: `SP140` perturbation and druggability audit.
- Wave56-L: `IL12A` comparator and prior-art control.

Integration logic:

- `SP140` is the lead forcing target only if target-resolved genetic or
  perturbation evidence appears. Otherwise it remains a cross-disease marker.
- `IL12A` is not a lead unless the comparator review identifies a genuinely
  non-obvious and local-module-compatible therapeutic angle.

## 2026-05-27 11:23 UTC

Wave56 dispatch attempt:

- First dispatch attempt failed because full-history forked agents inherit
  parent agent type and cannot specify `agent_type`.
- Retried immediately with inherited defaults.

Wave56 subagents dispatched:

- Wave56-J `019e692d-3375-76a1-925c-95168fc6fede` (`Turing`):
  `SP140` genetics and prior-art audit.
- Wave56-K `019e692d-34be-72e1-bf35-24aaa227525f` (`Godel`):
  `SP140` perturbation and druggability audit.
- Wave56-L `019e692d-3631-7362-9c9e-9be11b448a81` (`Averroes`):
  `IL12A` comparator and prior-art control.

## 2026-05-27 11:23 UTC

Local Wave56 started:

- Script: `scripts/v3_wave56_sp140_targeted_reopener_audit.py`.
- Scope: target `SP140` as the lead Wave55 reopener; include `IL12A` and
  `GALC` as comparators.
- Hard gates: target-resolved coloc/MR, strict MS local support,
  module-specific residual signal, real perturbation/foundation support,
  direct druggability, correct intervention direction, and early prior-art
  blocking.

## 2026-05-27 11:29 UTC

Local Wave56 integrated:

- Results: `phases/v3/results/wave56_sp140_targeted_reopener_audit/`.
- Verdict: `SP140` is `NO_GO_SP140_TARGETED_AUDIT`, 2/10 gates passed.
- Integration decision: `SP140` is demoted to marker/reopener status. It
  cannot serve as the V3 therapeutic central node without target-resolved
  causality, strict MS support, perturbation evidence, and a correct-direction
  restoration modality.

## 2026-05-27 11:33 UTC

Wave56-L returned:

- Agent `019e692d-3631-7362-9c9e-9be11b448a81` (`Averroes`) created
  `phases/v3/subagents/wave56l_il12a_comparator_prior_art.md`.
- Verdict: `DEMOTE_IL12A_TO_COMPARATOR_CONTROL`.
- Integration decision: `IL12A` remains a comparator/control. Selective
  IL-12p35 antagonism is biologically real but already covered by DM618 and
  `WO2025166228A1`; p40 MS trial precedent is unfavorable; p35 agonism/IL-35
  biology is a future research route, not a V3 promotion.

## 2026-05-27 11:33 UTC

Local Wave57 started:

- Script: `scripts/v3_wave57_intervention_first_geneformer_screen.py`.
- Scope: bounded Geneformer V2-104M token-deletion screen over
  intervention-first candidates from the lipid-lysosomal, external-genetics,
  surface/chemokine, and druggable comparator axes.
- Integration rule: Geneformer support is only triage. A candidate reopens
  only if model support aligns with cross-disease genetics and local
  recurrence; promotion still requires a full therapeutic audit.

## 2026-05-27 11:34 UTC

Wave56-J returned:

- Agent `019e692d-3375-76a1-925c-95168fc6fede` (`Turing`) created
  `phases/v3/subagents/wave56j_sp140_genetics_prior_art.md`.
- Verdict: demote `SP140` as a V3 therapeutic target nomination.
- Integration decision:
  - The sidecar agrees with local Wave56 demotion.
  - It strengthens the demotion because MS/Crohn target-resolved genetics are
    real, but direct SP140 modulation is already published and patented for
    autoimmune/inflammatory disease.
  - `SP140` remains useful as a comparator/stratification axis, not as
    `FINDING_V3`.

## 2026-05-27 11:40 UTC

Wave56-K returned:

- Agent `019e692d-34be-72e1-bf35-24aaa227525f` (`Godel`) created
  `phases/v3/subagents/wave56k_sp140_perturbation_druggability.md`.
- Support script:
  `scripts/v3_wave56k_sp140_perturbation_druggability_audit.py`.
- Outputs:
  `phases/v3/results/wave56k_sp140_perturbation_druggability/`.
- Verdict: `DEMOTE_FOR_V3_PROMOTION; PARK_AS_SP140_HIGH_IBD_TOOL_COMPOUND_AND_STRATIFICATION_ROUTE`.
- Integration decision:
  - Local Wave56 was too strict in saying no direct perturbation evidence;
    published `SP140` siRNA and GSK761 evidence exists.
  - That evidence still does not rescue V3 promotion because it is mostly
    early IFN/NF-kB macrophage suppression, not a clean lipid-lysosomal module
    rescue; local MS support is null; CNS/lead-like feasibility is weak; and
    direct SP140 inhibition is prior art.
  - Added the support script to `scripts/entrypoints/run_v3_analysis.sh` for reproducibility.

## 2026-05-27 11:40 UTC

Local Wave57 integrated:

- Results: `phases/v3/results/wave57_intervention_first_geneformer_screen/`.
- Model: bounded Geneformer V2-104M token-deletion screen using revision
  `04c2b2e84da7c0f385c3f9ad8f3ec24bab6650e5`.
- Contexts: 11 disease-relevant tissue/cell contexts across IBD, psoriasis,
  Sjogren, T1D, and RA.
- Candidate genes screened: 26.
- Promotions: 0.
- Reopeners: 2.
  - `CXCR2`: `REOPEN_MODEL_SUPPORTED_INTERVENTION_FIRST`; model support in
    `IBD_myeloid`; cross-disease Open Targets genetics in AS/Crohn/psoriasis/
    RA/UC; local positives in Crohn/psoriasis/UC; no MS genetic anchor.
  - `IL7R`: `REOPEN_MODEL_SUPPORTED_INTERVENTION_FIRST`; model support in
    `ra_myeloid_dendritic`; cross-disease genetics in seven diseases including
    MS; local positives in Crohn/T1D/UC; strict MS local anchor failed.
- Integration decision: dispatch focused audits. `CXCR2` is intervention-
  tractable but MS-weak; `IL7R` is genetically broad/MS-anchored but prior-art
  and biology crowded.

## 2026-05-27 11:41 UTC

Wave58 dispatch plan added:

- Wave58-M: `CXCR2` therapeutic reopener audit.
- Wave58-N: `IL7R` therapeutic reopener audit.
- Wave58-O: hostile review of both Wave57 reopeners.

Integration logic:

- `CXCR2` must overcome weak MS anchoring and generic neutrophil-chemotaxis
  prior art.
- `IL7R` must overcome canonical lymphocyte/T-cell survival biology and
  anti-CD127 prior art.
- Neither branch can promote from Geneformer triage alone.

## 2026-05-27 11:41 UTC

Wave58 subagents dispatched:

- Wave58-M `019e693e-220a-7b22-bf91-83afe0f71d6a` (`Curie`):
  `CXCR2` therapeutic reopener audit.
- Wave58-N `019e693e-2550-71e3-b0ca-6b333e602558` (`Cicero the 2nd`):
  `IL7R` therapeutic reopener audit.
- Wave58-O `019e693e-23e0-7532-9833-4ddc202b6c7e` (`Meitner`):
  hostile review of `CXCR2` and `IL7R`.

## 2026-05-27 11:42 UTC

Local Wave58 started:

- Script: `scripts/v3_wave58_cxcr2_il7r_targeted_audit.py`.
- Scope: hard-gated targeted audit of `CXCR2` and `IL7R`, joined to local
  Wave57/Wave55/broad evidence plus live ChEMBL, UniProt, Europe PMC,
  ClinicalTrials.gov, and patent-search URLs.
- Manual hard gates:
  - `CXCR2` must not collapse into generic neutrophil chemotaxis.
  - `IL7R` must not collapse into generic lymphocyte survival.

## 2026-05-27 11:47 UTC

Local Wave58 integrated:

- Results: `phases/v3/results/wave58_cxcr2_il7r_targeted_audit/`.
- Verdicts:
  - `CXCR2`: `NO_GO_WAVE58_TARGETED_AUDIT`, 4/9 gates passed.
  - `IL7R`: `NO_GO_WAVE58_TARGETED_AUDIT`, 5/9 gates passed.
- Integration decision:
  - `CXCR2` has real chemical matter and a Geneformer/local recurrence
    reopener, but fails MS genetics, strict MS local support, real
    perturbation/efferocytosis, module specificity, and prior-art gates.
  - `IL7R` has stronger MS/cross-autoimmune genetics and a biologic modality
    precedent, but fails strict MS local support, real perturbation,
    module-specificity, and prior-art gates.
  - No Wave57 branch remains promotable.

## 2026-05-27 11:48 UTC

Wave58-O returned:

- Agent `019e693e-23e0-7532-9833-4ddc202b6c7e` (`Meitner`) created
  `phases/v3/subagents/wave58o_hostile_review_cxcr2_il7r.md`.
- Verdict: close both `CXCR2` and `IL7R` for V3 therapeutic promotion.
- Integration decision:
  - The hostile review agrees with local Wave58 closure.
  - It adds direct prior-art concerns: `CXCR2` demyelination/CNS-penetrant
    antagonist work and IL7R/CD127 clinical/patent programs.
  - Continue pivot away from canonical trafficking/survival targets.

## 2026-05-27 11:48 UTC

Local Wave59 started:

- Script: `scripts/v3_wave59_lysosomal_sphingolipid_model_reopener_audit.py`.
- Scope: audit the strongest Wave57 non-canonical model signals among
  lysosomal/sphingolipid enzymes (`CTSB`, `ASAH1`, `HEXB`, `HEXA`, `CTSS`,
  `CTSD`, `PSAP`, `LIPA`, `GALC`, `GBA1`, `SMPD1`).
- Hard gate: a lysosomal enzyme cannot promote unless intervention direction
  is safe and selective. Generic lysosomal inhibition/enhancement is not
  sufficient.

## 2026-05-27 11:54 UTC

Wave58 subagent closure:

- Closed Wave58-M `019e693e-220a-7b22-bf91-83afe0f71d6a` (`Curie`).
  Report: `phases/v3/subagents/wave58m_cxcr2_therapeutic_audit.md`.
  Integration decision: `CXCR2` closed for V3 promotion.
- Closed Wave58-N `019e693e-2550-71e3-b0ca-6b333e602558`
  (`Cicero the 2nd`). Report:
  `phases/v3/subagents/wave58n_il7r_therapeutic_audit.md`.
  Integration decision: `IL7R` closed for V3 promotion.
- Closed Wave58-O `019e693e-23e0-7532-9833-4ddc202b6c7e` (`Meitner`).
  Report: `phases/v3/subagents/wave58o_hostile_review_cxcr2_il7r.md`.
  Integration decision: hostile review supports closure of both branches.

## 2026-05-27 11:55 UTC

Local Wave59 integrated:

- Results: `phases/v3/results/wave59_lysosomal_sphingolipid_model_reopener_audit/`.
- Verdict: no lysosomal/sphingolipid single-enzyme target is promotable.
- Key decision rows:
  - `GALC`: 4/10 gates; genetic/local hints, but failed model support,
    strict MS white-matter, module-residual, perturbation/efferocytosis,
    directionality, and prior-art gates.
  - `CTSB`: 3/10 gates; strongest model support among the direct enzyme
    rows, but no MS genetic anchor, weak local recurrence, no strict MS
    support, unresolved efferocytosis, unsafe/nonspecific inhibition route,
    and heavy prior art.
  - `ASAH1`: 2/10 gates; model/druggability hints only; no genetics or local
    recurrence and unresolved/toxic ceramide-axis direction.

Integration decision:

- Do not promote any direct lysosomal enzyme.
- Treat this as evidence that the module is real but probably requires an
  upstream state-transition controller, not direct housekeeping-organelle
  modulation.
- Next orchestration move: circuit/stratification pivot rather than another
  one-gene inflammatory receptor reopener.

## 2026-05-27 12:00 UTC

Wave60 dispatch plan added:

- Wave60-P: `C15ORF48/MOCCI` mitochondrial/inflammatory switch audit.
- Wave60-Q: `OSM/OSMR/IL6ST` tissue-niche circuit audit.
- Wave60-R: hostile methods review of the circuit-level pivot.

Integration logic:

- The local orchestrator will run a donor-level circuit-coupling analysis
  across existing h5ad module/gene scores.
- Subagents audit whether the strongest local circuit candidates have
  external mechanism, therapeutic tractability, and novelty.
- No subagent may claim `FINDING_V3`; their outputs are treated as untrusted
  until reconciled with local code and prior-art checks.

## 2026-05-27 12:01 UTC

Wave60 subagents dispatched:

- Wave60-P `019e694f-6d85-7521-91c4-f8561900121e`
  (`Galileo the 2nd`): `C15ORF48/MOCCI` circuit audit.
- Wave60-Q `019e694f-6db2-7cb3-aa28-98cabf336adb`
  (`James the 2nd`): `OSM/OSMR/IL6ST` circuit audit.
- Wave60-R `019e694f-6dcc-7e33-a542-51547e080e16`
  (`Newton the 2nd`): hostile methods review of the circuit pivot.

Local non-overlapping work:

- Implement Wave60 donor-level circuit-coupling analysis while sidecars run.

## 2026-05-27 12:06 UTC

Local Wave60 integrated:

- Script: `scripts/v3_wave60_circuit_coupling_pivot.py`.
- Outputs: `phases/v3/results/wave60_circuit_coupling_pivot/`.
- Result: 0 full reopeners, 63 parked expression-coupling hypotheses.
- Interpretation: donor-level circuit coupling produces biologically
  suggestive rows (`GPNMB`, `OSMR`, `C15ORF48`, complement/C1q), but no row
  combines coupling, disease recurrence, MS support, and perturbation/model
  support.

Integration decision:

- Do not promote local circuit coupling.
- Use Wave60-P/Q only to decide whether external mechanism/prior art closes or
  parks `C15ORF48` and `OSM/OSMR`.
- Begin a perturbation-first intervention mining pivot.

## 2026-05-27 12:06 UTC

Wave60-R returned and was closed:

- Agent `019e694f-6dcc-7e33-a542-51547e080e16` (`Newton the 2nd`).
- Report: `phases/v3/subagents/wave60r_circuit_pivot_hostile_review.md`.
- Verdict: `NO_GO` for promoting current donor-level circuit coupling.

Integration decision:

- Accepted the critique.
- A circuit cannot enter `FINDING_V3.md` without donor-blocked, tissue-aware,
  residualized, perturbation- or response-validated evidence plus prior-art
  clearance.
- Next branch must be external perturbation-first unless Wave60-P/Q return
  unexpectedly strong validated mechanism.

## 2026-05-27 12:12 UTC

Wave61 dispatch plan added:

- Wave61-S: intervention-level perturbation mining audit across existing V3
  real perturbation, L1000, Mixscale, resolution, and efferocytosis outputs.
- Wave61-T: translational feasibility and prior-art audit for perturbation
  routes that have any mechanistic support.
- Wave61-U: hostile review of the perturbation-first operationalization.

Integration logic:

- Local orchestrator will build a stricter intervention scorer that treats
  real perturbation and guardrails as primary evidence, with L1000 used only
  as weak directional support.
- Any candidate must beat generic IFN/JAK/NF-kB collapse, broad transcription
  suppression, toxicity/stress, and prior-art gates before it can be reopened.
- Wave60-P/Q remain active sidecars; their outputs can only rescue
  `C15ORF48` or `OSM/OSMR` if they add real perturbation, translational, and
  novelty evidence beyond expression coupling.

## 2026-05-27 12:13 UTC

Wave61 initial dispatch attempt failed:

- Attempted to spawn Wave61-S/T/U with `fork_context=true` plus explicit worker
  settings.
- Tool returned that full-history forked agents inherit role/model settings and
  should omit those overrides.

Routing decision:

- Redispatch without full-history fork and include the necessary project context
  in each prompt.

## 2026-05-27 12:14 UTC

Wave61 subagents dispatched:

- Wave61-S `019e695a-06f6-7f02-9c29-cd1ecf93455a`
  (`Hegel the 2nd`): perturbation-first intervention mining audit.
- Wave61-T `019e695a-0760-7842-b806-107d1522eba4`
  (`Einstein the 2nd`): translational feasibility and prior-art audit.
- Wave61-U `019e695a-0848-7cb0-8b1f-9fe41fbecc5a`
  (`Darwin the 2nd`): hostile review of perturbation-first branch.

## 2026-05-27 12:15 UTC

Wave60-P returned and was closed:

- Agent `019e694f-6d85-7521-91c4-f8561900121e`
  (`Galileo the 2nd`).
- Report: `phases/v3/subagents/wave60p_c15orf48_mocci_circuit_audit.md`.
- Verdict: `C15ORF48`/MOCCI is assay-only.

Integration decision:

- Accepted the demotion.
- `C15ORF48` remains a useful mechanistic readout for mitochondrial
  inflammatory adaptation, but it is not a target or therapeutic anchor:
  canonical `C15ORF48`-up/`NDUFA4`-down switch appears in only 1/17 local
  compartments, MS support is weak, Geneformer perturbation is unusable, and
  druggability/directionality are unresolved.
- Continue perturbation-first mining; `C15ORF48` can be used as a guardrail or
  assay endpoint, not as a claim.

## 2026-05-27 12:19 UTC

Wave60-Q returned and was closed:

- Agent `019e694f-6db2-7cb3-aa28-98cabf336adb`
  (`James the 2nd`).
- Report: `phases/v3/subagents/wave60q_osm_osmr_circuit_audit.md`.
- Verdict: `OSM`/`OSMR`/`IL6ST` is a comparator and possible IBD OSM-high
  stratification axis, not a V3 therapeutic target.

Integration decision:

- Accepted demotion.
- The signal is real but IBD-centered, with weak/module-only extension to T1D
  and null/insufficient RA, Sjogren, psoriasis, and MS support.
- External trial/prior-art status blocks promotion: anti-OSM Crohn withdrawn
  for narrow-window concerns, vixarelimab UC terminated for futility, and MS
  literature raises wrong-direction repair/protection risks.

## 2026-05-27 12:20 UTC

Wave61 local guardrail scorer first run failed:

- Script: `scripts/v3_wave61_intervention_guardrail_scorer.py`.
- Failure: `pandas.DataFrame.to_markdown()` required optional dependency
  `tabulate`, absent from `.venv_v3_py312`.
- Routing: patched local Markdown table rendering to avoid adding an
  environment dependency.

## 2026-05-27 12:22 UTC

Wave61-U returned and was closed:

- Agent `019e695a-0848-7cb0-8b1f-9fe41fbecc5a`
  (`Darwin the 2nd`).
- Report: `phases/v3/subagents/wave61u_hostile_review_perturbation_first.md`.
- Verdict: abandon perturbation-first as a V3 finding route under current
  evidence; keep it as hypothesis-generation only.

Integration decision:

- Accepted the critique.
- Minimum credible bar now requires human primary/ex vivo disease-cell
  perturbation, dose/target engagement, held-out readouts, repair/efferocytosis
  guardrails, and claim-specific prior-art clearance.

## 2026-05-27 12:24 UTC

Local Wave61 guardrail scorer rerun completed:

- Outputs: `phases/v3/results/wave61_perturbation_first_guardrail/`.
- Evidence rows: 395.
- Direct perturbation rows: 186.
- L1000 rows: 180.
- Resolution rows: 29.
- Promotion candidates: 0.
- Reopened perturbation candidates: 0.

Integration decision:

- Do not use perturbation-first as the V3 finding route.
- `MED16` and `GSK3B` remain mechanistic comparators only: both pass real
  perturbation/selectivity/stress/primary-system gates, but fail repair,
  cross-disease/MS, genetics, druggability, and manual safety gates.
- Pivot to genetics-first or assay-first. Since the session needs continued
  computational execution, choose genetics-first target-resolution as the next
  local branch while assay-first remains a wet-lab design endpoint.

## 2026-05-27 12:25 UTC

Wave61-T failed:

- Agent `019e695a-0760-7842-b806-107d1522eba4`
  (`Einstein the 2nd`) errored from model context-window exhaustion.
- No owned report file was produced.
- Closed the failed agent; no output is used.

Routing decision:

- Treat the translational/prior-art audit as missing.
- Replace later with a narrower, candidate-specific audit only if a new
  candidate survives genetics-first target resolution.

## 2026-05-27 12:31 UTC

Wave61-S returned and was closed:

- Agent `019e695a-06f6-7f02-9c29-cd1ecf93455a`
  (`Hegel the 2nd`).
- Report: `phases/v3/subagents/wave61s_intervention_mining.md`.
- Verdict: no intervention candidate earns promotion.

Integration decision:

- Accepted. This independently confirms the local Wave61 scorer and Wave61-U
  hostile review.
- `MED16`/Mediator and `GSK3B` remain the strongest perturbation-first
  comparators but are blocked by tractability/safety and disease-evidence
  failures.

## 2026-05-27 12:32 UTC

Wave62 genetics-first target-resolution branch opened:

- Manual API probe showed the current Open Targets Platform GraphQL exposes
  `studies`, `credibleSets`, `l2GPredictions`, and `colocalisation`.
- Example: `FINNGEN_R12_G6_MS` credible set
  `d8042fac4818035ae4af8557e0cbf623` has L2G `IFI30` score 0.650 and QTL
  colocalisation rows, including monocyte `IFI30` eQTL rows.

Subagents dispatched:

- Wave62-V `019e6967-377f-7582-a3fd-e31187f31749`
  (`Planck the 2nd`): Open Targets target-resolution audit.
- Wave62-W `019e6967-37a0-78d0-abcf-0389f03aec82`
  (`Anscombe the 2nd`): hostile review of genetics-first method.

Local non-overlapping work:

- Build a reproducible script that pulls disease credible sets, L2G
  predictions, and QTL colocalisation rows for the autoimmune panel and ranks
  target-resolution evidence with module/druggability/prior-branch context.

## 2026-05-27 12:36 UTC

Wave62 first local script run failed:

- Script: `scripts/v3_wave62_opentargets_target_resolution.py`.
- Failure: `KeyError: 'biosample_name'` in target summarization for an empty
  MS-relevant QTL-colocalisation subset.
- Patch: added a defensive `unique_join()` helper for empty dataframes.
- Rerun will use cached API JSON from the partially completed first pass.

## 2026-05-27 12:38 UTC

Wave62 local target-resolution rerun completed after stricter gating:

- Script: `scripts/v3_wave62_opentargets_target_resolution.py`.
- Runner entry: `scripts/entrypoints/run_v3_analysis.sh`.
- Output directory:
  `phases/v3/results/wave62_opentargets_target_resolution/`.

Counts:

- 539 study rows.
- 95 eligible GWAS studies.
- 2506 credible sets.
- 4821 L2G rows.
- 16823 QTL colocalisation rows.
- 2028 target summaries.
- 0 reopen calls.
- 32 park calls.

Integration:

- High-scoring broad genetics targets that were already demoted by prior
  branches are now explicitly blocked by `manual_blocker` or
  `prior_context_blocker`.
- No target satisfies MS genetic resolution, cross-disease breadth,
  module/state evidence, and actionable intervention modality simultaneously.
- Keep Wave62 as a target-resolution table for future pivots; do not use it
  as a therapeutic claim.

Outstanding:

- Wave62-V remains pending after a 10 second wait at 12:38 UTC.
- If it returns later, vet against the local stricter result before using.

## 2026-05-27 12:42 UTC

Wave62-V returned and was vetted:

- Agent: `019e6967-377f-7582-a3fd-e31187f31749`
  (`Planck the 2nd`).
- Report: `phases/v3/subagents/wave62v_opentargets_target_resolution.md`.
- File length: 196 lines.
- ASCII check: passed.

Accepted points:

- No Open Targets target-resolution candidate is promotable.
- `IFI30` has real MS target-resolution evidence including monocyte eQTL
  colocalisation, but is one-disease/MS-only in the queried panel.
- `BACH2` and `IRF5` are strong benchmarks for broad cross-autoimmune
  target-resolved genetics, but are not lipid-lysosomal/APC therapeutic
  mechanisms and fail correct-direction druggability/prior-art gates.
- `IL7R`, `SP140`, `IL12A`, `STAT4`, and `CD40` are upgraded genetics
  comparators but remain blocked by tissue relevance, mixed direction,
  prior art, or safety.

Integration decision:

- Use Wave62-V to calibrate what strong target-resolution looks like.
- Do not promote any Wave62-V candidate.
- Continue the transition-controller branch using Wave62 parked rows plus
  broad genetics benchmarks as comparators only.

## 2026-05-27 12:42 UTC

Wave63 first dispatch attempt failed:

- Intended agents: Wave63-X, Wave63-Y, Wave63-Z.
- Cause: the tool rejected full-history forked agents when `agent_type` or
  `reasoning_effort` overrides were supplied.

Action:

- Retry with plain forked agents inheriting model/type/effort.

## 2026-05-27 12:43 UTC

Wave63 agents dispatched successfully:

- Wave63-X `019e6976-4ee2-72a3-a4ad-19f7a330d34a`
  (`Beauvoir the 2nd`): SP140-to-topoisomerase transferability audit.
- Wave63-Y `019e6976-502a-7600-9b8f-9c13302706b5`
  (`Fermat the 2nd`): broad genetics benchmark audit.
- Wave63-Z `019e6976-5187-78c1-ba4a-4f8dd115a89b`
  (`Pascal the 2nd`): hostile transition-controller review.

Local non-overlapping work:

- Build a transition-controller intersection table from Wave62 parked genes,
  broad cell-state/residual evidence, perturbation outputs, foundation-model
  screens, and druggability/prior blockers.

## 2026-05-27 12:47 UTC

Wave63-Y returned and was accepted:

- Agent: `019e6976-502a-7600-9b8f-9c13302706b5`
  (`Fermat the 2nd`).
- Report: `phases/v3/subagents/wave63y_broad_genetics_benchmark.md`.
- Verdict: no promotion.

Accepted integration:

- Broad genetics hits remain calibration controls.
- `IFI30` is module-relevant but MS-only.
- `IRF5`, `STAT4`, `IL12A`, and `CD40` are blocked by prior art,
  breadth/specificity issues, or nonselective intervention routes.

## 2026-05-27 12:49 UTC

Wave63-Z returned and was accepted:

- Agent: `019e6976-5187-78c1-ba4a-4f8dd115a89b`
  (`Pascal the 2nd`).
- Report: `phases/v3/subagents/wave63z_transition_controller_hostile.md`.
- Verdict: no transition-controller candidate should be promoted.

Accepted methodological corrections:

- Do not count re-scored tables from the same atlas as independent
  convergence.
- Require direct perturbation in a human disease-relevant system.
- Require held-out state readouts, leave-family-out modules, repair and
  host-defense guardrails, correct directionality, and claim-specific
  prior-art clearance.
- Tighten druggability to exact therapeutic direction.

Local response:

- Patched `scripts/v3_wave63_transition_controller_integrator.py` to remove a
  pseudo-gate, import Wave45/Wave59 blockers, and stop inheriting druggability
  through target annotation or unrelated SP140 chemistry.

## 2026-05-27 12:51 UTC

Wave63-X returned and was accepted:

- Agent: `019e6976-4ee2-72a3-a4ad-19f7a330d34a`
  (`Beauvoir the 2nd`).
- Report: `phases/v3/subagents/wave63x_sp140_topoisomerase_transfer.md`.
- Verdict:
  `DEMOTE_FOR_V3_PROMOTION; PARK_AS_CROHN_SP140_LOF_STRATIFICATION_AND_MECHANISTIC_COMPARATOR`.

Final Wave63 local result:

- Script: `scripts/v3_wave63_transition_controller_integrator.py`.
- Candidates evaluated: 55.
- Promotions: 0.
- Parked: 2 (`IL7R`, `GALC`), both blocked from V3 promotion.

Integration decision:

- Close transition-controller intersection as a promotion route.
- Use Wave63 products as a guardrail table only.
- Pivot to genuinely new evidence rather than reweighting the same module
  outputs.

## 2026-05-27 12:55 UTC

Wave64 dispatch planned.

Rationale:

- Wave26 already demoted treatment-response baseline biomarker claims because
  the best rows failed global correction and independent replication.
- Wave63 closed transition-controller intersections because they lacked direct
  disease-relevant perturbation and functional guardrails.
- The next branch must add a genuinely new evidence channel: public human
  perturbation/treatment-response datasets with directionality, and orthogonal
  non-expression modalities where feasible.

Planned agents:

- Wave64-A: public autoimmune perturbation/treatment-response dataset scout.
- Wave64-B: public non-expression modality scout.
- Wave64-C: hostile perturbation-gate reviewer.

Local work while agents run:

- Inspect existing Wave18/Wave23/Wave26 treatment-response code and data.
- Build a stricter perturbation-first inventory rather than rerunning the old
  baseline-response score audit.

## 2026-05-27 12:56 UTC

Wave64 first dispatch attempt failed:

- Intended agents: Wave64-A, Wave64-B, Wave64-C.
- Cause: full-history forked agents rejected explicit `reasoning_effort`
  overrides, same tool constraint seen in Wave63.

Action:

- Retry with plain full-context agents inheriting model and reasoning effort.

## 2026-05-27 12:57 UTC

Wave64 second dispatch:

- Wave64-A `019e6981-dfdf-7473-9a66-791235909312`
  (`Euclid the 2nd`) launched successfully.
- Wave64-B `019e6981-e120-7ae1-b71d-4a64d4ddcd81`
  (`Dewey the 2nd`) launched successfully.
- Wave64-C initially failed because the thread limit was reached.

Cleanup:

- Closed completed prior agents:
  - Wave62-V `019e6967-377f-7582-a3fd-e31187f31749`.
  - Wave63-X `019e6976-4ee2-72a3-a4ad-19f7a330d34a`.
  - Wave63-Y `019e6976-502a-7600-9b8f-9c13302706b5`.
  - Wave63-Z `019e6976-5187-78c1-ba4a-4f8dd115a89b`.

Retry:

- Wave64-C `019e6982-355f-7f70-b8ce-a88780102d2a`
  (`Bohr the 2nd`) launched successfully after cleanup.

## 2026-05-27 13:06 UTC

Wave64 agents returned and were vetted:

- Wave64-A `019e6981-dfdf-7473-9a66-791235909312`
  (`Euclid the 2nd`): accepted. Report:
  `phases/v3/subagents/wave64a_perturbation_dataset_scout.md`.
- Wave64-B `019e6981-e120-7ae1-b71d-4a64d4ddcd81`
  (`Dewey the 2nd`): accepted. Report:
  `phases/v3/subagents/wave64b_nonexpression_modality_scout.md`.
- Wave64-C `019e6982-355f-7f70-b8ce-a88780102d2a`
  (`Bohr the 2nd`): accepted. Report:
  `phases/v3/subagents/wave64c_hostile_perturbation_gate.md`.

Vetting:

- Wave64-A and Wave64-B files are ASCII-clean and have concrete accessions.
- Wave64-C is ASCII-clean and provides implementable gate columns and stop
  rules.

Accepted recommendations:

- Prioritize real perturbation/treatment datasets over another observational
  module overlap.
- Immediate lightweight follow-up: `GSE198520` paired RA synovial anti-TNF
  RNA-seq.
- Heavier follow-up: `GSE282122` IBD anti-TNF longitudinal single-cell atlas,
  if compute/network allow.
- Orthogonal follow-up: class-level metabolomics/lipidomics meta-analysis
  across Metabolomics Workbench studies.

Closed agents:

- All three Wave64 sidecars were closed after acceptance.

## 2026-05-27 15:14 CEST

Wave65 local RA anti-TNF audit completed without new subagents.

Artifacts:

- Script: `scripts/v3_wave65_gse198520_ra_synovium_antitnf_audit.py`.
- Outputs:
  `phases/v3/results/wave65_gse198520_ra_synovium_antitnf_audit/`.

Integration decision:

- Accepted as a negative perturbation/tissue pharmacodynamic result.
- This does not invalidate the cross-autoimmune lipid-lysosomal/APC module, but
  it weakens any route that relies on bulk anti-TNF response as a specific
  readout of the module.
- Next orchestration choice: route around bulk tissue response by prioritizing
  either cell-resolved treatment/perturbation (`GSE282122`) or orthogonal
  non-expression lipidomics/proteomics from Wave64-B.

## 2026-05-27 15:17 CEST

Wave66 dispatch plan recorded in `SUBAGENTS_V3.md`.

Planned sidecars:

- Wave66-A: Metabolomics Workbench access scout for exact file/metadata paths
  across prioritized autoimmune studies.
- Wave66-B: `GSE282122` feasibility scout for constrained cell-resolved IBD
  anti-TNF pseudobulk analysis.

Local orchestrator task while sidecars run:

- Build the biochemical class-level meta-analysis path so the session does not
  remain dependent on another transcriptomic perturbation surrogate.

## 2026-05-27 15:18 CEST

Wave66 first dispatch attempt failed:

- Cause: full-history forked agents reject explicit `agent_type` overrides.
- Action: relaunch Wave66-A and Wave66-B as inherited full-context agents.

## 2026-05-27 15:18 CEST

Wave66 second dispatch succeeded:

- Wave66-A `019e6995-4cbc-7ce1-b896-53d41f009798`
  (`Kierkegaard the 2nd`) launched.
- Wave66-B `019e6995-4ea2-7403-9aad-c247e198c282`
  (`Boyle the 2nd`) launched.

## 2026-05-27 15:32 CEST

Wave66 local metabolomics branch completed and both Wave66 sidecars returned.

Local result:

- `scripts/v3_wave66_metabolomics_class_convergence.py`.
- Outputs: `phases/v3/results/wave66_metabolomics_class_convergence/`.
- No biochemical class was promoted.
- Ceramide/glycosphingolipid classes are weak orthogonal hints but not a target
  nomination.

Sidecar vetting:

- Wave66-A `019e6995-4cbc-7ce1-b896-53d41f009798`
  (`Kierkegaard the 2nd`): accepted as an access scout. Report:
  `phases/v3/subagents/wave66a_metabolomics_access_scout.md`.
  - It confirmed no-auth access for the main Metabolomics Workbench studies.
  - It corrected the TEDDY route: use `untarg_data`, but `cc` labels remain
    unresolved without a data dictionary. TEDDY therefore remains conditional.
- Wave66-B `019e6995-4ea2-7403-9aad-c247e198c282`
  (`Boyle the 2nd`): accepted as a feasibility scout. Report:
  `phases/v3/subagents/wave66b_gse282122_feasibility.md`.
  - It identified Zenodo record `14007626`, `myeloid_final.h5ad`, and
    `paired_sample_list.csv` as the feasible path for `GSE282122`.
  - GEO-only route is demoted because it lacks integrated myeloid annotations.

Closed agents:

- Wave66-A and Wave66-B closed after acceptance.

Integration decision:

- Continue to Wave67: local `GSE282122` myeloid pseudobulk anti-TNF analysis.

## 2026-05-27 15:47 CEST

Wave67 local `GSE282122` myeloid pseudobulk analysis completed.

Artifacts:

- Script: `scripts/v3_wave67_gse282122_myeloid_pseudobulk.py`.
- Outputs: `phases/v3/results/wave67_gse282122_myeloid_pseudobulk/`.

Integration decision:

- Accepted as a high-value negative perturbation result for the pre-specified
  lipid-lysosomal/APC target modules.
- Do not promote lipid-loader, lysosomal-APC, or complement-phagocytosis module
  intervention axes from anti-TNF myeloid perturbation.
- The strongest raw signals are HLA-II/MIF-CD74-like and outside the current
  module gate. Proceed to an unrestricted gene-level perturbation screen in the
  same myeloid object, then intersect with Wave62 target-resolution genetics.

## 2026-05-27 15:54 CEST

Wave68 local unrestricted gene screen completed and corrected.

Artifacts:

- Script: `scripts/v3_wave68_gse282122_unrestricted_gene_screen.py`.
- Outputs: `phases/v3/results/wave68_gse282122_unrestricted_gene_screen/`.

Integration decision:

- Accept Wave68 as a corrected negative gate for direct gene-level target
  reopening in `GSE282122`.
- Reject the initial SP140 reopen because it conflicts with earlier
  V3-specific prior-art/directionality/MS-local-null audits.
- Continue with a successor-intervention branch: use the 13 parked
  genetic/perturbation intersections as anchors, but search for druggable
  upstream/downstream controllers rather than assuming the anchor genes
  themselves are viable targets.

## 2026-05-27 15:55 CEST

Wave69 dispatch.

Failed dispatch:

- First Wave69-A attempt used an explicit `agent_type` with full-history fork
  and was rejected by the agent runtime. Retried without explicit overrides.

Launched agents:

- Wave69-A `019e69b8-8918-7773-845d-169f176b050b`
  (`Gibbs the 2nd`): hostile triage of the 13 Wave68 parked genes as direct
  targets and upstream/downstream intervention hints.
- Wave69-B `019e69b8-aa8e-74d2-b3bf-094e6347a546`
  (`Pauli the 2nd`): independent validation scout for parked gene/controller
  signals in MS, RA, psoriasis, and IBD local/feasible datasets.
- Wave69-C `019e69b8-c8ef-7fa2-bf4c-b6eed98906a0`
  (`Carver the 2nd`): foundation-model/comparable perturbation feasibility
  audit and recommendation for an executable in-silico perturbation test.

Local orchestrator task while sidecars run:

- Build a reproducible controller-ranking analysis over the 13 parked genes
  using local target-resolution output, pathway/controller databases that are
  feasible to query, and explicit druggability/prior-art guardrails.

## 2026-05-27 16:15 CEST

Wave69 sidecars returned and were closed.

Accepted sidecar outputs:

- Wave69-A `019e69b8-8918-7773-845d-169f176b050b`
  (`Gibbs the 2nd`): report
  `phases/v3/subagents/wave69a_parked_gene_controller_triage.md`.
- Wave69-B `019e69b8-aa8e-74d2-b3bf-094e6347a546`
  (`Pauli the 2nd`): report
  `phases/v3/subagents/wave69b_independent_validation_scout.md`, script
  `scripts/v3_wave69b_independent_validation_scout.py`, outputs
  `phases/v3/results/wave69b_independent_validation_scout/`.
- Wave69-C `019e69b8-c8ef-7fa2-bf4c-b6eed98906a0`
  (`Carver the 2nd`): report
  `phases/v3/subagents/wave69c_foundation_model_feasibility.md`.

Local analyses:

- `scripts/v3_wave69_parked_controller_rank.py` added and added to
  `scripts/entrypoints/run_v3_analysis.sh`.
  - First run failed only during report rendering on missing Enrichr columns.
  - Patched Enrichr submission and broad-kinase blockers; final run succeeded.
- `scripts/v3_wave69d_gse282122_geneformer_remission_centroid.py` added and
  added to `scripts/entrypoints/run_v3_analysis.sh`.
  - First run failed only during report rendering because per-context support
    flags were missing.
  - Patched metric annotation; final run succeeded.

Integration decision:

- The only unblocked controller scouts from network/druggability ranking were
  `PRKDC` and `BLK`; both failed the bounded Geneformer remission-centroid
  screen.
- Treat Wave69 as a negative gate for direct parked-gene or immediate
  controller promotion.
- Carry forward the biological pattern, not the targets: Fc receptor/ROS
  myeloid handling plus APC checkpoint/costimulation/JAK response repeatedly
  appears, but the obvious intervention nodes are prior-art, broad, or unsafe.

## 2026-05-27 16:16 CEST

Wave70 dispatch.

Rationale:

- Wave69 closed direct parked-gene and immediate-controller promotion.
- The remaining coherent biology is Fc receptor/ROS myeloid handling. The next
  question is whether a less-blocked, modality-specific inhibitory regulator
  can rebalance this circuit without broad Fc/JAK/checkpoint suppression.

Launched agents:

- Wave70-A `019e69cb-d220-78e1-b2fc-69c2b5eba3a6`
  (`Helmholtz the 2nd`): hostile prior-art/translational audit for
  Fc/ROS-resolution intervention points such as `INPP5D`, `PTPN6`, `LILRB*`,
  `LAIR1`, `SIGLEC10`, `CD300A`, `BTK`, `PIK3CD/G`, and TAM receptors.
- Wave70-B `019e69cb-f92b-76d2-bd23-874b8cbfe82c`
  (`Archimedes the 2nd`): local computational scout for the same candidate
  nodes across existing GSE282122, Wave69B RA, broad h5ad, MS GSE111972,
  Wave37 efferocytosis, and Wave57 data.

Local orchestrator task while sidecars run:

- Build an independent local Wave70 Fc/ROS candidate matrix so sidecar outputs
  can be vetted rather than accepted uncritically.

## 2026-05-27 16:23 CEST

Wave70 local matrix completed before sidecar returns.

Local output:

- `scripts/v3_wave70_fc_ros_resolution_matrix.py`
- `phases/v3/results/wave70_fc_ros_resolution_matrix/`

Integration status:

- No target promoted.
- The high-evidence Fc/ROS nodes are blocked comparator biology:
  `FCGR2A`, `NCF1`, `NCF2`, `CYBB`, `LYN`, `SYK`, `BTK`, and `PIK3CD`.
- The only less-blocked candidate with more than one local evidence channel is
  `LILRB2`, but its directionality is unresolved and support is limited to
  `GSE282122` plus broad Crohn/UC myeloid recurrence.

Next orchestrator step:

- Run a focused Geneformer token-deletion remission-centroid test across
  `LILRB1/2/3/4`, inhibitory phosphatases, inhibitory receptors, TAM nodes,
  and blocked Fc/ROS comparators. This is a falsification step, not a claim
  generation shortcut.

## 2026-05-27 16:27 CEST

Wave70-B computational scout completed.

Output:

- Report: `phases/v3/subagents/wave70b_fc_ros_computational_scout.md`.
- Script: `scripts/v3_wave70b_fc_ros_computational_scout.py`.
- Results: `phases/v3/results/wave70b_fc_ros_computational_scout/`.

Vetting:

- Treated as a bounded local scout, not an autonomous finding claim.
- Directly recomputed candidate-only `GSE282122` h5ad pseudobulk rather than
  relying only on precomputed Wave68 rows.
- Recomputed RA `GSE198520` candidate-level paired and response tests for all
  Wave70-B candidates.
- Cross-checked against local MS `GSE111972`, broad h5ad recurrence, Wave37
  efferocytosis, and existing Geneformer artifacts.

Result:

- No target promoted.
- `LILRB2` is the strongest falsification target:
  - `GSE282122` DC adjusted remission beta `-0.949`, FDR `0.0191`.
  - broad Crohn/UC recurrence, 2 positive compartments, 1 FDR10.
  - local MS signal is nominal down but not FDR-supported.
  - RA anti-TNF does not replicate.
  - no local cross-autoimmune genetic anchor from Wave68/Wave62.
- `INPP5D`, `PTPN6`, and `CD300A` remain comparator/readout nodes.
- TAM and kinase nodes remain blocked by directionality, prior-art, or broad
  host-defense/safety concerns.

Integration decision:

- Accept the negative/comparator conclusion.
- Do not convert the Fc/ROS branch into a target nomination unless a later
  perturbation test directly shows that modulating `LILRB2`/related inhibitory
  receptors improves disease-relevant myeloid function without suppressing
  repair, phagocytosis, or host-defense guardrails.

## 2026-05-27 16:33 CEST

Wave70 closure.

Sidecars:

- Wave70-A closed. Accepted as hostile prior-art/translational audit:
  no Fc/ROS candidate is promotable; `INPP5D`/SHIP1 only worth bounded
  fail-fast testing.
- Wave70-B closed. Accepted as local computational scout:
  `LILRB2` strongest falsification target, but no promotion.

Local Wave70-C:

- Script: `scripts/v3_wave70c_inhibitory_receptor_geneformer_direction.py`.
- Output: `phases/v3/results/wave70c_inhibitory_receptor_geneformer_direction/`.
- Result: model direction support concentrated on blocked `NCF1`, `FCGR2A`,
  `CYBB`, and `NCF2`; `LILRB2`, `LILRB1`, `LILRB4`, `INPP5D`, `PTPN6`, and
  `SIGLEC10` did not clear the threshold for a real-perturbation reopener.

Integration decision:

- The Fc/ROS branch is now closed as a target branch.
- Keep the branch as evidence that the non-remission myeloid/DC state is
  Fc/NOX-sensitive, but do not continue to proxy-satisfice by searching nearby
  inhibitory receptors without stronger perturbation or genetics.
- Next wave: broad survivor search across all prior V3 branches outside the
  Fc/ROS neighborhood.

## 2026-05-27 16:36 CEST

Wave71 dispatch.

Rationale:

- Wave70 closed the Fc/ROS-resolution target branch.
- The next pivot must mine all previous V3 branches for survivors that were
  parked for tractability rather than falsified, while avoiding known
  prior-art/safety/proxy traps.

Launched agents:

- Wave71-A `019e69dd-176b-7a82-b4ac-24132f1506f3`
  (`Singer the 2nd`): worker to build
  `scripts/v3_wave71_global_survivor_meta_rank.py` and corresponding
  reproducible candidate meta-rank outputs.
- Wave71-B `019e69dd-17a8-79b1-b8c2-1e27af831e28`
  (`Bacon the 2nd`): explorer to synthesize prior branch statuses and
  blockers from V3 reports/checkpoints.
- Wave71-C `019e69dd-17c5-7920-8d3c-398bfe74efb9`
  (`Godel the 2nd`): explorer to scout cross-autoimmune intervention points
  outside the closed Fc/ROS, NAMPT, ACSL1, and SP140 branches.

Local orchestrator task while sidecars run:

- Independently inspect existing V3 status tables and high-number reports for
  candidates with cross-disease breadth, perturbation evidence, and a plausible
  intervention point not already blocked.

## 2026-05-27 16:49 CEST

Wave71 returns and integration.

Wave71-B:

- Agent `019e69dd-17a8-79b1-b8c2-1e27af831e28` completed.
- Artifact: `phases/v3/subagents/wave71b_prior_branch_status_synthesis.md`.
- Accepted as hostile branch-memory synthesis.
- Integration decision: do not reopen prior V3 branches from expression
  recurrence, module coupling, mapped-gene genetics, ChEMBL availability, or
  Geneformer-only support.

Wave71-C:

- Agent `019e69dd-17c5-7920-8d3c-398bfe74efb9` completed.
- Artifact: `phases/v3/subagents/wave71c_cross_autoimmune_intervention_scout.md`.
- Accepted as a scout, not a claim.
- Key proposal: test biochemical/context-stratified intervention routes outside
  Fc/ROS, especially `NAAA`, `EPHX2`, `GPR183`, and `P2RX7`; keep `MFGE8`,
  `GPR65`, and `SLC15A4` as comparators.

Wave71-A:

- Agent `019e69dd-176b-7a82-b4ac-24132f1506f3` completed.
- Accepted outputs:
  - `scripts/v3_wave71_global_survivor_meta_rank.py`
  - `phases/v3/results/wave71_global_survivor_meta_rank/`
  - `phases/v3/subagents/wave71a_global_survivor_meta_rank.md`
- Result: no global survivor reopens.
- Top non-reopening rows: `CD58`, `CARMIL1`, `RAD51B`, `PARK7`, `ADCY3`,
  `FADS1`, `CCDC88B`, `PRR5L`, `YDJC`, `ARID5B`.
- Integration decision: Wave71-A is a negative triage rank and does not support
  a `FINDING_V3.md` claim.

Local Wave72:

- Script: `scripts/v3_wave72_lipid_mediator_intervention_scout.py`.
- Output: `phases/v3/results/wave72_lipid_mediator_intervention_scout/`.
- Added to `scripts/entrypoints/run_v3_analysis.sh`.
- Initial run failed because `pandas.to_markdown()` required optional
  dependency `tabulate`; fixed by adding an internal Markdown-table formatter.
- Validation:
  - `.venv_v3_py312/bin/python -m py_compile scripts/v3_wave72_lipid_mediator_intervention_scout.py`
  - `.venv_v3_py312/bin/python scripts/v3_wave72_lipid_mediator_intervention_scout.py`
- Calls:
  - `NAAA`: `NO_GO_WAVE72`.
  - `EPHX2`: `PARK_ORTHOGONAL_BIOCHEMICAL_SCOUT`.
  - `GPR183`: `NO_GO_WAVE72`.
  - `P2RX7`: `PARK_ORTHOGONAL_BIOCHEMICAL_SCOUT`.

Convergence checkpoint:

- Wrote `CONVERGENCE_CHECK_33.md`.
- Decision: no `FINDING_V3.md`; open a bounded Wave73
  `P2RX7`/purine-inflammasome stratification test because purine metabolomics
  is broad but target-level gene evidence is weak.

## 2026-05-27 16:59 CEST

Wave73 local branch completed and vetted.

- Script: `scripts/v3_wave73_p2rx7_stratification_test.py`.
- Outputs: `phases/v3/results/wave73_p2rx7_stratification_test/`.
- Added to `scripts/entrypoints/run_v3_analysis.sh`.
- Verdict: `PARK_P2RX7_STRATIFICATION_NEEDS_TARGET_LEVEL_DATA`.
- Integration:
  - accepted as a negative/parked target-resolution result.
  - P2RX7 remains a possible assay axis only if future target-level purine,
    protein, or baseline-responder data appear.
  - no therapeutic or stratification claim is permitted from current evidence.
- Wrote `CONVERGENCE_CHECK_34.md`.
- Next dispatch direction:
  - bounded Wave74 `EPHX2` direct biochemistry test using raw metabolomics.
  - proceed only if paired epoxide/diol features support a soluble epoxide
    hydrolase activity ratio; otherwise close branch as proxy-limited.

## 2026-05-27 17:05 CEST

Wave74 local branch completed and vetted.

- Script: `scripts/v3_wave74_ephx2_direct_ratio_audit.py`.
- Outputs: `phases/v3/results/wave74_ephx2_direct_ratio_audit/`.
- Added to `scripts/entrypoints/run_v3_analysis.sh`.
- Verdict: `NO_GO_EPHX2_DIRECT_RATIO_UNAVAILABLE`.
- Accepted correction:
  - tightened oxylipin parser after detecting generic `oxo` over-counting.
- Integration:
  - EPHX2 is not promoted.
  - available public metabolomics has product-only or unmatched features, not a
    direct soluble epoxide hydrolase activity ratio.
- Wrote `CONVERGENCE_CHECK_35.md`.
- Next direction:
  - shift back to intervention points controlling the recurrent
    interferon/APC and lysosomal/APC myeloid state, using perturbation-response
    evidence rather than expression recurrence alone.

## 2026-05-27 17:07 CEST

Dispatched Wave75 parallel sidecars after closing P2RX7/EPHX2 target-resolution
routes.

Launched agents:

- Wave75-A `019e69f9-499b-7741-b3b0-0d634e9f26fc` (`Helmholtz`):
  perturbation-first controller hunt over existing V3 artifacts. Deliverable:
  `phases/v3/subagents/wave75a_perturbation_first_controller_hunt.md`.
- Wave75-C `019e69f9-796d-7651-8a46-0be994cf1618` (`Herschel`):
  cross-disease targetability scout for IFN/APC plus lysosomal/APC state.
  Deliverable: `phases/v3/subagents/wave75c_cross_disease_targetability_scout.md`.
- Wave75-Gamma `019e69f9-9c63-7780-8c89-4014f88e5455` (`Kierkegaard`):
  hostile critique of the pivot away from lipid enzymes toward state-control
  intervention points. Deliverable: `phases/v3/subagents/wave75g_hostile_critique.md`.

Local orchestrator task while sidecars run:

- Build a treatment-response module stratification analysis over available
  RA/IBD response datasets to test whether the recurrent IFN/APC and
  lysosomal/APC state has response-predictive value beyond generic
  inflammation.



## 2026-05-27 16:58 CEST

Wave73 local execution and closure.

- Script: `scripts/v3_wave73_p2rx7_stratification_test.py`.
- Output: `phases/v3/results/wave73_p2rx7_stratification_test/`.
- Added to `scripts/entrypoints/run_v3_analysis.sh`.
- Call: `PARK_P2RX7_STRATIFICATION_NEEDS_TARGET_LEVEL_DATA`.

Integration decision:

- The purine branch supplies cross-disease biochemical context but not a
  target nomination.
- `P2RX7` fails specificity against generic inflammatory/APC modules and fails
  MS, IBD response, and RA responder-support gates.
- Do not reopen without target-level baseline/purine/protein or perturbation
  data that directly measures `P2RX7` activity.

## 2026-05-27 17:00 CEST

Wave74 dispatch.

Rationale:

- Wave73 parked the purine branch because broad biochemistry did not resolve
  to `P2RX7` as a target.
- The next work must test orthogonal biochemical/context routes with stronger
  specificity gates before any claim is considered.

Launched agents:

- Wave74-A `019e69f3-d362-7bb1-a4fd-d1f2086cec2f`
  (`Hypatia the 2nd`): worker for an `EPHX2`/oxylipin specificity audit.
  Ownership: `scripts/v3_wave74_ephx2_oxylipin_specificity.py`,
  `phases/v3/results/wave74_ephx2_oxylipin_specificity/`,
  optional `phases/v3/subagents/wave74a_ephx2_oxylipin_specificity.md`.
- Wave74-B `019e69f4-08fa-7f63-a58b-864a56e9178b`
  (`Mendel the 2nd`): worker for a `GPR183`/oxysterol-niche audit.
  Ownership: `scripts/v3_wave74_gpr183_oxysterol_niche.py`,
  `phases/v3/results/wave74_gpr183_oxysterol_niche/`,
  optional `phases/v3/subagents/wave74b_gpr183_oxysterol_niche.md`.
- Wave74-C `019e69f4-2afc-7ce0-a520-fa25f4a7f1a6`
  (`Peirce the 2nd`): explorer for hostile prior-art/druggability scouting of
  `EPHX2`, `GPR183`, and `P2RX7`.

Local orchestrator task while sidecars run:

- Mine existing integrated result tables for candidates with support outside
  expression recurrence and outside already-blocked Fc/ROS, NAMPT, ACSL1,
  SP140, cathepsin, complement, and purine branches.

## 2026-05-27 17:05 CEST

Wave74-C returned and was vetted.

- Agent `019e69f4-2afc-7ce0-a520-fa25f4a7f1a6` completed.
- Artifact: `phases/v3/subagents/wave74c_prior_art_druggability_scout.md`.
- Accepted as a hostile blocker audit.

Subagent calls:

- `EPHX2`: `BLOCKED_BY_PRIOR_ART`.
- `GPR183`: `BLOCKED_BY_PRIOR_ART`.
- `P2RX7`: `TRANSLATION_BLOCKED`.

Orchestrator verification:

- Verified `WO2000023060A2` claims soluble epoxide hydrolase inhibitors for
  immunological/autoimmune disorders and lists MS, psoriasis, Crohn disease,
  UC, RA, Sjogren syndrome, and diabetes-relevant language.
- Verified published EAE/sEH inhibition literature via PubMed/PMC search.
- Verified `IPG11406`/`GPR183` active clinical-trial listings for ulcerative
  colitis and lupus nephritis via ClinicalTrials search snippets, plus a
  published RA antagonist medicinal-chemistry article.
- Verified `P2RX7` prior clinical RA and Crohn trial literature and the
  MS-specific P2X7 antagonist patent `EP1655032B1`.

Integration decision:

- Even if Wave74-A or Wave74-B finds a local-data signal, promotion cannot be
  a broad `EPHX2`, `GPR183`, or `P2RX7` autoimmune-use claim.
- Any remaining possible delta must be narrow: biomarker-stratified subgroup,
  disease-compartment-specific delivery/PD, non-obvious combination, or a
  different intervention point upstream/downstream of the blocked target.

## 2026-05-27 17:11 CEST

Wave74-B returned and was vetted.

- Agent `019e69f4-08fa-7f63-a58b-864a56e9178b` completed and closed.
- Accepted outputs:
  - `scripts/v3_wave74_gpr183_oxysterol_niche.py`
  - `phases/v3/results/wave74_gpr183_oxysterol_niche/`
- Added script to `scripts/entrypoints/run_v3_analysis.sh`.
- Validation: `.venv_v3_py312/bin/python -m py_compile
  scripts/v3_wave74_gpr183_oxysterol_niche.py`.

Call:

- `PARK_GPR183_OXYSTEROL_NICHE`.

Key result:

- Broad receptor/response signal exists but does not form a coherent
  cross-disease ligand-production plus direct-`GPR183` plus response program.
- Ligand-production module is effectively T1D-restricted.
- Direct `GPR183` receptor anchor is positive in Crohn, Sjogren, and UC, with
  one psoriasis negative disease.
- MS `GSE111972` does not support `GPR183` or the migration modules.
- IBD and RA response modules have some support, but this is not sufficient
  given failed MS, failed ligand cross-disease coherence, no oxysterol
  metabolite support, and Wave74-C prior-art blockage.

Integration decision:

- Do not promote `GPR183`.
- Keep only as a mechanistic/niche comparator for immune trafficking.
- A promotable delta would require direct spatial ligand/receptor colocalized
  niche evidence plus a novelty path outside active `IPG11406`/GPR183
  autoimmune programs.

## 2026-05-27 17:12 CEST

Wave74-A returned and was vetted.

- Agent `019e69f3-d362-7bb1-a4fd-d1f2086cec2f` completed and closed.
- Accepted outputs:
  - `scripts/v3_wave74_ephx2_oxylipin_specificity.py`
  - `phases/v3/results/wave74_ephx2_oxylipin_specificity/`
- Also accepted pre-existing/local direct-ratio audit:
  - `scripts/v3_wave74_ephx2_direct_ratio_audit.py`
  - `phases/v3/results/wave74_ephx2_direct_ratio_audit/`
- Added Wave74-A worker script to `scripts/entrypoints/run_v3_analysis.sh`.
- Validation under V3 environment:
  `.venv_v3_py312/bin/python -m py_compile
  scripts/v3_wave74_ephx2_oxylipin_specificity.py
  scripts/v3_wave74_ephx2_direct_ratio_audit.py
  scripts/v3_wave74_gpr183_oxysterol_niche.py`.

Calls:

- Wave74-A specificity audit: `NO_GO`.
- Direct-ratio audit: `NO_GO_EPHX2_DIRECT_RATIO_UNAVAILABLE`.

Key result:

- Existing local metabolomics has EPHX2-relevant epoxide/diol features but no
  same-study same-site epoxide/diol pair for direct soluble epoxide hydrolase
  activity ratios.
- EPHX2-specific biochemical support is one supportive disease and one
  normalizing treatment hit.
- Target-level `EPHX2` support is absent across Wave62 target resolution,
  broad h5ad, MS white matter, IBD anti-TNF, RA anti-TNF, and Geneformer.
- Specificity against generic lipid/inflammatory/lysosomal comparators fails.

Integration decision:

- Close `EPHX2` as a V3 target route.
- Together with Wave73 and Wave74-B/C, close the current biochemical
  NAAA/EPHX2/GPR183/P2RX7 route for promotion.

## 2026-05-27 17:15 CEST

Wave75 pivot dispatch.

Rationale:

- Wave74 closed the biochemical mediator route for promotion.
- Next mechanism class: genetically anchored inflammatory macrophage regulatory
  programs, starting with the `ETS2` gene-desert/macrophage axis because local
  prior-art caches repeatedly surfaced it as an AS/IBD macrophage mechanism
  adjacent to the V3 cross-autoimmune myeloid module.

Launched agent:

- Wave75-C `019e6a00-3679-7df0-b6d1-6bf1bf30ce0c`
  (`Kuhn the 2nd`): hostile prior-art and directionality scout for direct
  `ETS2`, MEK/ERK upstream, enhancer/gene-desert, and AP-1/ETS macrophage
  routes.

Local orchestrator task:

- Implement a non-conflicting `ETS2` local-data audit covering broad h5ad,
  MS white matter, Wave62 target resolution, IBD anti-TNF response, RA
  anti-TNF response, and foundation-model outputs.

## 2026-05-27 17:20 CEST

Wave75 `ETS2` local audit and prior-art scout integrated.

Local audit:

- Script: `scripts/v3_wave75_ets2_macrophage_program_audit.py`.
- Outputs: `phases/v3/results/wave75_ets2_macrophage_program_audit/`.
- Added to `scripts/entrypoints/run_v3_analysis.sh`.
- Validation:
  `.venv_v3_py312/bin/python -m py_compile
  scripts/v3_wave75_ets2_macrophage_program_audit.py` and script run.

Local call:

- `PARK_IBD_MYELOID_PROGRAM_NOT_PROMOTABLE`.

Local evidence:

- `ETS2` direct broad h5ad support:
  - 2 positive diseases: Crohn disease and ulcerative colitis.
  - best context: UC myeloid effect `1.972`, p `0.0002169`, FDR `0.00079`.
- `ETS2` macrophage-program broad support:
  - 3 positive diseases: Crohn disease, T1D, UC.
  - 1 negative disease: psoriasis.
- Specificity:
  - only 1 specificity-pass context; the ETS2-labeled program generally does
    not beat generic NF-kB/TNF, IFN/APC, or lysosome/APC comparators.
- MS:
  - direct `ETS2` mean effect `-0.0608`, p `0.8649`, FDR `0.9802`.
  - ETS2 macrophage program mean effect `-0.0145`, p `0.8943`.
- IBD anti-TNF:
  - mono/macrophage direct `ETS2` remission delta `-0.653`, p `0.0649`,
    FDR `0.967`; not supportive after correction.
  - paired treatment effect does not lower `ETS2`.
- RA anti-TNF:
  - ETS2/AP1/program pharmacodynamic drops exist, but responder support fails
    and generic NF-kB/IFN/lysosome comparators are at least as strong.
- Wave62:
  - `ETS2` remains `NO_GO_WAVE62_TARGET_RESOLUTION`.
- Foundation models:
  - `ETS2` absent or below support threshold in Wave57 and Wave69D outputs.

Prior-art scout:

- Agent `019e6a00-3679-7df0-b6d1-6bf1bf30ce0c` completed and closed.
- Artifact: `phases/v3/subagents/wave75c_ets2_prior_art_directionality.md`.
- Call: `PARK_NARROW_DELTA_ONLY`.
- Hostile conclusion: broad ETS2 inflammatory macrophage biology is already
  published, IBD and AS are directly covered, direct ETS2 is not conventionally
  druggable, and MEK/ERK is broad/prior-arted/toxic.

Integration decision:

- Do not promote `ETS2`.
- Retain as a comparator for the kind of IBD-myeloid program that can look
  compelling locally but fails cross-disease/MS/specificity/modality gates.

## 2026-05-27 17:24 CEST

Interrupted-work integration completed.

Subagent returns integrated:

- Wave75-A perturbation-first controller hunt:
  `phases/v3/subagents/wave75a_perturbation_first_controller_hunt.md`.
  - Call: no immediate finding.
  - MED16 is a non-druggable positive-control benchmark.
  - LILRB family (`LILRB2`, `LILRB1`, `LILRB4`) is the only bounded target
    family recommended for a response-direction audit.
  - `CD300A` and `INPP5D` remain low-priority.
- Wave75-C cross-disease targetability scout:
  `phases/v3/subagents/wave75c_cross_disease_targetability_scout.md`.
  - Call: no promotable target.
  - Strict local follow-up shortlist: `CD58`, `SPNS1`, `P4HB`, `SEL1L3`.
  - `IFI30` benchmark only.
- Wave75-gamma hostile critique:
  `phases/v3/subagents/wave75g_hostile_critique.md`.
  - Core criticism: proxy-satisficing remains unless a target/intervention
    node survives held-out state correction, beats generic controls, and has
    modality plus safety guardrails.
  - Requested two next tests:
    1. treatment-response specificity meta-test.
    2. controller perturbation specificity/guardrail matrix.

Local orchestrator work completed:

- `scripts/v3_wave75_response_state_stratification.py` and
  `phases/v3/results/wave75_response_state_stratification/`.
- `scripts/v3_wave76_adjusted_response_specificity.py` and
  `phases/v3/results/wave76_adjusted_response_specificity/`.
- `scripts/v3_wave77_ets2_macrophage_axis_audit.py` and
  `phases/v3/results/wave77_ets2_macrophage_axis_audit/`.
- Added all three scripts to `scripts/entrypoints/run_v3_analysis.sh`.

Integration decision:

- Wave76 satisfies the hostile critique's first requested analysis and parks
  the response-state signal as generic-limited.
- Wave77 independently confirms the existing ETS2 no-go.
- Proceed to Wave78 LILRB family target-level audit before any renewed claim.

## 2026-05-27 17:37 CEST

Wave78 LILRB family audit integrated.

Subagent:

- Wave78-A `019e6a0b-8503-7bd0-b101-ec603041af8b`
  (`Nietzsche the 2nd`) completed and closed.
- Artifact: `phases/v3/subagents/wave78a_lilrb_prior_art_feasibility.md`.
- Call: `PARK_DIRECTIONALITY`.

Local audit:

- Script: `scripts/v3_wave78_lilrb_family_target_audit.py`.
- Outputs: `phases/v3/results/wave78_lilrb_family_target_audit/`.
- Added to `scripts/entrypoints/run_v3_analysis.sh`.
- Call: `NO_GO_LILRB_TARGET_LEVEL_CONVERGENCE`.

Integration decision:

- Do not promote `LILRB1/2/3/4` or adjacent inhibitory-receptor nodes.
- The family has biologic and biologics-druggability plausibility, but local
  evidence says the signal is IBD-heavy, LILRA/myeloid-family nonspecific,
  not RA-replicated, not genetically broad, and not MS-compatible for the best
  suppression candidate `LILRB2`.
- The sidecar adds a translational blocker: autoimmune agonism and oncology
  antagonism point in opposite directions, with both sides prior-art crowded.

Next orchestrator decision:

- Do not continue inhibitory-receptor family mining unless a cell-selective
  SLE plasma-cell hypothesis is explicitly opened.
- Pivot to a strict targetability shortlist or fresh target-first route.

## 2026-05-27 17:33 CEST

Wave78 LILRB branch integrated.

Local orchestrator work:

- Script: `scripts/v3_wave78_lilrb_inhibitory_receptor_audit.py`.
- Outputs: `phases/v3/results/wave78_lilrb_inhibitory_receptor_audit/`.
- Added to `scripts/entrypoints/run_v3_analysis.sh`.
- Validation passed:
  - py_compile.
  - script execution.
  - shell syntax check.

Subagent:

- Wave78 sidecar `019e6a0c-49f8-7703-af96-f561232c93a7` (`Dirac`).
- Artifact: `phases/v3/subagents/wave78_lilrb_prior_art_directionality.md`.
- Bottom line: do not promote LILRBs as therapeutic targets; keep `LILRB2`
  only as a bounded biomarker/falsification lead if useful.

Integration decision:

- Local audit and sidecar agree.
- The LILRB family has credible biology but fails target-level V3 promotion
  because response specificity is not cross-dataset stable, MS support is
  absent or adverse, Geneformer direction remains no-go, direct perturbation is
  absent, and the intervention direction conflicts with oncology antagonist
  prior art.
- Next branch: Wave79 non-LILRB targetability shortlist
  (`CD58`, `SPNS1`, `P4HB`, `SEL1L3`).

## 2026-05-27 17:42 CEST

Wave79 non-LILRB targetability audit completed.

Local orchestrator work:

- Script: `scripts/v3_wave79_targetability_shortlist_audit.py`.
- Outputs: `phases/v3/results/wave79_targetability_shortlist_audit/`.
- Added to `scripts/entrypoints/run_v3_analysis.sh`.
- Validation passed:
  - py_compile.
  - script execution.

Subagent:

- Wave79 sidecar `019e6a13-66bf-7c70-a4f2-b596a1210978` (`Pascal`) was
  dispatched for prior-art/druggability/directionality review and is still
  pending at this checkpoint.

Integration decision:

- `P4HB`, `SPNS1`, and `SEL1L3` closed for targetability.
- `CD58` is not promoted but is the only shortlist node with enough signal for
  a narrow follow-up:
  - MS L2G `0.951`.
  - Crohn/MS QTL support.
  - Crohn/UC myeloid recurrence.
  - strong RA anti-TNF response association.
  - weak IBD response after generic controls.
- Proceed to Wave80 CD58/CD2-axis deepening while sidecar continues.

## 2026-05-27 17:44 CEST

Wave80 `CD58`/CD2-axis deepening completed.

Local orchestrator work:

- Script: `scripts/v3_wave80_cd58_cd2_axis_deepening.py`.
- Outputs: `phases/v3/results/wave80_cd58_cd2_axis_deepening/`.
- Added to `scripts/entrypoints/run_v3_analysis.sh`.
- Validation passed:
  - py_compile.
  - script execution.
  - shell syntax check.

Result:

- Call: `PARK_CD58_CD2_AXIS_PRIOR_ART_OR_IBD_LIMITED`.
- RA baseline `CD58` responder association survived T-cell and effector-memory
  adjustment:
  - coefficient `0.870`, p `0.00871`.
- Wave79 IBD replication remains weak:
  - p `0.173`, target/generic ratio `1.62`.
- Prior-art/direction:
  - published MS genetics support CD58 biology but point toward higher CD58 and
    Treg support;
  - alefacept/CD58-Ig/CD2 intervention is already psoriasis/T1D autoimmune
    prior art and has a mixed block/deplete/agonize mechanism.

Integration decision:

- `CD58` remains a serious biomarker/context signal but not a V3 therapeutic
  finding.
- Do not continue expression-targetability re-ranks unless a new modality or
  direct perturbation source is introduced.

## 2026-05-27 17:40 CEST

Wave79 sidecar returned and was integrated.

Subagent artifact:

- `phases/v3/subagents/wave79_targetability_prior_art_directionality.md`

Bottom line:

- Do not promote any of `CD58`, `SPNS1`, `P4HB`, or `SEL1L3` as a V3
  therapeutic target from this shortlist.
- `CD58` is the strongest evidence-bearing node, but it is blocked as a novel
  target by alefacept/CD2-CD58 autoimmune prior art and by direction conflict:
  expression recurrence/CD2 blockade logic points toward inhibition, while MS
  genetics points toward higher/restored CD58 as protective.
- `SPNS1` is biologically interesting and less prior-art crowded, but lacks MS
  target resolution, chemical matter, direct perturbation, and a safe
  intervention direction.
- `P4HB` has chemical matter but is generic ER/redox/PDI biology with
  coagulation and broad chaperone toxicity concerns.
- `SEL1L3` remains an under-characterized membrane marker with no actionable
  mechanism or modality.

Integration decision:

- Downgrade Wave80 from "CD58 target deepening" to "CD58 closure/falsification
  unless a non-target stratification claim is explicitly opened".
- Do not spend additional target-discovery effort on `P4HB`, `SPNS1`, or
  `SEL1L3` as therapeutic nodes.
- Main route should pivot toward perturbation-first or stratification-first
  analyses with direct treatment-response or intervention evidence, not another
  expression-derived surfaceome shortlist.

## 2026-05-27 18:02 CEST

Wave81 ranking bug and proxy-support problem found during continuation.

Orchestrator correction:

- Initial Wave81 report sorted calls alphabetically, which put blocked rows
  above reopened rows; fixed ranking priority in
  `scripts/v3_wave81_perturbation_first_rescue.py`.
- The first corrected output appeared to reopen `SP140`, `RGS14`, and `STAT4`,
  but inspection showed the model-support and direct-perturbation flags were
  too weak:
  - `SP140`: Geneformer table rows had `support_contexts=0`, and CRISPR
    efferocytosis call was `UNRESOLVED`.
  - `RGS14`: Geneformer table rows had `support_contexts=0`; no direct
    perturbation support.
  - `STAT4`: Mixscale call was `null_or_wrong_direction`; Geneformer support
    was not positive.
- Replaced table-presence flags with stricter support gates:
  - foundation support now requires at least one positive support context with
    token coverage;
  - direct perturbation now requires a non-unresolved CRISPR/efferocytosis call
    or a non-not-nominated selective transcript perturbation.

Dispatch:

- `019e6a2c-d95b-7bb1-bf18-40a6e4f782af` (`Meitner the 2nd`):
  hostile translational feasibility/prior-art audit for Wave82 parked
  perturbation candidates.
- `019e6a2c-fafb-7942-9805-88ed76ea0b5d` (`Aristotle the 2nd`):
  cross-disease evidence stress test for the same candidate set.

Decision:

- Wave81 does not produce a promotable target after stricter operationalization.
- Open Wave82 on the least-bad parked perturbation candidates, but treat them
  as untrusted until sidecar and local audits converge.

## 2026-05-27 18:13 CEST

Wave82 sidecars returned and local intervention-route audit completed.

Subagent returns:

- `019e6a2c-d95b-7bb1-bf18-40a6e4f782af`
  (`phases/v3/subagents/wave82a_parked_perturbation_feasibility.md`):
  - no candidate gets ranked;
  - `LYN`, `HEXA/HEXB`, `SP140`, and `STAT4` have some modality/prior-art
    evidence but are blocked by directionality, safety, or prior art;
  - `DAB2`, `CD9`, `PARK7`, `PSAP`, and `RGS14` fail direct targetability or
    selective autoimmune direction.
- `019e6a2c-fafb-7942-9805-88ed76ea0b5d`
  (`phases/v3/subagents/wave82b_cross_disease_evidence_stress_test.md`):
  - `STAT4` and `SP140` have true cross-autoimmune breadth but are blocked;
  - `RGS14` has genetics without cross-disease state breadth;
  - `LYN` has state/model signal without genetics;
  - remaining candidates fail breadth.

Local audit:

- `scripts/v3_wave82_parked_perturbation_intervention_audit.py`
- `phases/v3/results/wave82_parked_perturbation_intervention_audit/`
- Call: `NO_PROMOTABLE_INTERVENTION_ROUTE`.

Integration decision:

- Close Wave82 as non-promotable.
- Next branch is genetics-first/druggable-survivor sweep across all
  target-resolved rows, looking for a target that was missed because it did not
  pass perturbation-first gates.

## 2026-05-27 18:05 CEST

Subagent recovery after interruption:

- Logged Wave82 sidecars `019e6a2c-d95b-7bb1-bf18-40a6e4f782af` and
  `019e6a2c-fafb-7942-9805-88ed76ea0b5d` were not present in the current
  registry after continuation and no corresponding artifacts existed.
- Closed completed Wave81 sidecar `019e6a1d-e558-7500-bfb2-8381e4c3a33d`
  (`Jason`) to free capacity.
- Spawned Wave82 translational/prior-art sidecar
  `019e6a2e-feea-75c3-b3e9-445f848c4e7d` (`Carver`):
  - artifact requested:
    `phases/v3/subagents/wave82_translational_prior_art_residuals.md`;
  - scope: `DAB2`, `CD9`, `PSAP`, `LYN`, `FAM49B`, `LRRC61`, `HEXA`, `HEXB`,
    `DAP`, `PARK7`, `FMNL2`.
- Closed still-running but already integrated Wave79 sidecar
  `019e6a13-66bf-7c70-a4f2-b596a1210978` to free capacity.
- Spawned Wave82 cross-disease stress-test sidecar
  `019e6a2f-645d-7801-a0ea-ea792e448925` (`Beauvoir`):
  - artifact requested: `phases/v3/subagents/wave82_cross_disease_residuals.md`;
  - same candidate scope.

Local Wave82 correction:

- The pre-existing Wave82 script was stale. It included `RGS14`, `BIRC3`, and
  `CCL20`, and missed corrected Wave81 residuals.
- Patched `scripts/v3_wave82_parked_intervention_route_audit.py` to audit:
  - residual candidates: `DAB2`, `CD9`, `PSAP`, `PARK7`, `LYN`, `FAM49B`,
    `LRRC61`, `HEXA`, `HEXB`, `DAP`, `FMNL2`;
  - false-positive controls: `SP140`, `RGS14`, `STAT4`.
- Also patched `scripts/v3_wave81_perturbation_first_rescue.py` to treat
  missing blocker values as empty instead of string `nan`.

Local Wave82 result:

- Script: `scripts/v3_wave82_parked_intervention_route_audit.py`.
- Outputs: `phases/v3/results/wave82_parked_intervention_route_audit/`.
- Call counts:
  - `PARK_ROUTE_POSSIBLE_BUT_EVIDENCE_INCOMPLETE`: 1 (`PARK7`).
  - `NO_GO_NO_CREDIBLE_INTERVENTION_ROUTE`: 10.
  - `NO_GO_FALSE_POSITIVE_CONTROL`: 3.
- No residual candidate is promotable.

Integration decision:

- Do not wait idly for sidecars; continue with a new local branch while they
  run.
- Next branch should invert the search order: start from reachable intervention
  classes or modalities, then test module/cell-state relevance. The
  perturbation-first residual-gene branch has not yielded a target.

## 2026-05-27 18:18 CEST

Wave82 cross-disease residual sidecar returned after continuation.

Artifact:

- `phases/v3/subagents/wave82_cross_disease_residuals.md`

Result:

- Promotion count: `0`.
- Parked only: `LYN`, `PSAP`, `PARK7`, `DAB2`, `FAM49B`.
- No-go: `LRRC61`, `CD9`, `FMNL2`, `DAP`, `HEXA`, `HEXB`.

Strict sidecar interpretation:

- The residual set does not contain a clean pan-autoimmune
  lipid-lysosomal/myeloid target.
- `DAB2` and `CD9` have direct efferocytosis perturbation plus nominal MS
  white-matter expression, but Crohn/UC myeloid expression is directionally
  negative and no genetics/route exists.
- `PSAP`, `HEXA`, and `HEXB` are lysosomal-proximal but have weak or
  contradictory cross-disease myeloid evidence.
- `LYN`, `FAM49B`, `LRRC61`, `DAP`, and `FMNL2` show nominal breadth in places,
  but tissue-cell mismatch, FDR failure, missing MS genetics, and/or absent
  perturbation support dominate.

Integration decision:

- Treat Wave82 residual-gene rescue as closed for target promotion.
- Continue with the planned inverted branch: reachable intervention class
  first, then require MS/cross-autoimmune module evidence and perturbation
  direction.

## 2026-05-27 18:29 CEST

Wave83 local branch completed.

Artifact:

- `scripts/v3_wave83_intervention_class_first_scan.py`
- `phases/v3/results/wave83_intervention_class_first_scan/`

Dispatch equivalent:

- No external subagent was used for this branch; it is an orchestrator-run
  local computational audit over existing V3 evidence tables.

Result:

- `REOPEN_REACHABLE_INTERVENTION_CANDIDATE`: `0`.
- `PARK_REACHABLE_BUT_EVIDENCE_INCOMPLETE`: `10`.
- `NO_GO_REACHABLE_BUT_BIOLOGY_INCOMPLETE_OR_BLOCKED`: `39`.
- `NO_GO_NOT_REACHABLE_FIRST_CLASS`: `152`.

Integration decision:

- Route-first scanning did not identify a target.
- The parked reachable axes (`MMP7`, `CD274`, `IL15`, `CASP4`, `KCNJ2`,
  `CD74`, `HLA-DRB1`, `APOL1`, `TIMP1`, `IL23A`) are too broad, prior-art
  saturated, or MS-unanchored for direct target promotion.
- Redirect to stratification-first testing: determine whether the module
  identifies a response-relevant inflammatory state rather than a novel target.
## 2026-05-27 18:17 CEST

Continuation after usage-limit interruption. Per user instruction, the waiting
gap does not count toward working-hour accounting; V3 remains active and
EXHAUSTION is not available.

Wave83 reopened as an orchestrator-led survivor sweep:

- local track: harden `scripts/v3_wave83_intervention_class_first_scan.py` so
  it includes genetics-first target-resolution rows, global survivor meta-rank
  context, and explicit prior-closure/blocker checks;
- sidecar A: independent prior-closure/druggability audit for genetics-first
  survivors outside the Wave81/Wave82 parked perturbation set;
- sidecar B: independent intervention-class scan for reachable mechanisms
  adjacent to the lipid-lysosomal/myeloid module.

Subagent outputs remain non-authoritative until reconciled against local code
outputs.

Dispatch:

- `019e6a3a-6519-7043-819e-1b0173103894` (`Socrates the 2nd`): Wave83A
  genetics-first prior-closure/druggability audit.
- `019e6a3a-8615-76d2-b721-6a2a9520dddc` (`Copernicus the 2nd`): Wave83B
  intervention-class scout around lipid-lysosomal/myeloid biology.

Returns integrated:

- Wave83B wrote `phases/v3/subagents/wave83b_intervention_class_scout.md` and called
  `NO_REACHABLE_CLASS_FINDING`. It suggested a conditional metabolite-first
  lipid-flux branch, but local reconciliation found this was already tested in
  Waves 72-74 (`NAAA`, `P2RX7`, `EPHX2`, `GPR183`) and did not satisfy the
  branch's own minimum data requirements.
- Wave83A wrote `phases/v3/subagents/wave83a_genetics_first_prior_closure_audit.md`
  and independently called no unblocked intervention-grade genetics-first
  survivor. This agrees with the hardened Wave83 local result.

Integration decision:

- Close Wave83 intervention nomination tracks.
- Continue Wave84 external stratification validation. The active question is
  whether the tissue `lysosomal_apc__resid_inflammatory_nfkb` baseline response
  signal replicates in external anti-TNF cohorts strongly enough to support a
  biomarker-guided trial concept.

## 2026-05-27 18:21 CEST

Wave83 meta-rank reconciliation completed locally.

Artifact:

- `phases/v3/results/wave83_intervention_class_meta_rank/`

Vetting note:

- Initial meta-rank output falsely reopened `CD58_TARGETABILITY`.
- The orchestrator rejected the reopen because it contradicted its source
  `PARK` call and had only one support channel; code was patched and rerun.

Corrected integration result:

- no reopened intervention class;
- one parked forcing route: `GPR183_EBI2_OXYSTEROL_NICHE`;
- `CD58` remains closed for target nomination but retained as a
  stratification comparator.

Routing decision:

- Stop target-rescue cycling for now.
- Dispatch Wave84 as a stratification-first response-analysis branch using
  treatment datasets already present in the workspace before attempting new
  downloads.

## 2026-05-27 18:22 CEST

Wave84 sidecars dispatched after closing stale completed agents.

Dispatch:

- `019e6a41-0fdf-70d2-8980-ce67ea811634` (`Euclid`):
  hostile statistical critique of baseline lysosomal/APC response
  stratification.
- `019e6a41-116b-73a0-93b3-713c98135135` (`Einstein`):
  independent treatment-response dataset and prior-art scout.

Local critical path:

- Implement predictive stratification audit using existing RA anti-TNF,
  IBD anti-TNF, and UC tofacitinib local artifacts.

## 2026-05-27 18:38 CEST

Wave85 returned and demoted the residual lysosomal/APC anti-TNF stratification
endpoint. The external IBD data instead show a strong generic
inflammatory/IFN-high nonresponse pattern.

Subagent handling:

- Attempted to spawn a fresh Wave86 prior-art sidecar.
- Spawn failed because the session already has the maximum six agents.
- Reused existing agent `019e6a3a-8615-76d2-b721-6a2a9520dddc`
  (`Copernicus the 2nd`) with a new queued task.

Dispatched task:

- Audit prior art for baseline mucosal inflammatory/NFKB/IFN-high anti-TNF
  nonresponse signatures and candidate genes/routes (`OSM`, `TREM1`, `IL1B`,
  `CXCL8`, chemokines, `TNF`, `NFKBIA`, IFN/APC genes).
- Write:
  `phases/v3/subagents/wave86_prior_art_antitnf_inflammatory_nonresponse.md`.

Local orchestrator task in parallel:

- Build Wave86 gene-level decomposition of the Wave85 external GEO signal.

## 2026-05-27 19:42 CEST

Continuation after external usage-limit interruption. Per the user's
instruction, idle waiting time is excluded from active working-hours accounting.

Current integration state:

- `FABP5` was the strongest lipid-neighborhood controller from Wave91 but is
  blocked by direct MS/EAE prior art in Wave92.
- `LPL` remains a cross-disease lipid-state marker, not a safe intervention
  target.
- Direct module-internal genes are now deprioritized. The next forcing question
  is whether an upstream/druggable state-transition controller can preserve the
  lipid-lysosomal biology without inheriting direct lipid-enzyme prior-art or
  systemic-lipid safety blockers.

Wave93 sidecars dispatched to existing agents:

- `019e6a0b-8503-7bd0-b101-ec603041af8b`: GPR183/EBI2 oxysterol-niche
  prior-art audit across MS/EAE, IBD, RA, psoriasis, T1D, Sjogren, and lupus.
- `019e6a18-7aa6-7112-8dbd-f42060a94c51`: GPR183 druggability,
  ligand/antagonist, selectivity, delivery, and safety audit.
- `019e6a2c-d95b-7bb1-bf18-40a6e4f782af`: hostile peer review of a GPR183
  pivot, with emphasis on MS anchor, ligand/receptor coherence, genetics,
  disease breadth, foundation-model relevance, and novelty.

Local orchestrator task in parallel:

- Implement a target-level Wave93 forcing test for `GPR183`, `CH25H`,
  `CYP7B1`, `HSD3B7`, and related oxysterol-niche biology across MS,
  direct single-cell/spatial contrasts, external anti-TNF response datasets,
  target-resolution outputs, and prior Wave74/Wave83 artifacts.

## 2026-05-27 19:50 CEST

Wave93 local forcing test completed before sidecar returns.

Integration result:

- `GPR183_EBI2_OXYSTEROL_NICHE` is closed as a V3 therapeutic route.
- The IBD anti-TNF response signal is strong, but the route fails the central
  therapeutic gates:
  - no positive MS receptor anchor;
  - no positive MS ligand-production module;
  - no coherent cross-disease ligand + receptor + response contexts;
  - genetics breadth only `2` diseases;
  - response support only `1` system;
  - direct MS/EAE prior art already exists.

Sidecar handling:

- Keep the dispatched prior-art, druggability, and hostile-review outputs as
  confirmatory/contradictory evidence when they return.
- Do not wait on them before pivoting because the local hard gates are already
  sufficient to close the branch.

## 2026-05-27 19:55 CEST

Wave94 sidecars dispatched to force the next route systematically rather than
hand-picking another lipid gene.

Dispatch:

- `019e6a2c-fafb-7942-9805-88ed76ea0b5d`: evaluate
  `APOC1`/`APOE`/`LPL` lipid-associated macrophage/apolipoprotein axis.
- `019e6a3a-6519-7043-819e-1b0173103894`: evaluate `CD82` and `FXYD5` as
  underexplored accessible cell-state transition handles from Wave39.
- `019e6a3a-8615-76d2-b721-6a2a9520dddc`: hostile rank of remaining
  intervention classes after closure of ACSL1, NAMPT, OSM/TREM1/IL1B/LAMP3,
  FABP5, and GPR183.

Local orchestrator task in parallel:

- Build Wave94 systematic accessible-state candidate rerank from existing
  surfaceome, target-resolution, MS, broad h5ad, anti-TNF response, and
  foundation-model artifacts.

## 2026-05-27 19:41 CEST

Wave88-Wave91 integration checkpoint.

Subagent returns already vetted:

- `wave87_hostile_critique_inflammatory_nonresponse.md` argued that the
  inflammatory nonresponse circuit might be a generic tissue-composition proxy.
- `wave87_prior_art_translational_feasibility.md` found no unblocked
  intervention route among the Wave86 inflammatory leaders.
- `wave87_cross_disease_circuit_evidence.md` recommended parking rather than
  claiming the inflammatory circuit.

Local follow-through:

- Wave88 tested the hostile critique directly and found that the
  `IL1B/TREM1/CXCL8/OSM` circuit adds only `0.00698` AUC beyond neutrophil,
  stromal, epithelial, generic inflammation, and IFN proxies in external IBD
  anti-TNF cohorts; permutation p `0.26`.
- Wave89 added psoriasis adalimumab baseline response as a third disease stress
  test. `IL1B` was weak same-direction, `LAMP3` reversed, and `LPL` emerged as
  the strongest small-sample signal.
- Wave90 audited `LPL` across IBD, RA, psoriasis, MS white matter, and direct
  h5ad comparisons. It remained a lipid-state marker but failed direct target
  promotion because of direct atlas conflict and systemic lipolysis risk.
- Wave91 tested all 45 candidate module genes as intervention nodes and found
  zero reopened candidates.

Integration decision:

- Close direct module-gene nomination.
- Continue with an upstream/downstream controller branch for the lipid-loader
  myeloid state.

## 2026-05-27 19:56 CEST

Controller-route integration update.

Local additions:

- Wave91 module-wide lipid/lysosomal intervention rank closed all 45 measured
  module genes as direct intervention nodes.
- Wave92 lipid-state controller route audit tested 15 route-level controllers
  across IBD, RA, psoriasis, MS white matter, and broad h5ad contrasts.
  Result: no reopened controller route.
- Older Wave91 lipid-neighborhood scan and Wave92 FABP5 prior-art audit remain
  integrated:
  - `FABP5` is the best local lipid-neighborhood controller signal.
  - `FABP5` is blocked as a novel MS target by direct MS/EAE prior art.
- Wave93 GPR183 forcing test was patched and rerun:
  - fixed IBD expression-score orientation;
  - fixed empty ChEMBL result handling;
  - current reproducible run records DNS failures for PubMed/ChEMBL APIs.

Integration decision:

- `FABP5` closed for novelty.
- `GPR183` closed on biological gates independent of API access.
- Route-level controller search currently leaves no V3-grade therapeutic
  nomination.
- Continue broadening rather than recycling the same lipid-route targets.

## 2026-05-27 20:08 CEST

Continuation after usage-limit interruption. The waiting gap is not counted as
active working time.

Dispatched sidecar wave for the next forcing decision:

- CD300-family receptor-specific lipid/efferocytosis tuning prior-art,
  druggability, and direction audit.
- `SEL1L3` accessible-state route audit.
- `NRCAM` accessible-state route audit.
- `C15ORF48`/MOCCI myeloid metabolic-state controller audit.
- `CD200`/`CD200R1` inhibitory checkpoint audit.
- Hostile integration review across the five branches.

Local orchestrator task while sidecars run:

- Build Wave95 to force the statistical Wave94 top genes and the mechanistic
  Wave92 CD300 route into one comparable triage matrix.

## 2026-05-27 20:08 CEST

Continuation after usage-limit interruption. The idle gap is excluded from
working-time accounting.

Wave94 re-dispatch:

- `019e6a9f-b100-7cc1-9019-299327c67bee`: accessible/non-lipid
  intervention sidecar, focused on CD82, FXYD5, CD58/CD2, MFGE8, P2RX7, and
  any overlooked reachable target in Wave39/Wave71/Wave82/Wave83/Wave91/Wave92.
- `019e6a9f-c7fe-77e0-946a-90b9e7f4dfbb`: hostile critique of the post-Wave93
  trajectory and next-pivot criteria.
- `019e6a9f-e3e0-7f70-bb3f-0a914c8bba33`: prior-art/translational scout for
  CD82/FXYD5, CD58/CD2, MFGE8, and P2RX7 route classes.

Local orchestrator task while sidecars run:

- Build a systematic Wave94 rerank from existing artifacts instead of
  hand-picking another lipid or response-marker candidate.

## 2026-05-27 20:22 CEST

Integrated Wave94 sidecars and corrected broad Wave95 triage.

Subagent integration:

- Accessible/non-lipid sidecar demoted CD58/CD2, CD82, FXYD5, MFGE8, P2RX7,
  P4HB, and SEL1L3 as claim-grade intervention routes.
- Hostile critique emphasized the core failure mode: state-marker/controller
  confusion and overuse of bulk-style response proxies.
- Prior-art/translational sidecar left only wet-lab kill tests for MFGE8 and
  FXYD5; CD58/CD2 and P2RX7 are blocked, CD82 and SEL1L3 lack actionability.

Orchestrator validation:

- Patched Wave95 mechanistic triage to restore missing response fields, tighten
  CRISPR FDR handling, and fix `NOT_BLOCKED_BUT_*` route prior parsing.
- Re-ran `scripts/v3_wave95_mechanistic_forcing_triage.py`.
- Result: zero promoted candidates across 15 genes/routes.

Integration decision:

- Stop direct promotion of Wave94 accessible hits.
- Continue with Wave96: de novo druggable-controller search around the
  `C15ORF48` mitochondrial inflammatory-brake state.

## 2026-05-27 20:36 CEST

Wave97 sidecar dispatch after Wave96.

Wave96 produced no reopened C15 controller candidate, but parked 13 proximal
intervention candidates: `CCL20`, `IL23A`, `CD200`, `PLEK2`, `LITAF`,
`FKBP1A`, `CASP4`, `JAK3`, `IL15`, `SLPI`, `PIK3R2`, `MTHFD2`, and `PDPN`.

Dispatched sidecars:

- `019e6abb-821e-7ba3-9ae4-9850f64225b3` (`Lagrange`): prior-art,
  patent/trial, and translational audit for the 13 parked candidates.
- `019e6abb-83c8-7602-8d4d-ac7bc0a9eced` (`Anscombe`): mechanistic
  directionality audit around C15ORF48/MOCCI versus parallel inflammatory
  marker status.
- `019e6abb-856d-7373-a41d-d50acfbb2ba6` (`Popper`): hostile critique of the
  Wave96 operationalization and next required fixes.

Local orchestrator task while sidecars run:

- Implement a residual donor-level co-state falsification test for parked
  C15-proximal candidates, controlling for generic inflammatory/metabolic
  module burden.

## 2026-05-27 20:50 CEST

Continuation after another usage-limit interruption. The waiting gap is not
counted as active working time.

Recovered and integrated the still-open Wave95 sidecar returns into
`phases/v3/subagents/wave95_sidecar_returns_integrated.md`.

Attempted to retrieve the Wave97 sidecars dispatched at 20:36 CEST:

- `019e6abb-821e-7ba3-9ae4-9850f64225b3`
- `019e6abb-83c8-7602-8d4d-ac7bc0a9eced`
- `019e6abb-856d-7373-a41d-d50acfbb2ba6`

Runtime result: all three returned `not_found`, so their outputs are not
available and cannot be used.

After closing the completed Wave95 agent slots, re-dispatched CCL20-specific
sidecars because Wave97 reopened only `CCL20` after residual co-state
falsification:

- `019e6ac5-5d68-7600-9701-513620954055` (`Goodall the 2nd`): CCL20/CCR6
  prior-art, patent, trial, and feasibility audit across the autoimmune cluster.
- `019e6ac5-5f4d-70f3-8a0f-03f3ab10dfbf` (`Descartes the 2nd`):
  mechanistic directionality of CCL20/CCR6 relative to C15ORF48/MOCCI and the
  lipid-lysosomal myeloid state.
- `019e6ac5-6138-7940-8dc8-f5a7497d631a` (`Maxwell the 2nd`): hostile review
  of the C15ORF48 -> CCL20 branch.

Local orchestrator task while sidecars run:

- Build Wave98: force-test CCL20/CCR6 as a cross-autoimmune intervention axis
  against local recurrence, MS anchoring, treatment-response direction,
  genetics, perturbation, druggability, and prior-art gates.

## 2026-05-27 20:59 CEST

Wave99 sidecar dispatch after Wave98 successor audit.

Wave98 closed `LITAF`, `PLEK2`, `CASP4`, and `PIK3R2` as target nominations.
`LITAF` remains only a wet-lab perturbation-ordering hypothesis and `CASP4`
is close-prior/safety blocked. The next non-overlapping question is whether an
endogenous brake of the CASP4/LITAF inflammatory-stress axis is more tractable
than directly drugging the stress generators.

Dispatched sidecars:

- `019e6acf-7c89-7e01-82ef-59fe34129770` (`Kepler`):
  prior-art/druggability sidecar for endogenous inflammasome/caspase brakes
  (`CARD16`, `CARD17`, `CARD18`, `SERPINB1`, `IL18BP`, `CARD8`) and core
  pyroptosis comparators (`CASP1`, `CASP4`, `CASP5`, `GSDMD`, `NLRP3`,
  `IL1B`, `IL18`, `GBP1`, `GBP2`, `GBP5`).
- `019e6acf-7e3d-7c92-bc43-c269f7777f87` (`Mill`): directionality sidecar on
  whether disease-high endogenous brakes should be
  interpreted as protective counter-regulators, disease drivers, or generic
  inflammation markers in relation to `C15ORF48`/MOCCI and anti-TNF remission
  direction.

Local orchestrator task while sidecars run:

- Implement Wave99 using local MS, cross-disease residual, anti-TNF response,
  perturbation, genetics, druggability, and foundation-model evidence.

Wave99 sidecar returns and integration:

- `019e6acf-7c89-7e01-82ef-59fe34129770` (`Kepler`) wrote
  `phases/v3/subagents/wave99_inflammasome_brake_prior_art_sidecar.md`.
  Bottom line: no GO; `CARD16` only PARK as a brake-state/order hypothesis.
- `019e6acf-7e3d-7c92-bc43-c269f7777f87` (`Mill`) wrote
  `phases/v3/subagents/wave99_inflammasome_brake_directionality_sidecar.md`.
  Bottom line: `CARD16` is the strongest local C15-linked clue but
  directionally unsafe; `SERPINB1` has cleaner published brake mechanism but
  weak local MS/C15 support.

Local orchestrator result:

- Added `scripts/v3_wave99_endogenous_inflammasome_brake_audit.py`.
- Added it to `scripts/entrypoints/run_v3_analysis.sh`.
- First run with system `python3` failed because `numpy` was absent.
- Re-ran with `.venv_v3_py312/bin/python`.
- Patched an MS-signature column-name bug (`delta_log2`, not
  `delta_log2_cpm`) and re-ran.
- Final call:
  `NO_REOPEN_ENDOGENOUS_INFLAMMASOME_BRAKE_TARGET`.

Integration decision:

- Close endogenous inflammasome-brake rescue as a therapeutic nomination.
- Keep `CARD16`, `SERPINB1`, and `IL18BP` only as wet-lab ordering controls.
- Write `CONVERGENCE_CHECK_55.md`.
- Pivot to a broader intervention-first search rather than further C15
  expression-adjacency tests.

## 2026-05-27 21:12 CEST

Wave100 cAMP-restoration class pivot.

Reason:

- The intervention-class meta-rank left no C15-proximal target, but `ADCY3`
  had broad genetics plus a nominal MS white-matter signal, `GPR65` had
  GPCR druggability and broad genetics but prior local mismatch, and
  `PDE4B/PDE4D` represent a clinically reachable cAMP-restoration route.
- The right forcing test is class-level: does restoring cAMP signaling have
  convergent MS, cross-disease, perturbation, response, and druggability
  evidence, or is it another generic immunomodulatory axis?

Local orchestrator task:

- Implement Wave100 cAMP-restoration intervention-class forcing audit using
  existing local evidence, L1000/PDE4 outputs, and target-resolution/genetics
  summaries.

Dispatched sidecars:

- `019e6ada-2ee6-7c72-99e8-7304b1531152` (`Pauli`):
  cAMP-route prior-art/trial/patent/translational audit.
- `019e6ada-309a-7511-8ea3-97a21ce93783` (`Lorentz`):
  cAMP directionality/modeling audit against the lipid-lysosomal/APC/C15 module.

## 2026-05-27 21:00 CEST

Wave98 CCL20/CCR6 integration.

Local result:

- `scripts/v3_wave98_ccl20_ccr6_forcing_audit.py`
- `phases/v3/results/wave98_ccl20_ccr6_forcing_audit/`
- Final call after bug fix:
  `NO_GO_CCL20_CCR6_PRIOR_ART_BLOCKED`.
- Claim-grade gates passed: `1/7`.

Sidecar returns:

- `019e6ac5-6138-7940-8dc8-f5a7497d631a` wrote
  `phases/v3/subagents/wave98_hostile_c15_ccl20_branch_review.md`; hostile call:
  do not promote because CCL20 is a known inflammatory chemokine passenger,
  C15 evidence is not MS-specific, residual survival is fragile, and prior art
  is severe.
- `019e6ac5-5d68-7600-9701-513620954055` wrote
  `phases/v3/subagents/wave98_ccl20_ccr6_prior_art_sidecar.md`; call:
  `NO_AUTOIMMUNE_THERAPEUTIC_NOVELTY_FOR_CCL20_CCR6_AXIS`.
- `019e6ac5-5f4d-70f3-8a0f-03f3ab10dfbf` wrote
  `phases/v3/subagents/wave97_ccl20_ccr6_mechanistic_sidecar.md`; call:
  CCL20 is downstream/parallel inflammatory chemokine output and CCR6 is not
  locally C15-state coupled.

Integration decision:

- Close CCL20/CCR6.
- Write `CONVERGENCE_CHECK_53.md`.
- Pivot locally to a perturbation-first audit of the upstream stress-generator
  class: `LITAF` and `CASP4`.

## 2026-05-27 21:14 CEST

Wave99 upstream stress-generator branch.

Dispatched sidecars:

- `019e6ace-fec4-7222-9d5b-1f5acdcbf5a0` (`Kepler the 2nd`):
  LITAF literature/trial/patent/druggability audit.
- `019e6acf-0076-7bc0-b446-d8becb3c75c4` (`Popper the 2nd`):
  CASP4 literature/trial/patent/druggability/selectivity audit.
- `019e6acf-032b-7150-8c20-36464a8bb16f` (`Plato the 2nd`):
  LITAF/CASP4 perturbation/modeling sidecar using local artifacts.

Local result while sidecars run:

- Added `scripts/v3_wave99_litaf_casp4_stress_generator_audit.py`.
- Added it to `scripts/entrypoints/run_v3_analysis.sh`.
- Output:
  `phases/v3/results/wave99_litaf_casp4_stress_generator_audit/`.
- Call:
  `NO_PROMOTABLE_LITAF_CASP4_STRESS_GENERATOR`.
- `LITAF`: parked as upstream stress marker with no modality.
- `CASP4`: parked as upstream pyroptosis node with prior-art/selectivity
  blockers.

Integration decision:

- Write `CONVERGENCE_CHECK_54.md`.
- Await sidecars for contradictions.
- If no contradiction, leave C15-proximal branch and resume intervention-first
  search across the broader lipid-lysosomal autoimmune module.

## 2026-05-27 21:20 CEST

Wave99 sidecars returned.

- `019e6ace-fec4-7222-9d5b-1f5acdcbf5a0` wrote
  `phases/v3/subagents/wave99_litaf_sidecar_audit.md`; call: LITAF remains a
  perturbation-ordering hypothesis / inflammatory stress marker, not target.
- `019e6acf-0076-7bc0-b446-d8becb3c75c4` wrote
  `phases/v3/subagents/wave99_casp4_sidecar_audit.md`; call: CASP4 remains
  `PARK/NO-GO` due prior art, CASP4/5 selectivity, and weak local MS anchor.
- `019e6acf-032b-7150-8c20-36464a8bb16f` wrote
  `phases/v3/subagents/sidecar_litaf_casp4_perturbation_modeling.md` and
  `scripts/v3_sidecar_litaf_casp4_ordering.py`; call: no direct perturbation
  dataset locally perturbs LITAF/CASP4 while measuring C15/NDUFA4/MOCCI.

Integration decision:

- No contradiction to Wave99.
- Close C15-proximal therapeutic target search.
- Next local wave: broader intervention-first search over the cross-autoimmune
  lipid-lysosomal module, prioritizing targets with direct perturbation,
  modality, MS evidence, and lower prior-art saturation.

## 2026-05-27 21:19 CEST

Wave100 cAMP-restoration returns and integration.

Local orchestrator result:

- Added and ran `scripts/v3_wave100_camp_restoration_class_audit.py`.
- Added it to `scripts/entrypoints/run_v3_analysis.sh`.
- Output:
  `phases/v3/results/wave100_camp_restoration_class_audit/`.
- Branch call:
  `NO_REOPEN_CAMP_RESTORATION_CLASS`.
- Candidate routes tested:
  `ADCY3`, `GPR65`, `PDE4B`, `PDE4D`, `PTGER4`, `ADORA2A`, `ADORA2B`,
  `HCAR2`, `HCAR3`, `FFAR2`.
- Promoted routes:
  `0`.

Sidecar returns:

- `019e6ada-309a-7511-8ea3-97a21ce93783` (`Lorentz`) wrote
  `phases/v3/subagents/wave100_camp_directionality_model_sidecar.md`.
  Verdict: no finding claimed. `PDE4B` is the best local perturbation
  hypothesis; `PTGER4` is the strongest genetics-rich comparator but
  direction-conflicted; other cAMP routes are marker/comparator routes.
- `019e6ada-2ee6-7c72-99e8-7304b1531152` (`Pauli`) wrote
  `phases/v3/subagents/wave100_camp_prior_art_sidecar.md`.
  Verdict: no route is a GO. PDE4B/D local cAMP restoration is only a
  prior-art-aware comparator/stratification branch; `GPR65` is secondary PARK;
  `ADCY3`, `PTGER4`, `ADORA2A/B`, `HCAR2`, and generic cAMP controls are
  no-go for target promotion.

Integrated decision:

- Close cAMP restoration as a V3 therapeutic target-nomination branch.
- Preserve `PDE4B/D` as a mechanistic comparator for future wet-lab ordering,
  not as a novel target claim.
- The repeated no-go pattern is now clear for C15/cAMP-adjacent routes:
  expression/state proximity without direct perturbation and clean modality
  repeatedly fails. The next branch must start from intervention tractability
  and perturbation evidence, then ask whether it intersects the autoimmune
  lipid-lysosomal module.
- Write `CONVERGENCE_CHECK_56.md`.

## 2026-05-27 21:29 CEST

Wave101 accessible-survivor forcing triage.

Local orchestrator result:

- Added and ran `scripts/v3_wave101_accessible_survivor_forcing_triage.py`.
- Added it to `scripts/entrypoints/run_v3_analysis.sh`.
- Fixed the first-run ranking bug by introducing explicit call priorities.
- Output:
  `phases/v3/results/wave101_accessible_survivor_forcing_triage/`.
- Branch call:
  `NO_PROMOTABLE_ACCESSIBLE_SURVIVOR_YET`.
- Parked forcing candidates:
  `SEL1L3`, `FXYD5`, `APOC1`.

Integrated decision:

- Do not claim an accessible-survivor target.
- Open a narrow Wave102 route only if sidecars or local residual tests can add
  target-specific perturbation, directionality, or modality support for
  `SEL1L3` or `FXYD5`.
- Treat `APOC1` as a lipid-state confounder comparator unless a non-systemic
  intervention route appears.
- Dispatch next sidecars for prior art/novelty, mechanism/directionality, and
  topology/modality.

Dispatched sidecars:

- `019e6aeb-45c2-76c2-8557-a57935e95cd7` (`Meitner`):
  Wave101 prior-art/novelty/translational audit for `SEL1L3`, `FXYD5`,
  `APOC1`, with `CD82`/`LAPTM5` comparators.
- `019e6aeb-4789-79a3-bcf0-87d227556772` (`Ohm`):
  Wave101 mechanism and directionality audit for `SEL1L3` versus `FXYD5`,
  with `APOC1`/`CD82`/`LAPTM5` comparators.
- `019e6aeb-4950-7d43-9b96-4c651fa02180` (`Kuhn`):
  Wave101 topology, modality, and selectivity feasibility audit for
  `SEL1L3` and `FXYD5`, with comparators.

## 2026-05-27 21:40 CEST

Wave101/Wave102 sidecar returns and closure.

Returns and local integrations:

- Wrote missing mechanism/direction sidecar:
  `phases/v3/subagents/wave101_accessible_survivor_mechanism_sidecar.md`.
  Verdict: neither `SEL1L3` nor `FXYD5` can currently be said to control a
  lipid-lysosomal inflammatory tissue state. `APOC1` should be killed as an
  intervention branch; `FXYD5` should be killed as an immediate target
  nomination and retained only as a wet-lab comparator.
- Existing sidecar:
  `phases/v3/subagents/wave102_sel1l3_fxyd5_mechanism_modality_sidecar.md`.
  Verdict: `SEL1L3` is topology-validation only; `FXYD5` is wet-lab kill-test
  only; neither is a therapeutic GO.
- Existing sidecar:
  `phases/v3/subagents/wave102_sel1l3_fxyd5_prior_art_sidecar.md`.
  Verdict: `SEL1L3` has sparse direct autoimmune therapeutic prior art but too
  little target biology; `FXYD5` is prior-art/safety crowded around
  dysadherin, barrier biology, Na/K-ATPase, and oncology antibody routes.
- Existing local analysis:
  `phases/v3/results/wave102_accessible_survivor_residual_compartment_test/`.
  Branch call: `NO_ACCESSIBLE_SURVIVOR_RESIDUAL_REOPEN`.
- Existing local analysis:
  `phases/v3/results/wave102_sel1l3_fxyd5_target_specific_evidence_audit/`.
  Branch call: `NO_PROMOTABLE_SEL1L3_FXYD5_TARGET_SPECIFIC_EVIDENCE`.
- New local analysis:
  `phases/v3/results/wave102_sel1l3_fxyd5_residual_controller_test/`.
  Branch call: `NO_REOPEN_ACCESSIBLE_SURVIVOR_AFTER_RESIDUAL_TEST`.

Integrated decision:

- Close the accessible-survivor branch as a target-nomination route.
- Preserve candidate genes only as localization, comparator, or wet-lab
  kill-test readouts.
- Pivot to a broader sender-to-myeloid pathway scan: the repeated signal is a
  paired tissue-to-myeloid module, not a promotable accessible-marker target.

## 2026-05-27 21:34 CEST

Wave102 accessible-survivor residual compartment test.

Local orchestrator result:

- Added and ran
  `scripts/v3_wave102_accessible_survivor_residual_compartment_test.py`.
- Added it to `scripts/entrypoints/run_v3_analysis.sh`.
- Output:
  `phases/v3/results/wave102_accessible_survivor_residual_compartment_test/`.
- Branch call:
  `NO_ACCESSIBLE_SURVIVOR_RESIDUAL_REOPEN`.
- No candidate survived either strict single-core-covariate gates or
  multivariable `core_all` residualization.

Integration decision:

- Treat `SEL1L3` and `FXYD5` as unpromoted markers unless sidecars produce a
  strong non-expression rescue.
- If sidecars agree with local residual evidence, close the accessible-survivor
  route and pivot to a new intervention-first axis.
- Write `CONVERGENCE_CHECK_58.md` after sidecar integration or, if sidecars are
  delayed, as a local negative checkpoint.

## 2026-05-27 21:49 CEST

Wave103 Fc/FcRn/efferocytosis route audit.

Local orchestrator result:

- Added and ran `scripts/v3_wave103_fc_receptor_efferocytosis_route_audit.py`.
- Added it to `scripts/entrypoints/run_v3_analysis.sh`.
- Output:
  `phases/v3/results/wave103_fc_receptor_efferocytosis_route_audit/`.
- Branch call:
  `NO_REOPEN_FC_EFFEROCYTOSIS_ROUTE`.

Integration decision:

- Close the Fc/FcRn/efferocytosis intervention-first branch for V3 target
  nomination.
- Preserve `FCGRT`, `DAB2`, and `CD9` as mechanistic comparators because each
  has one useful channel, but no candidate has the required independent
  convergence.
- Resume searching for a route that starts with both intervention tractability
  and disease/module anchoring.

## 2026-05-27 21:55 CEST

Wave104 accessible-survivor niche-controller test.

Sidecar integration:

- `019e6aeb-4789-79a3-bcf0-87d227556772` (`Ohm`) returned
  `phases/v3/subagents/wave101_accessible_survivor_mechanism_sidecar.md`.
  Verdict: do not promote `SEL1L3` or `FXYD5`; run a residualized
  tissue-niche controller test; kill `APOC1`; keep `CD82` and `LAPTM5` as
  comparators.

Local orchestrator result:

- Added and ran
  `scripts/v3_wave104_accessible_survivor_niche_controller_test.py`.
- Patched the initial over-parameterized adjustment with adaptive covariate
  trimming before logging the result.
- Output:
  `phases/v3/results/wave104_accessible_survivor_niche_controller_test/`.
- Branch call:
  `REOPEN_ACCESSIBLE_SURVIVOR_NICHE_CONTROLLER`.
- Only reopened candidate:
  `CD82`.

Integration decision:

- Treat `CD82` as a provisional reopener for Wave105 falsification.
- Do not revive `SEL1L3`, `FXYD5`, or `APOC1`.
- Next: test whether the `CD82` niche-controller signal survives simpler
  covariate models, permutation/leave-one-out robustness, and prior-art/modality
  sidecars.

Dispatched sidecar:

- `019e6b04-ca05-70f3-8666-059ae94066af` (`Franklin`):
  CD82-specific prior-art/novelty audit after the Wave104 niche-controller
  reopener.

Thread-limit note:

- Attempts to spawn separate CD82 modality/mechanism and hostile-methods
  sidecars failed because the thread limit was reached. I closed completed
  Wave100/Wave101 agents and continued the local Wave105 robustness audit on
  the critical path.

## 2026-05-27 21:37 CEST

Wave102 prior-art sidecar return for `SEL1L3` and `FXYD5`.

Return artifact:

- `phases/v3/subagents/wave102_sel1l3_fxyd5_prior_art_sidecar.md`

Vetting:

- The sidecar used local Wave101/Wave94 context plus PubMed E-utilities,
  Europe PMC, ClinicalTrials.gov v2, Google Patents, and targeted web searches.
- ClinicalTrials.gov returned zero studies for `SEL1L3`, `"SEL1L family member
  3"`, `FXYD5`, and `dysadherin`.
- PubMed disease-scoped counts found no SEL1L3 title/abstract autoimmune hits
  and only indirect FXYD5 hits in SLE/glomerulonephritis and thyroid/cancer
  contexts.
- External full-text/patent checks still found important blockers:
  SEL1L3 as RA marker/T1D preprint locus/PVRL autoantigen-immunotoxin prior;
  FXYD5 as Sjogren diagnostic autoantigen patent plus oncology antibody/EDC and
  Na,K-ATPase/barrier prior art.

Integrated call:

- `SEL1L3`: `PARK`.
- `FXYD5`: `PARK_KILL_TEST_ONLY`; `NO_GO` for target promotion now.
- The prior-art sidecar agrees with the local residual test: no
  accessible-survivor target should be promoted from the current evidence.

## 2026-05-27 21:38 CEST

Wave102 perturbation/model sidecar return for `SEL1L3` and `FXYD5`.

Return artifact:

- `phases/v3/subagents/wave102_sel1l3_fxyd5_perturbation_model_sidecar.md`

Supporting query artifacts:

- `phases/v3/results/wave102_sel1l3_fxyd5_perturbation_model_sidecar/public_perturbation_resource_queries.tsv`
- `phases/v3/results/wave102_sel1l3_fxyd5_perturbation_model_sidecar/targeted_public_perturbation_queries.tsv`
- `phases/v3/results/wave102_sel1l3_fxyd5_perturbation_model_sidecar/perturbseq_queries.tsv`
- `phases/v3/results/wave102_sel1l3_fxyd5_perturbation_model_sidecar/raw_api/`

Vetting:

- Local perturbation-first tables gave `0` Wave81 rows for both genes.
- The one local direct functional screen, GSE212008 efferocytosis CRISPR,
  contained both genes but called both `UNRESOLVED` with contrast FDR `1.0`.
- Local foundation-model support is absent for `FXYD5`; `SEL1L3` has only
  sparse Geneformer rows already labeled `model_only_no_real_perturbation_alignment`.
- Public GEO/GDS, LINCS Data Portal, Perturb-seq, and ChEMBL checks did not
  identify a target-specific perturbation or drug-modulation route.
- Public `FXYD5` perturbation literature exists, but does not establish
  autoimmune disease-state rescue or resolve the barrier/adhesion/Na,K-ATPase
  safety problem.

Integrated call:

- `NO_REOPEN_SEL1L3_FXYD5_FROM_PERTURBATION_OR_MODEL_EVIDENCE`.
- Together with the residual and prior-art sidecars, this closes the current
  `SEL1L3`/`FXYD5` accessible-survivor target route for V3 promotion.

## 2026-05-27 21:40 CEST

Wave102 convergence integration after all `SEL1L3`/`FXYD5` sidecars.

Output:

- `CONVERGENCE_CHECK_59.md`

Integrated decision:

- Close `SEL1L3` and `FXYD5` as V3 therapeutic-promotion candidates.
- Retain `SEL1L3` only as marker/topology-discovery assay material.
- Retain `FXYD5` only as a bounded wet-lab kill-test concept requiring
  non-depleting target engagement and preserved barrier function.
- Pivot main search back to intervention-first candidates with perturbation,
  foundation-model alignment, target genetics, or druggability present before
  expression recurrence is considered.

## 2026-05-27 21:50 CEST

Wave103 intervention-first successor triage integrated.

Output:

- `phases/v3/results/wave103_intervention_first_successor_triage/REPORT.md`
- `CONVERGENCE_CHECK_60.md`

Vetting:

- The script was patched before integration to include Wave81 MS-expression
  anchors, preventing a false no-MS-anchor call for perturbation-first genes.
- After the fix, no candidate survived all gates.
- Top perturbation candidates `CD9` and `DAB2` remain biologically useful but
  fail modality/direction gates.

Decision:

- Close intervention-first successor branch.
- Open Wave104 as target-resolved genetics-first lipid-state convergence audit.

## 2026-05-27 21:56 CEST

Wave104 genetics-first lipid-state convergence audit completed and sidecars
dispatched.

Output:

- `phases/v3/results/wave104_genetics_first_lipid_state_convergence_audit/REPORT.md`
- `phases/v3/results/wave104_genetics_first_lipid_state_convergence_audit/genetics_first_lipid_state_rank.tsv`

Integrated local call:

- `NO_PROMOTABLE_TARGET_BUT_DISPATCH_GENETICS_STATE_SIDECARS`.
- No gene reached `REOPEN_GENETICS_FIRST_TARGET_SIDECARS`.
- Sidecar set: `IFI30`, `IL7R`, `SP140`, `GALC`, `CD58`.

Dispatches:

- Genetics/colocalization sidecar: `019e6b01-c571-7ae1-b7e5-52a229d6efc6`.
- Perturbation/foundation sidecar: `019e6b01-e795-7a62-bc8e-0e5c48a4496f`.
- Modality/prior-art sidecar: `019e6b02-0a1a-79c0-b9ea-b569b965225b`.
- Cross-disease cell-state sidecar: `019e6b02-2706-7be3-ad4a-d8b0e8b410ca`.

Sidecars are explicitly bounded: they cannot claim a finding; they can only
recommend GO/PARK/NO_GO for target-specific follow-up.

## 2026-05-27 22:01 CEST

Wave104 genetics/colocalization sidecar returned.

Output:

- `phases/v3/subagents/wave104_genetics_coloc_sidecar.md`

Vetting:

- Used local Wave62 target-resolution summary, L2G rows, QTL-coloc rows, gate
  matrix, Wave55 external genetics breadth, and Wave104 dispatch rank.
- No internet verification was needed.
- `IL7R`, `SP140`, `GALC`, `CD58`, and `IFI30` all retain genetics-sidecar
  value, but none receives a therapeutic `GO`.

Decision:

- Keep `IL7R` and `SP140` as target-resolved comparator/stratification axes.
- Keep `IFI30`, `GALC`, and `CD58` as parked genetics benchmarks only.
- Do not advance any Wave104 sidecar gene to `FINDING_V3`.

## 2026-05-27 22:02 CEST

Wave105 local context decomposition completed while Wave104 sidecars were
running.

Output:

- `phases/v3/results/wave105_wave104_candidate_context_decomposition/REPORT.md`

Integration note:

- Local context evidence narrows the plausible non-control genes to `IFI30` and
  `SP140`; both have residual/state support but remain route-blocked.
- `GALC` is downgraded relative to Wave104 because raw cross-disease recurrence
  does not survive residual checks.

## 2026-05-27 23:45 CEST

Resumed after interruption; non-working waiting gap excluded from active-time
accounting.

Subagent reconciliation:

- Franklin `019e6b04-ca05-70f3-8666-059ae94066af` returned and was closed.
  - Output: `phases/v3/subagents/wave105_cd82_prior_art_sidecar.md`.
  - Call:
    `PARK_AS_NICHE_BIOMARKER_OR_MECHANISM_BRANCH_NO_GO_THERAPEUTIC_CD82`.
  - Integration decision: direct CD82 therapeutic modulation is blocked; CD82
    can only proceed as a mechanism/biomarker branch unless an indirect,
    non-CD82 intervention emerges.
- Meitner `019e6aeb-45c2-76c2-8557-a57935e95cd7` returned and was closed.
  - Output: `phases/v3/subagents/wave101_accessible_survivor_prior_art_sidecar.md`.
  - Integration decision: no Wave101 accessible-survivor candidate is
    promotable as a therapeutic target.
- Kuhn `019e6aeb-4950-7d43-9b96-4c651fa02180` did not return on a bounded
  wait and remains open.

Local Wave105 CD82 robustness audit completed.

Output:

- `phases/v3/results/wave105_cd82_niche_robustness_audit/REPORT.md`
- `phases/v3/results/wave105_cd82_niche_robustness_audit/summary.json`

Integration decision:

- Corrected branch call: `REOPEN_CD82_ROBUST_NICHE_SIGNAL`.
- The reopening is explicitly not a therapeutic nomination.
- The robust signal is restricted to Crohn and Sjogren matched epithelial-to-
  myeloid/APC niche coupling and is still vulnerable to donor-level tissue
  severity or unmeasured treatment confounding.

New sidecars dispatched:

- Fermat `019e6b66-88c7-7bb3-8ed0-0e67348d1560`: CD82 mechanism/modality
  audit for indirect intervention routes that avoid direct CD82 blockers.
- Bohr `019e6b66-a144-7521-bc9a-af7f8eda8675`: hostile methods review of
  Wave105 statistical validity and branch call.

## 2026-05-27 23:50 CEST

Fermat CD82 mechanism/modality sidecar returned.

Output:

- `phases/v3/subagents/wave105_cd82_mechanism_modality_sidecar.md`

Calls:

- Direct `CD82`: `NO_GO`.
- `CD82` as biomarker: `PARK`.
- Indirect intervention candidates: `PARK`, no current `GO`.

Integration decision:

- CD82 remains a robust matched-niche marker/mechanism branch, not an
  intervention point.
- The only defensible use is to stratify tissue contexts and test whether
  indirect lysosome/phagosome, MHC-II/APC, inflammasome, integrin/efferocytosis,
  or lipid-handling interventions normalize the CD82-associated myeloid state.
- Continue locally with a confounder-specificity audit before spending more
  effort on indirect intervention selection.

Bohr hostile methods sidecar and Kuhn older modality sidecar remain open after
bounded wait.

## 2026-05-27 23:55 CEST

Bohr hostile methods sidecar returned and was closed.

Output:

- `phases/v3/subagents/wave105_cd82_hostile_methods_review.md`

Integration decision:

- Accept the critique: Wave105's `REOPEN_CD82_ROBUST_NICHE_SIGNAL` was too
  permissive.
- CD82 should be downgraded unless it survives multiplicity correction,
  disease-level collapse, and specificity controls.

Fermat mechanism/modality sidecar was also closed after integration.

Local Wave106 specificity/confounder audit completed.

Output:

- `phases/v3/results/wave106_cd82_specificity_confounder_audit/REPORT.md`

Decision:

- CD82 is provisionally downgraded to a niche biomarker/readout.
- Crohn robust rows look like generic target APC activation coupling, not
  lipid-lysosomal specificity.
- Sjogren retains only one nominal, model-sensitive primary signal.
- Continue with Wave107 corrected multiplicity and disease-collapse audit to
  close the branch rigorously.

## 2026-05-28 00:02 CEST

Wave107 CD82 multiplicity/disease-collapse audit completed.

Output:

- `phases/v3/results/wave107_cd82_multiplicity_disease_collapse_audit/REPORT.md`

Decision:

- Branch call:
  `CD82_PROVISIONAL_NICHE_BIOMARKER_SIGNAL_NOT_REOPENED`.
- CD82 is closed for target nomination and indirect-intervention nomination.
- Remaining use: provisional matched-niche biomarker/readout for ex vivo
  assays.

Reason:

- No strict disease pass.
- Crohn is generic activation coupling.
- Sjogren is one provisional disease only.
- The result does not meet V3 therapeutic DoD and should not be rescued by
  narrative.

Next orchestration move:

- Pivot back to intervention-first target discovery within the lipid-lysosomal
  myeloid module.
- Prioritize nodes with direct perturbation/druggability evidence rather than
  marker-only tissue coupling.

## 2026-05-28 00:18 CEST

Wave108/Wave109 MFGE8 local debris-opsonin safety modeling completed.

Outputs:

- `phases/v3/results/wave108_mfge8_debris_opsonin_safety_window_model/REPORT.md`
- `phases/v3/results/wave109_mfge8_threshold_sensitivity_audit/REPORT.md`

Decision:

- MFGE8 is not promoted.
- Strict safety window fails under the model: no parameter point reached 2x
  conservative debris-clearance gain while keeping p90 viable loss <= 5%.
- A modest 1.5x window exists only with very high modeled debris-over-viable
  selectivity, minimum approximately 316x.

Integration:

- This is a useful wet-lab design constraint, not a V3 finding.
- MFGE8 remains an ex vivo/local-engineering comparator branch.
- Continue searching for a target or intervention with stronger real-data
  anchoring.

## 2026-05-28 00:45 CEST

Wave110 route map and GPR183 forcing branch completed.

Outputs:

- `phases/v3/results/wave110_post_closure_intervention_route_map/REPORT.md`
- `phases/v3/subagents/wave110_overlooked_intervention_route_scout.md`
- `phases/v3/results/wave111_gpr183_spatial_proxy_forcing_test/REPORT.md`
- `phases/v3/results/wave112_gpr183_compartment_contrast_fallback/REPORT.md`

Integration:

- Route map and sidecar selected GPR183/EBI2 as the next least-bad forcing test.
- Wave111 matched-donor spatial proxy could not run because donor-level gene
  scores for `GPR183` and ligand-axis genes were not precomputed.
- Wave112 fallback used weaker compartment-level h5ad contrasts and failed:
  coherent receptor/ligand compartment disease count was 0.

Decision:

- Close GPR183/EBI2 locally.
- Do not rebuild h5ad donor-level GPR183 scores unless a later independent
  route revives the axis.

## 2026-05-28 00:55 CEST

Wave113 PSAP recurrence/specificity audit completed.

Output:

- `phases/v3/results/wave113_psap_recurrence_specificity_audit/REPORT.md`

Integration:

- PSAP was the top local route-map candidate after CD82/MFGE8/GPR183 closure.
- Corrected audit shows no cross-disease or myeloid recurrence:
  positive disease count `1`, myeloid positive disease count `0`, negative
  disease count `2`.
- CRISPR/efferocytosis row is `UNRESOLVED`; no direct perturbation support.

Decision:

- Close PSAP locally as weak single-context marker/biology probe.

## 2026-05-28 06:41 CEST

Resume status and Wave114 P2RX7 closure.

Agent accounting:

- Kuhn `019e6aeb-4950-7d43-9b96-4c651fa02180` remains the only stale open
  sidecar from Wave101 after repeated bounded waits.
- All recent sidecars relevant to CD82, MFGE8, GPR183, and PSAP have returned
  and were integrated.
- Kuhn is non-blocking; do not wait on it for current routing.

Local analysis:

- Ran `scripts/v3_wave114_p2rx7_target_level_closure_audit.py` in the pinned
  V3 environment.
- Output:
  `phases/v3/results/wave114_p2rx7_target_level_closure_audit/REPORT.md`.

Integration:

- Branch call:
  `NO_REOPEN_P2RX7_TARGET_LEVEL_STRATIFICATION`.
- The target-level package fails all reopening gates: specificity `0`, no MS
  module support, no RA or IBD responder discrimination, and unresolved CRISPR
  evidence.

Decision:

- Close P2RX7 locally.
- Next route should not be another broad module score. It should either test a
  remaining route for controller behavior after residualization, or pivot to a
  new intervention-first mechanism with direct perturbation and modality
  support.

## 2026-05-28 06:50 CEST

Wave115 SPNS1 controller falsification completed.

Output:

- `phases/v3/results/wave115_spns1_controller_falsification_audit/REPORT.md`

Integration:

- Branch call:
  `NO_REOPEN_SPNS1_CONTROLLER_ROUTE`.
- Controller-pass diseases:
  `0`.
- Myeloid-pass contexts:
  `0`.
- External gates also fail: no MS anchor, response support, CRISPR support,
  target-resolution support, or modality readiness.

Decision:

- Close SPNS1 locally.
- The remaining path should be route-class re-ranking or a perturbation-first
  pivot, not another accessible-marker rescue.

## 2026-05-28 07:06 CEST

Wave116/Wave117 route rerank and PARK7 closure.

Outputs:

- `phases/v3/results/wave116_closure_aware_route_rerank/REPORT.md`
- `phases/v3/results/wave117_park7_stress_route_forcing_test/REPORT.md`

Integration:

- Closure-aware rerank first surfaced `eicosanoid_receptors`, but that route is
  explicitly `NO_GO_INTERVENTION_CLASS_META_RANK`; rerank logic was tightened
  to select non-closed and non-`NO_GO` rows for forcing tests.
- The selected actionable route was `PARK7` from Wave110.
- Wave117 result:
  `NO_REOPEN_PARK7_GENERIC_STRESS_ROUTE`.

Decision:

- Close PARK7 locally. Raw myeloid recurrence in Sjogren/UC does not survive
  the required evidence package: no MS anchor, no target-resolution support,
  no validated perturbation, no FDR response, and generic-stress collapse.
- Continue through the actionable rerank list, prioritizing routes with direct
  perturbation and MS evidence over broad pharmacology classes.

## 2026-05-28 07:16 CEST

Wave118 DAB2/CD9 efferocytosis directionality audit completed.

Output:

- `phases/v3/results/wave118_dab2_cd9_efferocytosis_directionality_audit/REPORT.md`

Integration:

- Branch call:
  `NO_REOPEN_DAB2_CD9_EFFEROCYTOSIS_ROUTE`.
- Both genes have nominal MS expression and a nominal Wave37 efferocytosis
  screen call, but both fail FDR support.
- Cross-disease direction is negative, not positive: `DAB2` has three negative
  diseases and `CD9` has two negative diseases in Wave81 broad summary.
- Neither has response support, target genetics, or a modality channel.

Decision:

- Close DAB2 and CD9 locally.
- Add both to closure-aware rerank penalties before selecting the next route.

## 2026-05-28 07:18 CEST

Agent cleanup.

- Closed stale Kuhn sidecar `019e6aeb-4950-7d43-9b96-4c651fa02180`.
- Previous status was `interrupted`; shutdown notification received.
- No active subagent output is needed for the current route selection.

## 2026-05-28 07:24 CEST

BLK prefilter closure.

Integration:

- Closure-aware rerank selected `BLK` after DAB2/CD9/PARK7 penalties.
- Local inspection showed no MS anchor, no response support, no FDR-supported
  CRISPR/efferocytosis support, and Wave62 `NO_GO_WAVE62_TARGET_RESOLUTION`.
- Broad cell-state support is single-disease Sjogren only.

Decision:

- Close BLK by prefilter.
- Continue rerank after adding BLK to closure penalties.

## 2026-05-28 07:30 CEST

LRRC61 prefilter closure.

Integration:

- Closure-aware rerank selected `LRRC61`.
- It has four nominal broad positive diseases, but no MS anchor, no genetics,
  no response support, no modality, and only two CRISPR guides with no
  Wilcoxon/FDR support.

Decision:

- Close LRRC61 by prefilter and add to closure penalties.

## 2026-05-28 07:36 CEST

Wave119 batch prefilter for remaining Wave110 survivors completed.

Output:

- `phases/v3/results/wave119_wave110_remaining_survivor_prefilter/REPORT.md`

Integration:

- Branch call:
  `NO_REMAINING_WAVE110_SURVIVOR_AFTER_PREFILTER`.
- None of the 14 tested survivor genes passed enough hard gates to justify an
  individual forcing script.
- The batch result closes the current Wave110 tail represented by `CLEC7A`,
  `FAM49B`, `LYN`, `CCDC121`, `CHST11`, `FBXO16`, `RECQL4`, `EFR3A`,
  `IGLON5`, `MAN1A2`, `MREG`, `PLIN4`, `SLC39A3`, and `YWHAE`.

Decision:

- Penalize all Wave119 no-go genes in the closure-aware rerank.
- Resume route selection outside this low-quality perturbation-first tail.

## 2026-05-28 07:39 CEST

McClintock sidecar returned.

Agent:

- `019e6cf0-44f9-7f33-b689-756e4fb924ff` (`McClintock`)

Sidecar call:

- No remaining route is a `GO`.
- `CLEC7A` is the highest remaining wet-lab forcing-test candidate, but only
  `PARK`, blocked by no MS anchor, no genetics/target resolution, and no
  modality.
- `FAM49B/CYRIA` is also `PARK` but weaker.
- `EPHX2/sEH` is `PARK`: the only obvious translational handle among the
  listed candidates, but local evidence is under-resolved.
- `LYN` is `NO-GO`; other Wave110 survivors are low PARK or NO-GO.

Integration decision:

- Wave119 already closed `CLEC7A` and `FAM49B` by hard-gate prefilter.
- Treat sidecar as independent confirmation that the perturbation-first tail
  lacks a promotable target.
- Pivot next to `EPHX2/sEH` only because it has real pharmacology; require
  target-PD coherence rather than broad lipid-inflammation scoring.
## 2026-05-28 08:05 CEST

Wave120 EPHX2/sEH target-PD coherence closure completed.

Inputs:

- Wave74 direct ratio audit.
- Wave74 oxylipin specificity audit.
- Wave74c prior-art/druggability sidecar.

Branch call:

- `NO_REOPEN_EPHX2_TARGET_PD_COHERENCE`.

Decision:

- Do not promote EPHX2/sEH as the central intervention point.
- The druggability handle is real, but the V3 evidence fails all strict gates:
  no paired target-PD ratio, no target-level EPHX2 support, no specificity over
  generic lipid-inflammation, no independent response replication, no adequate
  specific cross-disease biochemistry, and broad autoimmune prior art is blocked.
- Added `EPHX2` to Wave116 closure terms.

## 2026-05-28 08:16 CEST

Wave116 rerun selected `ABTB2` from Wave110 after EPHX2 closure.

Integration decision:

- Do not dispatch a new ABTB2 sidecar or forcing script.
- Local evidence already closes it: no MS anchor, no genetics/target
  resolution, no modality channel, no IBD response support, non-significant
  CRISPR FDR values, and Wave71 `NO_REOPEN_INSUFFICIENT_CONVERGENCE`.
- Added `ABTB2` to closure terms.
- Tightened Wave116 actionable selection to require a concrete next test.

## 2026-05-28 08:26 CEST

Wave116 selected `CD44` after the ABTB2 filter.

Integration decision:

- Treat this as a reranker parser defect, not a candidate promotion.
- Wave91 had already called CD44 `NO_GO_ROUTE_BLOCKED` with
  `NO_GO_ADHESION_MATRIX_PRIOR_ART_AND_BROAD_BIOLOGY`, but Wave116 did not parse
  Wave91-specific columns.
- Patched Wave116 to read `wave91_call`, `route_blocker`, and
  `module_intervention_score`.
- Added `CD44` and `SPP1` to closure terms.

## 2026-05-28 08:36 CEST

Wave116 selected `HLA-DPB1` after the Wave91 parser fix.

Integration decision:

- Do not reopen HLA-II as an intervention route.
- The route is broad antigen presentation with host-defense/selectivity
  liabilities; HLA-DRA already carried `NO_GO_BROAD_MHC_CLASS_II`.
- Added `HLA-DPA1`, `HLA-DPB1`, and `HLA-DRA` to closure terms.
- Patched Wave116 so no-go/blocker terms in `recommended_next_test` also count
  as `no_go_source`.

## 2026-05-28 08:50 CEST

Wave121 final wet-lab-only route closure completed.

Branch call:

- `NO_OPEN_ROUTE_AFTER_WETLAB_ONLY_AUDIT`.

Route decisions:

- `FPR2_ANXA1_BIASED_RESOLUTION`: `NO_REOPEN_WETLAB_ONLY_ROUTE`, 2/10 gates.
- `CD300_RECEPTOR_SPECIFIC_TUNING`: `NO_REOPEN_WETLAB_ONLY_ROUTE`, 2/10 gates.

Integration decision:

- Exclude both from further V3 computational route selection.
- These remain possible future wet-lab comparators only; they cannot support a
  V3 finding without new target-specific perturbation data.

## 2026-05-28 08:59 CEST

Wave116 fallback bug identified and patched.

Details:

- Manual inspection found `n_actionable_routes=0`.
- Summary still selected `eicosanoid_receptors` because Wave116 fell back to
  `top_open` when no actionable route remained.
- Removed that fallback so empty actionable routes produce
  `NO_OPEN_ROUTE_AFTER_CLOSURE_RERANK`.

## 2026-05-28 09:04 CEST

Wave116 branch closure confirmed.

Result:

- `NO_OPEN_ROUTE_AFTER_CLOSURE_RERANK`
- `n_actionable_routes=0`

Decision:

- Stop mining the Wave110/Wave91/Wave95 survivor-map family.
- Pivot to a fresh breadth-first target-class scan using closure terms as
  exclusions.

## 2026-05-28 09:08 CEST

Dispatched fresh-route sidecar.

Agent:

- `019e6cfd-14be-78d2-a3c8-8ae91f3fafcf` (`Boyle`)

Scope:

- Read-only inspection of existing local artifacts.
- Identify up to five fresh target-class or mechanism routes outside the current
  closure ledger.
- No autonomous finding claim; output is advisory only.

Local orchestrator action while sidecar runs:

- Build a fresh breadth-first local target-class scan over existing evidence
  products with closure exclusions.

## 2026-05-28 09:12 CEST

Boyle sidecar returned.

Agent:

- `019e6cfd-14be-78d2-a3c8-8ae91f3fafcf` (`Boyle`)

Call:

- No route survives V3 promotion gates from local artifacts.

Least-bad fresh forcing tests suggested:

1. `NRCAM`
2. `CD200` / `CD200R`
3. `MERTK` / TAM agonist-restoration
4. `CHI3L1`
5. `LIPA`

Integration decision:

- Treat Boyle as advisory only.
- Compare these against the local Wave122 breadth scan.
- If Wave122 converges on one of these, run a strict forcing audit. If Wave122
  instead ranks another route, require the same hard gates before proceeding.

## 2026-05-28 09:20 CEST

Wave122 fresh breadth target scan and Wave123 sidecar kill audit completed.

Wave122:

- `NO_FRESH_ROUTE_FROM_LOCAL_SCAN`
- 32,096 genes scanned.
- `n_testable=0`, `n_park=0`.
- Top gene: `NCF2`, but blocked by NOX2 host-defense/CGD risk and Wave62
  target-resolution no-go.

Wave123:

- `NO_REOPEN_ANY_SIDECAR_CANDIDATE`.
- Boyle's five suggestions (`NRCAM`, `CD200`, `MERTK`, `CHI3L1`, `LIPA`) all
  failed explicit reopening gates.

Decision:

- Do not promote the sidecar routes.
- Run a strict NCF2/NOX2 audit only because it is Wave122's strongest
  multi-channel signal; require safety/direction and target-resolution gates.

## 2026-05-28 09:32 CEST

Wave124 NCF2/NOX2 strict closure completed.

Branch call:

- `NO_REOPEN_NCF2_NOX2_ROUTE`

Gate result:

- 1/11 gates passed.
- Only nominal MS expression support passed.
- NOX2 host-defense/CGD safety, target-resolution, perturbation, model strength,
  modality, and prior-closure gates failed.

Decision:

- Close NCF2/NOX2 as a therapeutic route.
- Pivot to a mechanism-class failure map before selecting another target.

## 2026-05-28 09:50 CEST

Wave125 and Wave126 completed.

Wave125:

- `MECHANISM_FAILURE_MAP_COMPLETE`
- Dominant failure among top 300 Wave122 genes: response absent (297/300), no
  modality (280/300), no causal channel (274/300).
- Recommendation: stop expression-only target ranking; search upstream
  druggable regulators or add new perturbation modality.

Wave126:

- `NO_L1000_UPSTREAM_REOPENER`
- 123 recurrent L1000 compounds tested.
- No recurrent compound passed target/MOA, recurrence, generic-IFN selectivity,
  safety, relevance, and prior-triage gates.

Decision:

- Check local metadata for top unknown L1000 compounds before spending network
  calls on external deconvolution.

## 2026-05-28 10:00 CEST

Wave127 external spot-check for recurrent unknown L1000 hits completed.

Artifact:

- `phases/v3/literature/wave127_external_l1000_unknown_lookup.md`

Decision:

- Do not reopen recurrent unknown L1000 hits.
- `BRD-K05197617` has an external EGFR-inhibitor annotation, but that routes to
  broad oncology/growth-factor biology, not a V3 autoimmune target.
- `BRD-K35024477` remains without a clear external target/MOA.

## 2026-05-28 10:12 CEST

Wave128 genetics-first reopener completed.

Branch call:

- `NO_GENETICS_FIRST_REOPENER`

Result:

- 195 genetics-first candidates tested.
- 0 reopened.
- SP140 is the strongest residual genetics route but is already closed as a
  prior-art/direction-conflicted comparator with no local MS or modality gate.

Decision:

- Do not reopen genetics-first target nomination.
- Pivot to response/stratification scan as a distinct translational angle.

## 2026-05-28 10:24 CEST

Wave129 response/stratification salvage completed.

Branch call:

- `BIOMARKER_ONLY_SIGNAL_EXISTS`

Biomarker-only candidates:

- `IL1B`
- `LAMP3`

Decision:

- Keep as anti-TNF nonresponse biomarker information only.
- Do not promote either as a target.
- Check for MS treatment-response evidence before considering any MS-centered
  stratification route.

## 2026-05-28 07:31 CEST

Resume after external interruption. The interrupted/waiting gap is not counted
as active V3 work time.

Agent dispatch:

- Huygens: read-only local audit of GSE235357/GSE250453 MS treatment-response
  files. Returned that both are usable small-n paired response datasets, with
  IL1B/LAMP3 present and module coverage available.
- Gibbs: read-only fresh-route audit after Wave129. Returned no V3-ready route;
  least-bad forcing candidates/classes were eicosanoid/LTA4H-adjacent,
  retinoid/VDR/RXR, Mediator/CDK8/19-like, GALC sphingolipid, and unknown L1000
  reversers.

Agent state:

- Huygens closed.
- Gibbs closed.
- No active subagents remain after integration.

Wave130:

- `scripts/v3_wave130_ms_treatment_response_audit.py`
- Branch call:
  `GENERIC_IFN_APC_SIGNAL_ONLY_NO_LIPID_LYSOSOMAL_RESCUE`

Decision:

- Wave130 does not rescue IL1B/LAMP3, lysosomal APC, or lipid-loader routes in
  MS treatment response.
- Generic IFN/APC baseline signal is insufficient for a V3 therapeutic claim.
- Continue by forcing class-level intervention routes from Gibbs, starting with
  eicosanoid/LTA4H-adjacent and retinoid/VDR/RXR classes.

## 2026-05-28 07:31 CEST

Wave131 class-route forcing audit completed.

Branch call:

- `NO_CLASS_ROUTE_REOPENED_AFTER_WAVE130`

Result:

- 4 least-bad classes tested after Wave130.
- 0 reopened.
- Eicosanoid and retinoid routes fail prior-art, direction/safety, specificity,
  and target-resolution gates.
- MED16 retains perturbation interest but lacks safe selective druggability and
  MS anchoring.
- GALC retains a genetics row but still lacks MS/perturbation/direction support.

Decision:

- Do not promote any Gibbs sidecar class route.
- Next check the last Wave83 parked class, GPR183/EBI2, against later closure
  waves before pivoting again.

## 2026-05-28 07:31 CEST

Wave132 GPR183 post-Wave130 closure completed.

Branch call:

- `NO_REOPEN_GPR183_AFTER_POST_WAVE130_AUDIT`

Decision:

- GPR183 remains closed: Wave111 had no spatial proxy rows, Wave112 found zero
  coherent compartment diseases, and Wave130 does not rescue the lipid-
  lysosomal MS response context.
- The Wave83 parked route is no longer open after late-wave evidence.

## 2026-05-28 07:51 CEST

Resume/integration state after interruption:

- Active subagents checked: none remain open.
- Huygens and Gibbs from the MS treatment-response/class-route phase were
  already closed.
- Plato hostile critique returned and was integrated as untrusted review, not
  as a finding.

Plato critique accepted:

- Wave122 used the wrong Wave55 path and Wave122/Wave128 used substring
  closure matching.
- Wave130 PBMC treatment-response datasets are too small and peripheral to
  close CNS/non-expression mechanisms by themselves.
- Wave131 was intentionally narrow and should not be treated as global class
  exhaustion.
- Wave132 over-weighted missing spatial-proxy rows for GPR183.

Wave133 closure-hygiene correction completed.

Branch call:

- `HYGIENE_CORRECTION_REOPENS_ROUTE`

Interpretation:

- This was a mechanical hygiene result, not a V3 target nomination.
- Exact closure matching restored 22 genes that substring matching would have
  suppressed, but all restored genes remain `NO_GO_FRESH_SCAN`.
- The only corrected Wave122 testable route was `DAP`, driven by nominal MS
  expression, broad cell-state recurrence, and broad external genetics.

Wave134 DAP strict reopen audit completed.

Branch call:

- `NO_REOPEN_DAP_HYGIENE_ARTIFACT`

Decision:

- DAP is not reopened. It fails all critical therapeutic gates: FDR-grade MS
  expression, MS genetic anchor, target-resolved coloc/L2G, real perturbation,
  non-contradicted foundation/model support, reachable selective modality,
  defined intervention direction, and no-strict-blocker status.
- Continue with the remaining hostile-critique forcing tests rather than
  treating Wave133 as a positive result.

## 2026-05-28 07:51 CEST

Wave135 lipid-flux MS response sensitivity completed.

Branch call:

- `LIPID_FLUX_MS_SMALL_N_SIGNAL_NOT_PROMOTABLE`

Result:

- Stable small-n features: `oxylipin_resolution_axis`, `leukotriene_axis`,
  `LTA4H`, `ALOX5`, `critic_flux_panel`, `ppara_lipid_sensor_axis`.
- `gpr183_ligand_axis`: `NO_CROSS_MS_REPLICATION`.

Interpretation:

- The critique was correct that Wave130 was too narrow. A broader lipid-flux
  panel does show peripheral MS treatment-response sensitivity.
- The signal is not FDR-grade, not specific to one intervention node, and is
  mostly leukotriene/oxylipin biology already marked as prior-art-crowded and
  directionally ambiguous.

Wave136 leukotriene/oxylipin strict route audit completed.

Branch call:

- `NO_REOPEN_LEUKOTRIENE_AXIS_SMALL_N_ONLY`

Decision:

- Do not reopen the leukotriene/oxylipin class. It remains a biomarker/context
  clue only because it fails FDR-grade response, target-resolved genetics,
  class-reopen, direction/safety, prior-art, and single-node selectivity gates.

## 2026-05-28 07:51 CEST

Wave137 GPR183 ligand-axis fair closure completed.

Branch call:

- `NO_REOPEN_GPR183_FAIR_CLOSURE`

Evidence classes:

- Matched spatial proxy: `MISSING_NOT_NEGATIVE`
- Weak compartment contrast: `NEGATIVE`
- External response support: `MIXED_SUPPORTIVE`
- MS PBMC GPR183 gene response: `NO_CROSS_MS_REPLICATION`
- MS PBMC ligand-axis response: `NO_CROSS_MS_REPLICATION`

Decision:

- Keep GPR183 closed, but phrase the closure correctly: missing matched spatial
  data are not treated as negative evidence.
- The fair negative evidence is the fallback compartment result plus the lack
  of cross-dataset MS ligand-axis response replication.

## 2026-05-28 07:51 CEST

Subagent dispatch after Waves 133-137:

- Maxwell (`019e6d29-6362-79e3-894d-50d5c632dc91`): read-only search for
  remaining lipid-lysosomal/myeloid/metabolic successor candidates not already
  hard-closed by recent failure patterns.
- Turing (`019e6d29-7c6a-76a3-b510-1201f71a8797`): read-only genetics-first
  salvage audit for target-resolved cross-autoimmune support.
- Poincare (`019e6d29-97d1-7a41-b847-28d71f749be0`): read-only hostile critique
  of Waves 130-137 and orchestration state.

Active agents:

- Maxwell, Turing, Poincare.

Local orchestrator task while agents run:

- Continue non-overlapping local inventory of corrected post-Wave137 evidence
  and prepare the next computation from local outputs.

## 2026-05-28 07:51 CEST

Wave138 post-critique residual fresh-route map completed while sidecars run.

Branch call:

- `NO_STRICT_FRESH_ROUTE_AFTER_POSTCRITIQUE_FILTERS`

Result:

- 0 strict promote candidates.
- 0 residual testable candidates.

Active agents:

- Maxwell, Turing, Poincare still running at time of local Wave138 completion.

## 2026-05-28 08:05 CEST

Sidecar returns:

- Maxwell completed and closed. Output: parked falsification targets
  (`FABP5`, `CHI3L1`, `APOC1`, `SNX10`, `GPNMB`, `SCARB2`, `MSR1`, `LIPA`,
  `SCD`, `NPC1/NPC2`), no finding.
- Turing completed and closed. Output: no clean genetics-first salvage target;
  `IFI30`, `SP140`, `GALC` are only comparator/falsification priorities.
- Poincare completed and closed. Output: accepted critique that Wave130/Wave135
  replication logic was too loose, GSE250453 labels had an inconsistency,
  module-score scaling was not comparable, and several closure scripts need
  stricter input validation.

Corrections:

- Patched Wave130 response audit:
  - GSE250453 sample normalization now precedes response assignment.
  - Per-patient response consistency is asserted.
  - Module scores are computed over MS samples only.
  - Cross-dataset replication requires both datasets to have non-NO calls at
    the same endpoint/direction.
- Patched Wave135 to inherit those corrected semantics.
- Reran Waves 130, 135, 136, and 137.

Corrected branch:

- Wave135: `NO_LIPID_FLUX_MS_RESPONSE_RESCUE`

Decision:

- Supersede the earlier Wave135 small-n lipid-flux signal.
- No route from Waves 130-138 is promotable.

## 2026-05-28 08:05 CEST

Wave139 residual marker falsification integrator completed.

Branch call:

- `NO_RESIDUAL_MARKER_PROMOTABLE`

Result:

- 10 Maxwell residual candidates close as marker/readout.
- 3 Turing genetics candidates (`IFI30`, `SP140`, `GALC`) remain comparator
  rows, not targets.

Decision:

- The lipid-lysosomal module has been resolved for current data as a recurrent
  disease-state/readout program, not a tractable V3 therapeutic target route.
- Pivot away from lipid-lysosomal rescue attempts unless new orthogonal data
  appear.
## 2026-05-28 08:09 CEST - Wave140 Target-First Pivot Audit

Dispatch:
- Local orchestrator wave, no new subagent.
- Purpose: test whether any target-resolved genetics/state candidate survives
  after the lipid-lysosomal module was demoted to marker/readout and after
  Wave133 closure hygiene correction.

Inputs:
- `phases/v3/results/wave62_opentargets_target_resolution/target_resolution_summary.tsv`
- `phases/v3/results/wave104_genetics_first_lipid_state_convergence_audit/genetics_first_lipid_state_rank.tsv`
- `phases/v3/results/wave128_genetics_first_reopener/genetics_first_reopener_decisions.tsv`
- `phases/v3/results/wave133_closure_hygiene_correction/wave122_corrected_rank.tsv`

Return:
- `NO_TARGET_FIRST_PIVOT_AVAILABLE`.
- `0` pivot candidates.
- `37` genetics comparators.

Integration decision:
- Do not promote any Wave140 comparator.
- Treat Wave140 as a routing result: move away from genetics-first salvage
  toward perturbation-first or modality-first discovery, because the current
  genetics-rich nodes are blocked by prior art, missing modality, missing
  residual/perturbation evidence, or unclear direction.
- Current active subagent state remains closed: Maxwell, Turing, and Poincare
  were already returned and closed; no sidecar is pending.
## 2026-05-28 08:10 CEST - Wave141 Modality-First Successor Scan

Dispatch:
- Local orchestrator wave, no new subagent.
- Purpose: invert the search from target/genetics to actionable modality and
  perturbation route, then apply strict disease-biology gates.

Return:
- `NO_MODALITY_FIRST_SUCCESSOR_AVAILABLE`.
- `0` promotable candidates.
- `1` near miss with at least six of eight gates: `CXCR2`, failing `ms_anchor`
  and `prior_not_blocked`.

Integration decision:
- Do not reopen CXCR2: it is a prior-art/safety-saturated chemokine route and
  lacks sufficient MS anchor here.
- The lipid-lysosomal/APC evidence package now fails marker-first,
  genetics-first, target-first, and modality-first successor searches.
- Pivot to an orthogonal cross-autoimmune treatment-response/resistance axis.
## 2026-05-28 08:11 CEST - Post-Wave141 Sidecar Dispatch

Dispatch:
- Ramanujan (`019e6d36-ecbd-7452-aff5-ca96b0d6929d`): read-only
  treatment-response/resistance pivot outside lipid-lysosomal/APC.
- Chandrasekhar (`019e6d36-ed04-73c2-bb9e-db6d5aa4a14d`): read-only
  orthogonal cross-autoimmune mechanism search across non-myeloid modules.
- Newton (`019e6d36-ed5c-7a51-89fc-988f518c3d68`): read-only hostile critique
  of Waves 133-141 and the proposed pivot.

Local critical path while sidecars run:
- Inspect existing response/resistance outputs directly.
- Build Wave142 around a concrete forcing question only after local inspection
  or sidecar evidence identifies a testable axis.
## 2026-05-28 08:18 CEST - Sidecar Returns, Corrections, and Wave142

Returns:
- Ramanujan (`019e6d36-ecbd-7452-aff5-ca96b0d6929d`): response/resistance
  branch is biomarker-only; `IL1B/CXCL8/TREM1/OSM/LAMP3` do not yield a target.
- Chandrasekhar (`019e6d36-ed04-73c2-bb9e-db6d5aa4a14d`): no orthogonal
  mechanism promotable; recommends CD58/CD2 adaptive-synapse forcing test.
- Newton (`019e6d36-ed5c-7a51-89fc-988f518c3d68`): accepted critique of
  Wave140/Wave141 scope and pivot overclaim.

Corrections:
- Patched and reran Wave140 with scoped branch call:
  `NO_TARGET_FIRST_PIVOT_IN_CURRENT_LIPID_APC_CLOSURE_STACK`.
- Patched and reran Wave141 with scoped branch call:
  `NO_MODALITY_FIRST_SUCCESSOR_IN_CURATED_PRIOR_INPUTS`.
- Patched and reran Wave136 stale report language after corrected Wave135.
- Added Wave133 supersession metadata pointing to Wave134.

Wave142:
- Ran `scripts/v3_wave142_sender_bridge_strict_pivot_audit.py`.
- Branch call: `NO_ORTHOGONAL_BRIDGE_PIVOT_AVAILABLE`.
- Bridge-biology-only candidates: `HIF1A`, `CALR`, `ITGAV`; none target-worthy.

Integration decision:
- Treatment-response target pivot is closed as a target-finding route.
- Sender-to-myeloid bridge route is closed as target-finding route.
- Next local wave: CD58/CD2 adaptive-synapse forcing test with explicit
  abundance/covariate and prior-art gates.
## 2026-05-28 08:24 CEST - Wave143 CD58/CD2 Forcing Return

Dispatch:
- Local orchestrator wave.
- Purpose: test Chandrasekhar's strongest orthogonal candidate using explicit
  adaptive-synapse gates.

Return:
- `NO_CD58_CD2_ADAPTIVE_SYNAPSE_PROMOTION`.
- RA baseline signal survives T-cell/effector-memory adjustment but does not
  survive full mixture at p < 0.05.
- IBD replication after full mixture: `0` positive rows at p < 0.10.
- Alefacept/CD2-CD58 prior art and restore-vs-block direction conflict remain
  decisive blockers.

Integration decision:
- Keep CD58/CD2 as comparator biology only.
- Move to B-cell/plasma-autoantibody/complement effector route as the next
  orthogonal forcing class.
## 2026-05-28 08:29 CEST - Wave144 B-Cell/Complement Return

Dispatch:
- Local orchestrator wave.
- Purpose: test remaining orthogonal humoral/complement candidate class from
  disease-specialist reports.

Return:
- `NO_BCELL_COMPLEMENT_SHARED_THERAPEUTIC_TARGET`.
- `0` shared target candidates.
- `3` architecture-only axes.

Integration decision:
- Humoral/complement biology remains relevant disease architecture, but not a
  V3 cross-autoimmune target under current evidence.
- Build a route-inventory map to avoid re-testing closed classes and identify
  the next genuinely untested axis.
## 2026-05-28 08:23 CEST - Wave145 Strict Route Inventory Return

Dispatch:
- Local orchestrator wave.
- Purpose: merge the Wave83/Wave116 route universe with later closures so the
  session does not recycle already-falsified intervention classes.

Return:
- `NO_PROMOTABLE_ROUTE_AFTER_STRICT_INVENTORY`.
- `59` routes scanned.
- `0` promotable routes after strict inventory.

Integration decision:
- Treat the current lipid/APC intervention catalog as locally exhausted for
  target nomination, while explicitly not claiming global exhaustion.
- All post-Wave141 subagents remain closed; no agent is pending.
- Pivot outside the curated route catalog to a fresh disease-first architecture
  scan.
## 2026-05-28 08:23 CEST - Post-Wave145 Fresh Architecture Dispatch

Dispatch:
- Planck (`019e6d42-b53e-7553-8044-ee7def5b905e`): read-only
  tissue-entry/stromal-retention/barrier-interface architecture scout outside
  closed lipid/APC routes.
- Gauss (`019e6d42-d52d-76c2-9d7e-d23484f61f7c`): read-only genetics-first
  outside-catalog scout.
- Faraday (`019e6d42-ebfa-7a03-8719-dd496f0f58e1`): read-only hostile critique
  of Wave145 and the architecture pivot.

Local critical path while sidecars run:
- Build an explicit tissue-architecture inventory from existing disease reports
  and local single-cell/spatial module outputs.
## 2026-05-28 08:23 CEST - Post-Wave145 Sidecar Returns

Returns:
- Planck: recommends structured Wave146 architecture-first barrier/retention
  module scan. Candidate classes: endothelial entry, stromal retention,
  epithelial chemokine entry, TLS/lymphoid niche, TL1A comparator.
- Gauss: no genetics-first outside-catalog candidate is promotable. Recommends
  `TAGAP` as a strict adaptive-immune genetics benchmark, not a finding.
- Faraday: Wave145 branch direction is useful but scores are uncalibrated due
  to double penalties and brittle string vetoes. The architecture pivot is
  acceptable only with explicit sender/receiver gates and no stromal-marker
  proxy satisficing.

Integration decision:
- Treat Wave145 as qualitative route hygiene, not calibrated ranking.
- Run Planck/Faraday's structured architecture-first forcing test next.
- Park Gauss's `TAGAP` benchmark as the next separate genetics-first wave if
  architecture-first testing fails.
## 2026-05-28 08:23 CEST - Wave146 Architecture-First Return

Dispatch:
- Local orchestrator wave.
- Purpose: implement Planck/Faraday's structured barrier-interface and
  retention scan without treating stromal markers as mechanisms.

Return:
- `NO_ARCHITECTURE_FIRST_BARRIER_RETENTION_TARGET`.
- `2968` donor-score rows, `35` source disease tests, `80`
  sender-receiver tests.
- `0` passing modules.

Integration decision:
- Architecture-first scan is a useful negative result.
- Do not promote barrier/retention modules as V3 targets.
- Switch to Gauss's `TAGAP` adaptive-immune genetics benchmark as the next
  outside-catalog forcing test.
## 2026-05-28 08:23 CEST - Wave147 TAGAP Benchmark Return

Dispatch:
- Local orchestrator wave.
- Purpose: test whether broad cross-autoimmune TAGAP genetics maps to a
  disease T-cell state with direction, perturbation, and reachability support.

Return:
- `NO_TAGAP_ADAPTIVE_GENETICS_PROMOTION`.
- Genetics and MS target-resolution gates pass.
- Direction proxy, local T-cell recurrence, MS white-matter expression,
  perturbation, and reachable-modality gates fail.

Integration decision:
- Close `TAGAP` as benchmark/control.
- Inspect `TNFSF14`/LIGHT-LTBR as the next lymphoid-niche axis because it
  surfaced in MS genetics and Wave146 TLS behavior.
## 2026-05-28 08:23 CEST - Wave148 TNFSF14/LIGHT Return

Dispatch:
- Local orchestrator wave.
- Purpose: force-test the lymphoid-niche `TNFSF14`/LIGHT-HVEM/LTBR axis after
  Wave146 and Wave147 exposed it as a possible non-lipid/APC branch.

Return:
- `NO_TNFSF14_LIGHT_LYMPHOID_NICHE_PROMOTION`.
- Only MS target-resolved genetics passes.
- Cross-disease genetics, TLS architecture, MS expression FDR, directionality,
  prior-art, perturbation, and selective-modality gates fail.

Integration decision:
- Close TNFSF14/LIGHT as a V3 route.
- Move to the broad metabolite/barrier axes that Faraday identified as weaker
  prior closures, but require focused route-level evidence.
## 2026-05-28 08:23 CEST - Wave149 Metabolite/Barrier Return

Dispatch:
- Local orchestrator wave.
- Purpose: re-audit the broad metabolite/barrier axes Faraday identified as
  less directly falsified.

Return:
- `NO_METABOLITE_BARRIER_ROUTE_REOPENED`.
- `7` routes scanned; `0` passing routes.
- AHR, SCFA/HCAR, bile-acid FXR/TGR5, and retinoid/VDR routes remain blocked by
  absent local genetics, absent strict residual support, absent disease-signature
  L1000 support, and/or crowding/pleiotropy.

Integration decision:
- Close metabolite/barrier reopener branch.
- Inspect perturbation/drug-response evidence directly as a repurposing-first
  route.
## 2026-05-28 08:23 CEST - Wave150 Repurposing-First Return

Dispatch:
- Local orchestrator wave.
- Purpose: test whether L1000/perturbation evidence can yield a repurposing
  candidate after target-first routes failed.

Return:
- `NO_REPURPOSING_FIRST_CANDIDATE`.
- `123` recurrent compounds audited; `0` pass repurposing gates.
- MS white-matter L1000 q <= 0.05 hits for the MS query: `0`.
- Top recurrent hits are unknown-MOA, cytotoxic/stress/oncology compounds,
  steroids, or prior-art inflammatory targets.

Integration decision:
- Close repurposing-first branch under current local L1000 evidence.
## 2026-05-28 08:23 CEST - Euler Closure-Critique Return

Return:
- Euler accepts Wave147 as a fair TAGAP closure.
- Euler scopes Wave146 to paired myeloid/APC receiver biology, not all
  barrier/TLS biology.
- Euler flags Wave148 and Wave149 as conservative/proxy closures rather than
  direct computational falsifications.
- Euler scopes Wave150 to recurrent L1000 repurposing only.

Integration decision:
- Do not claim global exhaustion.
- Run Wave151: interface-cell perturbation-first audit for AHR, bile-acid,
  SCFA/HCAR/FFAR, LIGHT/HVEM/LTBR, endothelial-entry, stromal-retention, and
  TLS/lymphoid-niche modules.
## 2026-05-28 08:48 CEST - Wave151 Interface-Cell Perturbation Return

Dispatch:
- Local orchestrator wave.
- Purpose: answer Euler's critique by testing whether any barrier/interface
  route has direct disease-relevant perturbation support in human epithelial,
  endothelial, fibroblast, or TLS-like interface cells.

Return:
- `NO_INTERFACE_CELL_PERTURBATION_ROUTE`.
- `8` routes audited; `0` pass.
- The key negative is contextual rather than biological: local LINCS/L1000 and
  Perturb-seq evidence do not provide autoimmune interface-cell perturbation
  contexts for AHR, SCFA/HCAR/FFAR, bile acid FXR/TGR5, retinoid/VDR,
  LIGHT/HVEM/LTBR, endothelial entry, stromal retention/fibrosis, or TLS niche
  routes.

Integration decision:
- Do not close barrier or interface biology globally.
- Treat this as a data-availability blocker for local perturbation-first tests.
- Pivot to external public interface-cell perturbation datasets and primary
  sources, looking specifically for human epithelial/endothelial/fibroblast
  perturbation under inflammatory stimulation that can be chained to the
  cross-autoimmune module.
## 2026-05-28 08:50 CEST - External Interface Perturbation Scouts Dispatch

Dispatch:
- Darwin (`019e6d58-4468-7451-8982-38b3084b7c75`): epithelial/barrier-cell
  perturbation datasets for metabolite and epithelial rescue routes.
- Parfit (`019e6d58-6164-79b0-8b30-4a3276c93ebe`): endothelial, fibroblast,
  stromal, and mesenchymal perturbation datasets for barrier-entry and
  retention routes.
- Lovelace (`019e6d58-85ed-7fe3-8c52-16af984af860`): TLS/lymphoid-niche and
  LIGHT/HVEM/LTBR perturbation datasets.

Integration rule:
- Scouts may propose accessions only. The orchestrator must verify access,
  primary source characterization, and suitability before any accession becomes
  a Wave152 input.
## 2026-05-28 08:56 CEST - External Data Scout Partial Returns

Darwin return:
- Prioritized `GSE190634`, `GSE217552`, `GSE200309`, and `GSE162856` as
  human epithelial/barrier datasets with public processed data.
- Orchestrator verified GEO pages and processed-file availability for all four.

Lovelace return:
- Prioritized `E-MTAB-10638/E-MTAB-10645`, `GSE85895`, `GSE124649`,
  `GSE200362-200364`, `GSE262918`, and `GSE148356` for TLS/LTBR/FRC niche
  biology.
- Orchestrator has not yet promoted these to analysis input because several
  are mouse-only, weakly replicated, or indirect.

Integration decision:
- Build Wave152 first on human epithelial/barrier processed matrices, because
  they best answer the Wave151 missing-context blocker and are downloadable
  without controlled access.
- Keep TLS/LTBR/FRC datasets as a secondary Wave153 candidate after Parfit
  returns and after access is verified.
## 2026-05-28 09:00 CEST - External Data Scouts Closed And Wave152 Scope Expanded

Parfit return:
- Prioritized `GSE129488` as the strongest direct perturbation-rescue dataset:
  human RA/OA synovial fibroblasts with TNF, IL17A, TNF+IL17A, and siRNA
  perturbations against `CUX1`, `LIFR`, `STAT3`, `STAT4`, and `ELF3`.
- Prioritized `GSE213111` as the strongest endothelial-entry inflammatory
  perturbation dataset.
- Prioritized `GSE237845` as a focused colonic fibroblast TWEAK/TNFSF12
  perturbation dataset.

Agent status:
- Darwin, Parfit, and Lovelace are returned and closed.

Integration decision:
- Wave152 should not be epithelium-only. The best direct rescue evidence
  appears in human synovial fibroblasts, so Wave152 will test whether stromal
  retention/fibroblast inflammatory modules have perturbable controllers in
  `GSE129488`, and then compare direction against epithelial/endothelial
  datasets where available.
## 2026-05-28 09:08 CEST - Wave152 External Interface Perturbation Return

Dispatch:
- Local orchestrator wave.
- Purpose: test the Wave151 missing-context blocker using verified public human
  interface-cell perturbation matrices.

Return:
- `NO_EXTERNAL_INTERFACE_MODULE_ROUTE_REOPENED`.
- `96` module contrasts across `GSE190634`, `GSE200309`, `GSE217552`, and
  `GSE237845`.
- `0` modules pass the route gate requiring induction in at least two human
  interface datasets and nominal down-shift under treatment/ligand in at least
  one dataset.

Integration:
- Strong induction breadth exists for `epithelial_chemokine_entry` across all
  four datasets and `endothelial_entry` across three datasets.
- Keratinocyte treatments in `GSE217552` show global negative cosine against
  inflammatory induction, but not enough module-specific rescue for a target or
  drug claim.
- Prioritize resolving `GSE129488` subseries because it contains genetic siRNA
  perturbations in human synovial fibroblasts and is more suitable for causal
  controller testing than ligand-only epithelial matrices.
## 2026-05-28 09:21 CEST - Wave153 Synovial Fibroblast siRNA Rescue Return

Dispatch:
- Local orchestrator wave.
- Purpose: test whether `GSE129487`, the siRNA subseries of `GSE129488`,
  identifies a perturbable controller of the recurring interface chemokine /
  adhesion modules.

Return:
- `SYNOVIAL_FIBROBLAST_CONTROLLER_RESCUE_SIGNAL`.
- `192` samples, `120` matched rescue tests.
- `26` nominal rescue tests; `0` FDR q<0.10 rescue tests.
- `CUX1` siRNA produces the top effect: epithelial chemokine-entry module,
  TNF 6h, control induction `3.0536`, induction p=`6.44e-05`, siRNA effect
  `-0.5306`, siRNA p=`0.00223`, n donors=`4`.

Integration decision:
- Do not promote `CUX1` yet. The signal is nominal and multi-test fragile.
- Run a consistency-focused analysis across all induced module contexts to test
  whether CUX1 is a reproducible controller rather than the top of noisy
  multiple testing.
## 2026-05-28 09:27 CEST - Wave154 CUX1 Consistency Guardrail Return

Dispatch:
- Local orchestrator wave.
- Purpose: test whether the Wave153 CUX1 result is robust across all induced
  contexts, not a cherry-picked nominal hit.

Return:
- `CUX1_CONSISTENT_DIRECTIONAL_CONTROLLER_SIGNAL`.
- `CUX1`: `18/21` induced contexts negative, mean effect `-0.3069`,
  Wilcoxon one-sided p=`6.53e-05`, BH q=`0.00163`, binomial q=`0.00621`.

Comparator:
- `STAT4`: `19/21` negative, Wilcoxon q=`0.00123`.
- `STAT3`: `19/21` negative, Wilcoxon q=`0.00490`.

Integration decision:
- CUX1 is robust but not unique.
- The next discriminating analysis must ask whether CUX1 controls a more
  selective stromal/interface gene subset than STAT3/STAT4, because otherwise
  the result collapses into known JAK/STAT biology and is not a novel
  translational contribution.
## 2026-05-28 09:34 CEST - Wave155 CUX1 Gene Specificity Return

Dispatch:
- Local orchestrator wave.
- Purpose: determine whether CUX1 suppression is separable from STAT3/STAT4 at
  the individual gene level inside the recurrent interface modules.

Return:
- `CUX1_HAS_NOMINAL_NONSTAT_INTERFACE_GENE_SUBSET`.
- `72` induced gene-contexts tested.
- `37` CUX1 nominally suppressed gene-contexts.
- `20` CUX1-selective nominal gene-contexts.

Top gene pattern:
- `CXCL1`: `5/5` induced contexts CUX1-suppressed and `5/5` CUX1-selective;
  mean CUX1 effect `-1.5045`, mean STAT3 effect `-0.0555`, mean STAT4 effect
  `-0.3786`.
- `CXCL8`: `4/5` CUX1-suppressed, `3/5` CUX1-selective.
- `CXCL2`: `4/6` CUX1-suppressed, `3/6` CUX1-selective.

Integration decision:
- Refine the mechanism from "CUX1 controls interface modules" to "CUX1 may
  selectively maintain ELR+ chemokine output in inflammatory stromal/interface
  cells."
- Next audit must test whether this is translationally useful or blocked by
  known CXCR1/2 / IL-8 prior art and safety.
## 2026-05-28 09:49 CEST - Wave156 ELR+ Chemokine Intervention Audit Return

Dispatch:
- Local orchestrator wave.
- Purpose: determine whether the CUX1-selective ELR+ chemokine subset can be
  promoted as a therapeutic intervention point.

Return:
- `NO_ELR_CHEMOKINE_INTERVENTION_PROMOTION`.
- `CXCL1`, `CXCL2`, `CXCL3`, and `CXCL8` have CUX1-linked suppression signal,
  but local prior audits block direct intervention promotion because
  target-resolved causality/MS anchoring is absent or insufficient.
- `CXCL5` has no CUX1 signal in Wave155.

Bug handled:
- First run incorrectly promoted genes despite explicit
  `no_target_resolved_coloc_or_mr` blocker text. The blocker parser was fixed
  and the wave rerun before integration.

Integration decision:
- Close direct ELR+ chemokine intervention promotion.
- Continue only if the program can be reframed as a stratification biomarker or
  if a non-chemokine upstream controller with better tractability emerges.
## 2026-05-28 09:51 CEST - Epicurus Critique Dispatch

Dispatch:
- Epicurus (`019e6d69-6536-79d0-8c92-7f88036a210b`): hostile peer review of
  the proposed CUX1/ELR stratification-biomarker salvage route.

Integration rule:
- Do not promote a biomarker route unless it survives novelty, MS relevance,
  actionability, and generic-inflammation objections.
## 2026-05-28 09:56 CEST - Epicurus Return And Wave157 Biomarker Test Return

Epicurus return:
- The CUX1/ELR route is not promotable as a target or MS biomarker.
- It may only survive as a low-priority comparator/state marker if future work
  shows residual specificity, MS anchoring, and predictive value for a named
  therapy.

Wave157 return:
- `ELR_STATE_INDUCED_AND_TREATMENT_RESPONSIVE`.
- ELR state induced in `3` human interface datasets:
  `GSE190634`, `GSE217552`, `GSE237845`.
- One treatment-down contrast in `GSE217552`: fisetin+rapamycin vs activated,
  delta `-0.2171`, p=`0.0288`.

Integration decision:
- Despite Wave157's positive branch call, the route is parked because it lacks
  a named clinical endpoint, residual specificity, and MS source-compartment
  anchoring.
- Continue pivoting away from direct ELR/CUX1 promotion.

## 2026-05-28 09:14 CEST - Wave158 TNF/IL17 Synergy Controller Closure

Agent-state check:
- The written logs already had Darwin, Parfit, Lovelace, and Epicurus returned
  and closed.
- A direct close attempt for Epicurus returned `not found`, which is consistent
  with no active agent remaining for that handle.

Dispatch:
- Local orchestrator wave.
- Purpose: close or promote the broader TNF/IL17-CUX1/NFKBIZ-ELR synergy
  branch after the positive CUX1/ELR observations and hostile critique.

Return:
- `NO_TNF_IL17_SYNERGY_CONTROLLER_PROMOTION`.
- Audited `CUX1`, `NFKBIZ`, `STAT3`, and `STAT4`.
- Promoted genes: `0`.
- The strongest positive local fact is still narrow: Wave155 found `CXCL1`
  induced in `5/5` contexts and CUX1-selective nominal suppression in `5/5`
  contexts.

Integration decision:
- Close the route for V3 therapeutic and biomarker promotion.
- Reason: the circuit is biologically credible but prior-art/canonical,
  insufficiently MS-anchored, not target-resolved genetically for the V3 claim,
  and lacks a selective reachable intervention modality.
- Do not recycle ELR chemokines, CUX1, or NFKBIZ unless a new dataset answers a
  different, named treatment-response question.

## 2026-05-28 09:16 CEST - Post-Wave158 Sidecar Dispatch

Dispatch:
- Feynman (`019e6d70-546f-79d2-93dc-729ab6072a79`): read-only audit of
  TWEAK/Fn14 (`TNFSF12/TNFRSF12A`) prior art and translational saturation.
- Aquinas (`019e6d70-87db-7881-b004-919bc06f8089`): read-only scout for
  non-ELR, non-CUX1/NFKBIZ interface intervention candidates from local V3
  artifacts.

Local critical path while sidecars run:
- Build a TWEAK/Fn14 local perturbation and cross-anchor audit from GSE237845,
  Wave152/Wave157, and prior V3 target-resolution artifacts.

## 2026-05-28 09:18 CEST - Wave159 TWEAK/Fn14 Closure And Sidecar Returns

Feynman return:
- Recommendation: close `TNFSF12/TNFRSF12A` as discovery target route.
- Reason: GSE237845 is biologically real, but TWEAK/Fn14 autoimmunity is
  prior-art saturated across MS/EAE, IBD, RA, psoriasis, and lupus nephritis;
  RA and lupus nephritis BIIB023 trials and broad autoimmune patents already
  exist.

Aquinas return:
- Recommendation: no non-ELR interface candidate should be promoted yet.
- Best next active test: `LIFR/LIF`, because Wave153 contains direct
  synovial-fibroblast siRNA rescue signals outside CUX1/NFKBIZ/ELR.

Wave159 local return:
- `NO_TWEAK_FN14_ROUTE_PROMOTION`.
- Dataset: `GSE237845`.
- Genes tested: `18711`.
- FDR10 upregulated genes: `725`.
- Nominal non-ELR upregulated genes: `2096`.
- Promoted candidates: `0`.
- Top module was the closed ELR comparator:
  mean delta `2.2505`, `3` up genes p<0.05.

Integration decision:
- Close TWEAK/Fn14 as discovery branch; retain it as a positive-control
  interface-inflammatory perturbation axis.
- Start a targeted LIFR audit because it has real perturbation signal and is
  mechanistically distinct from CUX1/NFKBIZ/ELR and TWEAK/Fn14.

## 2026-05-28 09:18 CEST - Wave160 LIFR Guardrail Return

Dispatch:
- Local orchestrator wave.
- Purpose: test Aquinas's highest-priority non-ELR interface candidate against
  perturbation stability, MS anchor, cross-disease anchor, and prior local
  target scans.

Return:
- `NO_LIFR_ROUTE_PROMOTION`.
- LIFR induced contexts tested: `21`.
- LIFR nominal negative rescue contexts: `6`.
- LIFR FDR10 negative rescue contexts: `0`.
- LIFR mean siRNA effect: `-0.1443`.
- LIFR MS white-matter delta: `-0.7968`, FDR `0.9203`.

Integration decision:
- Park LIFR as a wet-lab perturbation follow-up candidate only.
- The interface route now has multiple real but non-promotable axes
  (CUX1/NFKBIZ/ELR, TWEAK/Fn14, LIFR). Continuing to mine single-source
  interface markers is low yield.

## 2026-05-28 09:20 CEST - Wave161 Route Reprioritization Return

Dispatch:
- Local orchestrator wave.
- Purpose: choose the next branch after interface-route closures without
  recycling recently closed candidates.

Bug handled:
- First run selected `PARK7` despite no concrete next test. I corrected the
  scoring to penalize no-next-test routes and older closed perturbation-first
  leftovers, then reran before integration.

Corrected return:
- `POST_INTERFACE_NEXT_BRANCH_SELECTED`.
- Routes ranked: `138`.
- Selected candidate: `FPR2_ANXA1_BIASED_RESOLUTION`.
- Selected next test: cross-disease ANXA1/FPR2 response-state support with MS
  lesion anchor; kill if no MS/resolution-state support.

Integration decision:
- Proceed to focused FPR2/ANXA1 audit.
- The route is high-risk: prior art is crowded, but it has a concrete
  cross-disease response-state test and a druggable GPCR architecture.

## 2026-05-28 09:22 CEST - Wave162 FPR2/ANXA1 Kill-Test Return

Dispatch:
- Local orchestrator wave.
- Purpose: execute the Wave161 selected test: require cross-disease
  response-state signal plus MS lesion anchor and perturbation anchor.

Return:
- `NO_REOPEN_FPR2_ANXA1_NO_MS_OR_PERTURBATION_ANCHOR`.
- FPR2 broad positive diseases: `Crohn disease;ulcerative colitis`.
- FPR2 MS white-matter delta: `-0.9326`, FDR `0.9141`.
- ANXA1 Wave36 up datasets: `4`.
- Promoted candidates: `0`.

Integration decision:
- Keep FPR2/ANXA1 as wet-lab-only pro-resolution biology, not V3 finding.
- Continue to next eligible route only if it has a non-redundant kill test.

## 2026-05-28 09:24 CEST - P2RX7 Skip And Wave163 CD300 Return

P2RX7 check:
- Existing Wave114 already closed the route:
  `NO_REOPEN_P2RX7_TARGET_LEVEL_STRATIFICATION`.
- It failed specificity, MS module support, RA/IBD response discrimination, and
  CRISPR support. I did not duplicate it with another script.

Wave163 return:
- `NO_REOPEN_CD300_DIRECTION_AND_MS_ANCHOR_FAIL`.
- Best cross-signal gene: `CD300E`, positive in `3` diseases.
- Best CRISPR trend gene: `CD300A`, LFC `1.3382`, FDR `0.9200`.
- Promoted candidates: `0`.

Integration decision:
- Close CD300 receptor-specific tuning for V3 promotion.
- The resolution/efferocytosis reopeners selected by Wave161 are now reclosed
  by focused kill tests.

## 2026-05-28 09:30 CEST - Wave164 Genetics-First Survivor Audit Return

Dispatch:
- Local orchestrator wave.
- Purpose: invert the search after interface/resolution route depletion and ask
  whether target-resolved cross-autoimmune genetics yields a direct promotable
  intervention candidate.

Bug handled:
- Reran after fixing a missing-ChEMBL bug. Pandas `NaN` values in
  `chembl_target_id` were previously stringified as `"nan"` and incorrectly
  counted as reachable target IDs.

Return:
- `GENETICS_FIRST_MECHANISM_BUT_NO_DIRECT_TARGET`.
- Candidates ranked: `2014`.
- Corrected top gene: `TYK2`, score `23.5`.
- Corrected top-gene blockers:
  `insufficient_cross_disease_ms_genetic_anchor;prior_or_local_no_go_blocker`.
- Promoted candidates: `0`.

Integration decision:
- Genetics-first direct-target search remains useful for mechanism discovery,
  but no current survivor satisfies direct druggability, cell-state support,
  MS/cross-disease genetic anchoring, and unblocked therapeutic direction.
- Next branch: `INAVA` neighborhood audit, because `INAVA` has a strong
  MS/cross-autoimmune genetic anchor but no direct modality. The forcing
  question is whether druggable `NOD2`/`RIPK2`/autophagy neighbors preserve
  the genetic and cell-state evidence or collapse into IBD-only prior art.

## 2026-05-28 09:32 CEST - Wave165 INAVA/NOD/RIPK Neighbor Audit Return

Dispatch:
- Local orchestrator wave.
- Purpose: test whether the strong `INAVA` genetics-first mechanism can be
  converted into a tractable intervention by moving to nearby innate/barrier
  nodes (`RIPK2`, `NOD2`, `NOD1`, `ATG16L1`, `IRGM`, `CARD9`).

Bug handled:
- First run used the wrong Wave62 path and mismatched Wave96 column names.
  Fixed the path/column mapping and reran before integration.

Return:
- `NO_INAVA_NOD_RIPK_NEIGHBOR_PROMOTION`.
- Genes tested: `7`.
- Best scored gene: `INAVA`, neighbor score `0`.
- Promoted candidates: `0`.
- `INAVA` genetics: strong L2G in `4` diseases (`AS;Crohn;MS;UC`), strong
  QTL colocalization in `5` diseases (`AS;Crohn;MS;PBC;UC`), MS L2G `0.6894`,
  MS QTL H4 `0.9828`.
- `INAVA` blockers: insufficient cross-disease cell-state recurrence, no
  positive MS white-matter expression anchor, no perturbation direction, no
  direct modality, prior/local no-go blocker.
- `NOD2` is reachable (`CHEMBL1293266`, `840` activity rows) but fails MS
  genetic and MS expression anchoring.
- `RIPK2` has IBD-local myeloid recurrence but no MS/cross-autoimmune genetic
  preservation and no FDR-supported perturbation direction.

Integration decision:
- Park `INAVA` as a genetics clue only.
- Do not promote the NOD/RIPK/autophagy neighbor route. Borrowed druggability
  is not enough when the neighbor loses the genetic anchor that made `INAVA`
  interesting.

## 2026-05-28 09:38 CEST - Wave166 Same-Gene Genetics/Cell-State Overlap Return

Dispatch:
- Local orchestrator wave.
- Purpose: reverse the failed Wave165 neighbor-borrowing strategy and rank only
  genes where target-resolved genetics and local cross-disease cell-state
  recurrence coexist on the same node.

Bug handled:
- First run exposed a blocker-parser weakness and listed apparent eligible
  routes including known-closed `SP140`.
- Tightened generic no-go/prior blocker detection and added explicit local
  known-closed genes, then reran before integration.

Return:
- `NO_UNBLOCKED_SAME_GENE_GENETICS_CELLSTATE_ROUTE`.
- Genes ranked: `25255`.
- Eligible routes after corrected guardrails: `0`.
- Top row: `SP140`, but hard-closed/prior-blocked.

Integration decision:
- Do not claim or pursue a same-gene genetics/cell-state target from this pass.
- Move to a different modality branch because local target-first, interface,
  resolution/efferocytosis, genetics-neighbor, and same-gene overlap routes are
  depleted under current guardrails.

## 2026-05-28 09:41 CEST - Post-Wave166 Sidecar Dispatch

Dispatch:
- Boole (`019e6d84-c36b-78b2-837a-78da8426c106`): read-only modality-pivot
  scout over existing perturbation/foundation/repurposing/intervention-first
  evidence.
- Linnaeus (`019e6d84-dbfb-7b72-a1e9-eaf2e9943919`): read-only hostile critique
  of Waves 164-166 and current pivot logic.

Immediate local work:
- Continue locally with a modality-pivot scan rather than waiting idle for the
  sidecars.

## 2026-05-28 09:46 CEST - Sidecar Returns And Wave167 Shadow Rank

Returns:
- Boole returned and was closed. Recommendation: route space is not empty, but
  remaining plausible pivots are modality-first: phenotype-first efferocytosis
  controller discovery and L1000 repurposing deconvolution.
- Linnaeus returned and was closed. Critique accepted: Wave166 depletion could
  be circular because inherited local labels were used as gates.

Local response:
- Added and ran `scripts/v3_wave167_shadow_no_label_overlap.py`.

Return:
- `SHADOW_RANK_READY_FOR_TARGET_QUALITY_AND_INDEPENDENT_STATE_VALIDATION`.
- Genes ranked: `25255`.
- Same-gene genetics + C15 state shadow-pass genes: `7`.
- Top no-label gene: `STAT4`, score `15.9`.
- Top-25 label classes: `20` prior-art/local-prior, `3` local no-go label,
  `2` unlabeled/data-blocked.

Integration decision:
- Wave166 depletion is not treated as final exhaustion.
- Next local branch: phenotype-first efferocytosis controller pivot, because it
  is modality-independent and does not require same-gene genetics as the first
  gate.

## 2026-05-28 09:50 CEST - Wave168 Efferocytosis Pivot Return

Dispatch:
- Local orchestrator wave.
- Purpose: implement Boole's phenotype-first pivot using Wave37 functional
  efferocytosis hits joined to autoimmune state recurrence, MS anchor, and
  intervention-handle evidence.

Return:
- `NO_EFFEROCYTOSIS_STATE_CONTROLLER_PROMOTION`.
- Screen hits tested: `128`.
- Promoted candidates: `0`.
- Best gene: `YWHAE`, score `6.0038`.
- Best-gene blockers:
  `no_ms_anchor;no_intervention_handle;no_genetic_anchor_annotation`.
- Notable near hits: `FAM49B` and `LRRC61` have functional/state signals but no
  MS anchor, intervention handle, or genetic annotation.

Integration decision:
- Phenotype-first repair-state biology is not empty, but it is not yet a
  translational target route.
- Continue to L1000 repurposing deconvolution, where the intervention handle
  exists first and target biology can be audited second.

## 2026-05-28 09:47 CEST - Waves169-170 L1000 Deconvolution Return

Wave169 dispatch:
- Local orchestrator wave.
- Purpose: revisit Wave150 `PARK_REVIEW` compounds as target-deconvolution
  candidates.

Wave169 return:
- `NO_L1000_REPURPOSING_PROMOTION`.
- Review rows tested: `33`.
- Best candidate: `XMD-1150/LRRK2`, score `12.0198`.
- Initial blocker: `weak_target_quality_proxy`.

Issue:
- Local target-quality proxy was incomplete for repurposing-first routes.

Wave170 external target-quality audit:
- Used approved `curl` to download ChEMBL raw JSON for top targets into
  `phases/v3/results/wave170_external_chembl_target_quality/raw/`.
- Parsed saved artifacts with
  `scripts/v3_wave170_external_chembl_target_quality.py`.

Wave170 return:
- `PROMOTE_AFTER_EXTERNAL_TARGET_QUALITY`.
- Quality-supported genes: `LRRK2`, `PTGIR`.
- Corrected promoted candidate: `XMD-1150/LRRK2`.
- LRRK2: `CHEMBL1075104`, single protein, `1000` downloaded activities,
  `312` unique molecules, best nM `0.39`.
- PTGIR: `CHEMBL1995`, single protein, `1000` downloaded activities,
  `785` unique molecules, best nM `0.0001`.

Integration decision:
- Treat `XMD-1150/LRRK2` as a provisional computational survivor only.
- Immediate next gate is novelty/prior-art and disease-fit kill test; no
  therapeutic claim is allowed until that passes.

## 2026-05-28 09:55 CEST - Wave171 LRRK2 Prior-Art Kill Test Return

Dispatch:
- Local orchestrator literature/patent kill test.
- Purpose: determine whether the Wave170 `XMD-1150/LRRK2` survivor is novel
  enough for V3.

Return:
- `NO_LRRK2_NOVELTY_OR_SPECIFICITY_PROMOTION`.
- Prior art includes URMC-099 in EAE (PubMed `30627663`), CNS-penetrant LRRK2
  inhibitor BIIB122 in Parkinson's disease (`NCT05348785`), and LRRK2 inhibitor
  patents explicitly naming MS/neuroinflammation and autoimmune indications
  (`WO2024182689A1`, `WO2023224894A9`).

Integration decision:
- Demote `XMD-1150/LRRK2` to prior-art-blocked comparator.
- The L1000 workflow remains useful, but this candidate fails novelty and
  target-resolved MS genetics.
